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ABSTRACT 
 
James Patrick Madigan  
Regulation of localization and function of the Rho family small GTPase, Rnd3 
(under the direction of Adrienne D. Cox) 
 
 The Rnd proteins (Rnd1, Rnd2, Rnd3/RhoE) form a distinct branch of the Rho family 
of small GTPases. Rnd3 decreases RhoA activity and regulates both cytoskeletal 
organization (to cause cell rounding, hence the name Rnd) and cell cycle progression. How 
Rnd3 itself, is regulated to cause these changes is still under investigation. One possible 
mechanism is spatiotemporal regulation of this constitutively activated GTPase by 
dynamically modulated post-translational modifications.  In this work, I have shown that, 
upon protein kinase C (PKC) agonist stimulation, Rnd3 undergoes an electrophoretic 
mobility shift and becomes metabolically labeled with 32P, and its subcellular localization 
becomes enriched at internal membranes. These changes are blocked by inhibition of 
conventional PKC isoforms and do not occur in PKCα-null cells or with a 
nonphosphorylatable mutant of Rnd3, indicating that Rnd3 is a target for PKCα-mediated 
phosphorylation. I have provided evidence that integrin engagement regulates the 
downstream signaling functions of Rnd3 by inducing PKCα-mediated phosphorylation. 
These processes result in increased downstream signaling to Rho-ROCK pathway targets 
such as cofilin and myosin light chain. Thus, integrin engagement is a physiological regulator 
of Rnd3 posttranslational modification by PKCα, and in turn is a mediator of Rnd3 
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subcellular localization and downstream signaling. Further, I have demonstrated that both 
localization and function of Rnd3 require post-prenyl processing. Rnd3 localization to the 
plasma membrane is inhibited both in cells devoid of the post-prenyl processing enzymes 
Ras converting enzyme1 (Rce1) and isoprenylcysteine carboxymethyltransferase (Icmt), and 
also upon mutation of the Rnd3 C-terminal tetrapeptide CAAX motif to one insensitive to 
Rce1/Icmt. The function of Rnd3 is also inhibited in the absence of post-prenyl processing.  
Ectopic expression of Rnd3 causes a smaller loss of stress fibers and less cell rounding in 
Rce1-/- and in Icmt-/- fibroblasts than in matched WT cells, and cells expressing the 
misprocessed Rnd3 CAAX mutant display more stress fibers than cells expressing WT Rnd3.  
Together, these results add an additional mechanism of Rnd3 regulation to those documented 
previously, and clarify how Rnd3 modulates Rho signaling to alter cytoskeletal organization. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
Introduction 
 The Ras and Rho branches of the Ras superfamily of small GTPases comprise 
important signaling molecules that become activated in response to a wide array of 
extracellular stimuli (1). These proteins are characterized as binary molecular switches by 
their ability to bind and hydrolyze GTP to GDP (2). When bound to GDP, these proteins are 
in an inactive state. When bound to GTP, they are active and are thus able to bind effector 
molecules and activate downstream signaling pathways. These downstream signaling 
pathways control gene expression and also regulate important cellular processes such as 
proliferation, differentiation, motility and survival (1). The importance of Ras can be seen in 
part by the large number of cancers that harbor activating mutations in Ras superfamily 
GTPases, particularly in the Ras proteins themselves (3). 
 The Rho family proteins constitute an important family of the larger Ras superfamily. 
Like the Ras proteins, Rho proteins are largely regulated by GDP/GTP cycling (4). Rho 
proteins have been shown to regulate numerous cellular functions such as cytoskeleton 
regulation, cell adhesion, cell polarity, endocytosis, vesicular trafficking, cell cycle 
progression, differentiation and gene transcription, and have also been shown to have a role 
in oncogenesis (5-8).   
  
 Much of the current information available on the Rho family of small GTPases has 
been gained through the three best characterized members: RhoA, Rac1 and Cdc42 (9, 10).  
Besides these well-studied, “classical” Rho GTPases, there exist several members of this 
family that are considered “atypical” (11). Members of the Rnd subfamily (Rnd1, Rnd2 and 
Rnd3/RhoE) are examples of atypical Rho proteins (12).  The main function attributed to the 
Rnd proteins to date is to counteract the functions of RhoA (13, 14), a key regulator of stress 
fiber formation.  The Rnd proteins can downregulate RhoA and cause cell rounding, hence 
the name, Rnd.  Rnd proteins lack intrinsic GTPase activity (15) and are exclusively GTP-
bound in vivo and are thus found constitutively in an “active” state (16).  Therefore, 
additional mechanisms of regulation must exist for these proteins.  Regulation at the 
transcriptional level and/or by post-translational mechanisms have been suggested (17).  
Characterizing additional modes of regulation for the GTPase-deficient, atypical Rho family 
GTPase protein, Rnd3, has been the major thrust of my dissertation research and will be 
discussed further below and in subsequent chapters. 
 
The Ras superfamily of small GTPases  
 The Ras superfamily of small GTPases comprises over 150 members, divided into 
five major branches based on both sequence and functional similarity (1, 18, 19): Ras, Rho, 
Rab, Ran and Arf  (Figure 1.1).  Ras GTPases are the founding members of this superfamily.  
The small GTPase Ras is a central hub in numerous intracellular signaling pathways. Ras 
proteins receive signals from diverse upstream activators such as receptor tyrosine kinases, 
G-protein coupled receptors and integrins (20, 21). These signals are transmitted through Ras 
to numerous downstream effectors and their pathways (22, 23). The most characterized 
2
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Rab 
Ras Arf 
Rho 
Ran 
Figure 1.1: The Ras superfamily of small GTPases. This superfamily can be divided 
into five major branches based upon sequence and functional similarity. Adapted from 
Wennerberg, Rossman and Der, 2005, J Cell Sci, 118: 843-846. 
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effectors leading directly from Ras are the serine/threonine kinase Raf (24), 
phosphatidylinositol 3-kinase (PI3-K) (25) and the Ral-guanine nucleotide exchange factor 
(Ral-GEF) (26, 27). Signaling through Ras affects gene transcription to alter such cellular 
processes as survival, proliferation, differentiation, adhesion and motility.  
 Ras proteins were initially identified as viral oncogenes (28, 29). Subsequent studies 
discovered mutated versions of Ras proteins in human cancers (30-32). The Ras proteins are 
considered oncoproteins due to the large number of human cancers that contain mutated and 
activated Ras proteins (3). Three genes encode the four major human Ras proteins (H-Ras, 
N-Ras, K-Ras4A and K-Ras4B). Oncogenic mutations result in Ras proteins that are 
constitutively GTP-bound and are therefore chronically active. Typically, these mutations 
occur at the hot spots of codons 12, 13 and 61 (3). Ras is the most frequently mutated 
oncogene in human tumors, and mutational activation of Ras proteins occur in roughly 30% 
of human tumors, with the prevalence as high as 90% in pancreatic cancer and 50% in colon 
cancer (33-36). Furthermore, even in cancers that lack Ras mutations, increased Ras 
signaling can result from either ras gene amplification or activating mutations in growth 
factor receptors (21). With such a high prevalence of Ras mutations found in human cancer, 
intense efforts have been focused on inhibiting Ras-dependent signaling pathways as possible 
therapies in cancer treatments (37). 
 Other members of the Ras family include R-Ras, Rap1, Ral and Rheb proteins and 
their relatives. The full role of R-Ras (and the closely related isoforms R-Ras2/TC21 and M-
Ras/R-Ras3) in cells is still under investigation. Currently, R-Ras has been shown to activate 
integrins (38) and increase Rho-ROCK activity (39) leading to cell migration. The Rap 
proteins (Rap1 and Rap2) are involved in several aspects of cell adhesion, including integrin-
4
  
mediated cell adhesion and cadherin-mediated cell junction formation (40). The Ral proteins 
(Ral A and B) constitute one of the three main effector arms of the Ras signal transduction 
pathway (41). They are involved in various cellular pathways such as vesicle sorting and 
gene expression and also have effects on the actin cytoskeleton (42). Recent work has shown 
that activation of RalA is critical for Ras-induced tumorigenesis (43). The Rheb (Ras 
homolog encriched in brain) (44) protein is largely known for its involvement in the 
insulin/mTOR/S6K signaling pathway. This pathway is involved in protein synthesis and has 
effects on both the cell cycle and cell size (45). Mutations in the GAP complex for Rheb 
(Tsc1/Tsc2) manifest in a genetic condition termed tuberous sclerosis leading to benign 
tumors and neurological disorders (46). 
 The Rab (Ras-like proteins in brain) family proteins are best known for their roles in 
regulating vesicular transport (47, 48). Studies have shown that these proteins are involved in 
the four major steps of vesicular membrane traffic: vesicle budding, vesicle delivery, vesicle 
tethering and fusion of the vesicle membrane with the membrane of the target compartment 
(49). 
 The Ran (Ras-like nuclear) protein is the only member of this Ras subfamily (50). 
Ran has been shown to be important in nucleocytoplasmic transport of RNA and proteins 
through its interaction with importin protein- and exportin protein-complexed cargo (51). 
Ran is also known to be important in mitotic control through mitotic spindle assembly and 
dynamics (52). 
 The Arf (ADP-ribosylation factor) subfamily, like the Rab subfamily, is involved in 
regulating vesicular transport. This subfamily is made up of six family members, with Arf1 
and Arf6 being the best characterized (53, 54). Arf1, by recruiting coat proteins, regulates the 
5
  
formation of vesicle coats for vesicular membrane formation in cargo sorting and release 
(55). Arf6 is known to be also involved in endocytic membrane trafficking (56) and actin 
remodeling (54). 
 The fifth Ras subfamily contains the Rho (Ras homologous) proteins (4). Much of the 
work I have performed has been centered around the Rho proteins, particularly a novel 
member of this family termed Rnd3. These proteins and their multiple modes of regulation 
will be described in detail below. 
 
The Rho family of small GTPases 
 As indicated above, the Rho family of proteins comprises one of the 5 major branches 
of the Ras superfamily of small GTPases. This family includes 25 distinct proteins encoded 
by 22 genes (4). Rho proteins share approximately 30% amino acid identity with other Ras 
superfamily members and 40-95% identity within the family (4).  Rho proteins have an 
additional “Rho insert” domain of 12-14 amino acids, located at residues ~123-137, between 
the fifth β strand and the fourth α helix in the GTPase domain (57).  Based on criteria 
including sequence identity and biological function, Rho family proteins can be further 
divided into five main subfamilies: RhoA-related (RhoA, RhoB and RhoC), Rac1-related 
(Rac1, Rac1b, Rac2, Rac3 and RhoG), Cdc42-related (Cdc42, bCdc42, TC10, TCL, Wrch-1 
and Chp/Wrch-2), RhoBTB (RhoBTB1 and RhoBTB2) and Rnd (Rnd1, Rnd2 and 
Rnd3/RhoE) (Figure 1.2).   Several other Rho proteins, such as RhoD, Rif and RhoH/TTF, do 
not fall into any of the five Rho subfamilies.  Additionally, another set of related proteins 
named the Miros (mitochondrial Rho) have been characterized (58). Although these proteins 
6
 
 
 
 
 
 
 
 
Figure 1.2: The Rho family of small GTPases. Rnd3/RhoE is a member of the Rnd 
subfamily, which also includes Rnd1 and Rnd2. Adapted from Wherlock and Mellor, 
2002, J Cell Sci, 115: 239-240. 
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contain two GTPase domains, they show a high level of divergence and are thus not 
considered true members of the Rho family. 
The canonical or classical Rho GTPases: RhoA, Rac1 and Cdc42, are the founding 
members of their respective subfamilies, and these proteins are very well characterized with 
respect to structure, regulation, interacting partners, subcellular localization and biological 
activity (4, 5, 9, 10, 59, 60).  In contrast, although the “atypical” GTPases display well-
defined GTP-binding domains, they possess unique N- and C-terminal extensions and often 
lack the ability to cycle GDP/GTP binding (11).  Examples of atypical GTPases include 
RhoH/TTF (61, 62), RhoBTBs (63), Wrch-1 (64-66), Chp (67-69) and the Rnd proteins (12).  
Because these proteins do not GDP/GTP cycle and are constitutively GTP bound, additional 
mechanisms of regulation must exist for these proteins.  Mechanisms of regulation at the 
transcriptional and/or post-translational levels have been explored; these will be discussed 
further for Rnd proteins below. 
Much of our information on the Rho family of small GTPases has been gained 
through studies of the canonical, founding members of this family, RhoA, Rac1 and Cdc42 
(4, 9, 10).  Activation of RhoA leads to formation of stress fibers and focal adhesions (70), 
while activation of Rac1 and Cdc42 lead to the formation of lamellipodia and filopodia, 
respectively (71, 72) (Figure 1.3).  These Rho proteins are well recognized for their role in 
each of the four major steps of cell migration: lamellipodium extension, formation of new 
adhesions, cell body contraction and tail detachment (73). Cell migration involves 
coordinated polarization and reorganization of the actin cytoskeleton.  In a polarized 
migrating cell, Rho GTPases are regulated in a spatiotemporally controlled manner.  Rac1 
and Cdc42 activities are found primarily in the front of the cell to regulate actin 
8
 
 
 
 
 
 
 
 
Figure 1.3: The effects of Rho protein expression on the actin cytoskeleton. A, 
Rho expression forms stress fibers. B, Rac1 expression forms lamellapodia. C, Cdc42 
expression forms filopodia. Arrows indicate structures. Pictures courtesy of Patricia J. 
Keller. 
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polymerization to promote protrusion and to control direction in response to extracellular 
signals, respectively.  RhoA was initially thought to be active primarily in the cell body to 
stimulate actin-myosin contractility to create cell tension (5).  However, the use of biosensor 
probes to detect the small pools of GTP-bound and active Rho proteins has also identified 
active RhoA at the leading edge of randomly migrating but not growth-factor stimulated 
migratory cells (74), where it is tightly regulated, in some cases by at least one cancer-
associated RhoGAP, DLC-1 (75).  
 Although no oncogenic mutations in Rho family proteins have been found in human 
cancers, overexpression of several Rho proteins, as well as dysregulation of their upstream 
activators (GEFs) and downstream negative regulators (GAPs, GDIs) leading to Rho 
hyperactivation has been documented. Rho proteins and their regulators, described in more 
detail below, have been demonstrated to play roles in cancer initiation, progression, invasion 
and metastasis (8, 76-80). 
  
Regulation of Rho GDP/GTP cycling: GEFs, GAPs and GDIs 
 Like the Ras proteins, Rho family GTPases act as molecular switches, cycling 
between an inactive, GDP-bound state and an active, GTP-bound state. Two regions, switch I 
and switch II, undergo a conformational change when the protein becomes GTP-bound (2), 
thereby promoting interaction with downstream effectors (59). The intrinsic GDP/GTP 
exchange and GTP hydrolysis of most small GTPases is slow. Therefore, two major classes 
of proteins regulate the cycling of Rho GTPases: GEFs and GAPs (Figure 1.4). 
 GEFs (guanine nucleotide exchange factors) accelerate the intrinsic GDP-GTP 
exchange activity to favor formation of the active GTP-bound protein (81, 82). The majority 
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Rho proteins function as molecular switches.  Rho-GDP is inactive, 
whereas Rho-GTP is active and can interact with downstream effectors to promote 
biological activity. GEFs activate Rho proteins by promoting the exchange of GDP for 
GTP. GAPs inactivate Rho proteins by accelerating their intrinsically slow GTPase 
activity, promoting the hydrolysis of GTP to GDP. RhoGDI sequesters Rho-GDP in the 
cytosol, preventing it from being activated. 
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of RhoGEFs belong to the Dbl family (83-85), which currently is known to comprise sixty-
nine members, characterized by the presence of tandem DH (Dbl homology) and PH 
(pleckstrin homology) domains important for their exchange activity. Another, smaller 
family of RhoGEFs consists of the DOCK family proteins (86). 
 GAPs (GTPase-activating proteins) inactivate GTPases by enhancing their intrinsic 
GTPase activity, leading to increased GTP hydrolysis and formation of the inactive GDP-
bound form (87, 88). GAPs, through the use of a commonly shared “arginine finger”, 
stabilize the nucleotide state, from GTP-bound to nucleotide-free, and facilitate reloading 
with GDP (2).  Approximately seventy Rho-specific GAPs have been identified to date (4). 
The large number of Rho-specific GEFs and GAPs is testimony to the multitude of signals 
that activate Rho proteins and to the need to tightly regulate their activity and their many 
downstream effects. 
 A third type of protein involved in regulating Rho but not Ras GTPases are the GDIs 
(guanine nucleotide dissociation inhibitors), of which there are three known human isoforms: 
RhoGDI-1, RhoGDI-2 (or D4/Ly-GDI) and RhoGDI-3, or α, β and γ.  GDIs bind to GDP-
bound Rho proteins and sequester them in the cytoplasm where they are unable to interact 
with GEFs, thus inhibiting GDP/GTP exchange (89-91). GDIs have also been shown to mask 
the C-terminal lipid modifications of Rho proteins and to shuttle them to the cytoplasm 
where they are unable to signal to downstream effectors (92, 93).  Conversely, palmitoylation 
of the C-termini of TC10 and RhoB was shown to inhibit GDI binding (94).  These lipid 
modifications are discussed in the following section. 
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Prenylation of small GTPases  
 Correct subcellular localization is required for proper biologial activity, and 
subcellular localization in turn of small GTPases is controlled by a combination of sequence 
information and post-translational modifications. Nearly all members of the Rho and Ras 
families terminate in a C-terminal CAAX motif (where C=cysteine, A=aliphatic residue and 
X=any amino acid) (95), a crucial signal for prenylation, a permanent post-translational 
modification required for correct GTPase subcellular localization and for biological activity.  
Proper localization relies in part on an ordered cascade of enzymatic reactions signaled by 
the CAAX motif, of which prenylation is the first and obligate step (96) (Figure 1.5).  The 
first reaction is stimulated by either of two cytosolic prenyltransferase enzymes: 
farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I) (97, 98). The “X” in 
the CAAX motif determines the prenylation specificity of that protein (99-103).  The 
classical Rho proteins terminate in X = L and are therefore substrates for GGTase I, which 
adds a C20 geranylgeranyl isoprenoid group to the cysteine of the CAAX motif, while Ras 
proteins (X = S or M) are substrates for FTase, which adds a C15 farnesyl isoprenoid group 
(95, 104, 105).  However, many of the nonclassical Rho GTPases are also farnesylated (106), 
including the Rnd3 protein that is the subject of this dissertation  (16).  
 It has been appreciated for some time that proper membrane targeting and 
transforming ability of the oncogenic Ras proteins requires processing through the 
prenylation pathway.  Due to this observation, protein prenyltransferases, most notably 
FTase, have been targets of anti-cancer drug discovery efforts (107-109).  To this end, FTase 
inhibitors (FTIs) have been developed and were shown to have promising preclinical anti-
tumor results.  Despite initial promising results, the anti-tumor efficacy of FTIs in the clinic 
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Figure 1.5: Proper membrane localization of Ras and Rho proteins involves a 
three step enzymatic cascade. Farnesyl transferase attaches a 15 carbon farnesyl 
isoprenoid group to the C-terminal cysteine of Ras proteins. Geranylgeranyl 
transferase attaches a 20 carbon geranylgeranyl isoprenoid group to Rho proteins.  For 
both Ras and Rho proteins, Rce1 cleaves off the –AAX sequence and Icmt methylates 
the exposed prenylated cysteine residue. 
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has been very disappointing.  One possible explanation may stem from the fact that K-Ras4B 
and N-Ras, the Ras isoforms most frequently mutated in cancers, undergoe a process termed 
alternative prenylation (110-112). Under normal circumstances, K-Ras4B and N-Ras 
undergoe only farnesylation, but when farnesylation is blocked, as with FTIs, K-Ras4B and 
N-Ras can also undergo geranylgeranylation.  Alternative prenylation is likely a major 
contributor to blunting the therapeutic potential of FTIs in treatment of cancers that are 
driven by oncogenic Ras.  Furthermore, it is thought that many of the observed cellular 
effects of FTIs may be due to inhibition of other CAAX motif-containing proteins, including 
farnesylated Rho GTPases (113). Additionally, with increasing evidence of misregulation of 
Rho proteins in cancer and other diseases (8, 76), inhibitors of GGTase I, termed GGTIs, are 
being tested and validated in preclinical studies (114, 115). 
 
Post-prenyl processing of small GTPases 
 Prenylation by either a C15 farnesyl or C20 geranylgeranyl isoprenoid group is not 
sufficient for complete CAAX-signaled processing; two further processing steps, termed 
post-prenyl processing, are needed (116, 117).  The first post-prenyl step involves proteolytic 
cleavage of the –AAX residues by an endoplasmic reticulum (ER)-localized protease termed 
Ras converting enzyme 1 (Rce1) (118, 119).  The second step involves carboxymethylation 
of the newly prenylated terminal cysteine residue, catalyzed by another ER-localized enzyme 
termed Isoprenylcysteine carboxyl methyltransferase (Icmt) (118, 120).  The end result of 
this enzymatic cascade involving both prenylation and post-prenyl processing is thought to 
make the carboxy-terminal domain of CAAX motif-containing proteins more hydrophilic, to 
better facilitate proper interactions with lipid-rich cell membranes (121). 
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Rce1 is the only enzyme found in vertebrates that facilitates –AAX proteolysis, and it 
acts on both farnesylated and geranylgeranylated proteins (122).  Rce1 was first identified by 
its role in processing yeast Ras proteins (123).  Rce1-mediated proteolysis of CAAX motif-
containing proteins is essential in mouse development.  Genetic disruption of Rce1 in mice 
caused an embryonic lethal phenotype at approximately embryonic day (E) 15.5 (119).  The 
exact cause for this lethality is still unclear, but targeted deletion of the Rce1 gene in the 
mouse heart caused severe cardiac defects and led to death by age 10 months (124).  Cells 
devoid of Rce1 were shown to contain mislocalized Ras proteins (119, 125, 126).  
Furthermore, it was shown that loss of Rce1-mediated –AAX proteolysis sensitized cells to 
FTI treatment (127).  
 Icmt was first identified in yeast due to its requirement in the processing of a-factor 
mating pheromone (128, 129).  Similar to Rce1, Icmt is the only enzyme found in vertebrates 
to catalyze the C-terminal prenylcysteine methylation reaction (130, 131).  Like Rce1, 
genetic ablation of Icmt causes embryonic lethality at E11.5.  The basis for this greater 
lethality when compared to Rce1 loss is unknown, albeit a defect in liver development was 
detected (132, 133). One proposed explanation is loss of methylation of a subset of Rab 
proteins, which are not Rce1 substrates, and which are important in membrane trafficking 
(131, 134).  Furthermore, unlike Rce1 ablation, which caused only minor disruption of 
oncogenesis, conditional ablation of Icmt caused a 50% decrease in the transformation of 
fibroblasts by the oncogenes K-ras4B and B-raf (135).  In Icmt -/- mouse embryonic stem 
cells, a large fraction of GFP-tagged K-Ras4B was trapped in the cytoplasm, and 
fluorescence at the plasma membrane was reduced (131). 
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 Beyond prenylation and the two post-prenyl processing steps, a second signal found 
in the C-terminus immediately upstream of the CAAX motif is needed for proper membrane 
localization of CAAX-terminating proteins. This second signal can be conferred either by 
palmitoylation of one or two cysteine residues or by the presence of a polybasic region (94, 
136-140). Additionally, the presence of a “third signal” has been suggested, as demonstrated 
by the loss of membrane binding upon mutation of sequences around sites of palmitoylation 
that do not affect the lipid modifications (141). 
These additional membrane targeting signals are found in the hypervariable region of 
Ras superfamily proteins, which consist of approximately 20 amino acids upstream of the 
CAAX motif. As its name implies, this region represents the largest degree of sequence 
variance between highly related family members. For example, RhoA, RhoB and RhoC are 
highly homologous throughout most of their primary sequence, but differ greatly in their 
hypervariable regions (142).  This sequence difference is thought to provide specificity for 
differential subcellular targeting of highly related GTPases.   Another function of the 
hypervariable region, as is the case with Ras proteins, is to contribute to interactions with 
downstream effectors and regulatory proteins (143-145).  
 A recent study found that, whereas farnesylated Ras proteins require full post-prenyl 
processing for proper membrane localization, geranylgeranylated Rho proteins do not (126).  
This study employed activated versions of GTPases.  Whether the WT proteins behave 
similarly would be interesting to determine. Furthermore, only the most characterized Rho 
proteins were studied.  Whether the less-studied Rho proteins follow this trend would be 
interesting to determine as well.  In Chapter 3 below, I have described my studies to 
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determine the role of post-prenyl processing in the proper subcellular localization and 
biological functions of the farnesylated Rho GTPase, Rnd3. 
 
RhoA-related subfamily of Rho proteins: similar but different 
 The RhoA-related subfamily is comprised of three members (RhoA, RhoB and RhoC) 
(146, 147) that share roughly 85% identity at the amino acid level, with the most divergence 
at their C-terminal hypervariable regions (Figure 1.6). Despite the high level of sequence 
identity, the three RhoA-related proteins have distinct expression profiles, posttranslational 
modifications and subcellular localizations. These Rho proteins are expressed in all tissues 
tested, but their levels vary greatly depending on the tissue type (142). While RhoA and 
RhoC are expressed constitutively, RhoB is an immediate-early gene whose expression is 
induced by growth factor signaling (148) in a cell cycle-dependent manner (149) and by 
exposure to stressors including irradiation and chemical agents (150, 151).   
RhoA, B and C all terminate in CAAX motifs and are thus post-translationally 
modified by isoprenylation (97). However, whereas RhoA and C are prenylated by a 
geranylgeranyl group, RhoB has been shown to be both geranylgeranylated and farnesylated 
(95).  This is surprising, given that all of these CAAX motifs terminate in leucine; however, 
the RhoB C-terminal sequence of CCKVL uniquely dictates both modifications (152), and is 
an example of how sequences upstream of the terminal X residue can also influence 
prenylation specificity.  In addition, the dual prenylation of RhoB confers distinct 
localization and functional properties on this otherwise highly related family member, as 
described below. 
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Figure 1.6: Sequence alignment of the RhoA family proteins. Highlighted are Switch I 
(green), Switch II (red), the Rho insert domain (orange) and the CAAX prenylation motif 
(cyan). Loop 6 is noted by a line above the corresponding sequence. "*" indicates that the 
residues in that column are identical in all sequences in the alignment. ":" indicates that 
conserved substitutions have been observed. "." indicates that semi-conserved 
substitutions are observed.  Accession numbers: NP_001655 (RhoA), NP_004031 (RhoB) 
and NP_786886 (RhoC). 
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RhoA and RhoC have been shown to localize to the plasma membrane and the 
cytoplasm (142, 152), whereas RhoB is localized primarily on endosomes (94, 152, 153). 
When RhoB is exclusively geranylgeranylated upon blocking of farnesylation, it is found 
mainly on the plasma membrane rather than in endosomes (154). This observation argues 
that not only is RhoB distinct from RhoA and RhoC, but also that the two differently 
prenylated forms of RhoB have different subcellular localizations and possibly different 
functions from each other.  
Variations in subcellular localization may explain some of the differences between 
the three Rho proteins in terms of biological functions. As mentioned previously, subcellular 
localization affects both effector binding patterns and GEF and GAP availabilities (81, 83, 
87, 88). While these highly related Rho proteins share many of the same GEFs and GAPs, 
some differences have been reported. For example, XPLN has been shown to be a GEF for 
both RhoA and RhoB, but not for RhoC (155).  Rho effector proteins will be discussed in a 
later section. 
 While the rhoA gene locus has not yet been targeted, mice lacking either rhoB or 
rhoC were found to be both viable and fertile.  Using rhoB -/- MEFs, it was found that RhoB 
is important for cell motility, but not for adhesion or spreading. Furthermore, it was shown 
that rhoB -/- mice are more susceptible to developing tumors when tested in a skin 
carcinogenesis assay (156). Through the use of rhoC -/- mice, it was determined that loss of 
RhoC does not affect tumor development, but decreases tumor cell motility and metastatic 
cell survival leading to a drastic inhibition of metastasis (157). A study where the cardiac-
specific activity of all three Rho proteins were abrogated by RhoGDI expression, led to 
embryonic lethality due to improper cardiac morphogenesis (158).  The availability of a 
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rhoA null mouse would surely help to uncover its role in development and further 
discriminate unique roles for these three highly related proteins. 
 While RhoA has been shown to be required for Ras transformation (159, 160), RhoB 
has a growth inhibitory function (161-163). Furthermore, RhoB expression has been shown 
to be downregulated by Ras through a PI3K/Akt-dependent pathway (164). Whereas RhoC 
overexpression does not increase transformation, its expression promotes metastasis (165).  
One study comparing the gene expression profiles of non-metastatic and highly metastatic 
melanoma cell lines showed that the gene encoding RhoC was expressed at a significantly 
higher level in the metastatic line versus non-metastatic line (166).  In the same study, the 
authors showed that overexpressed RhoC enhanced metastasis whereas dominant negative 
RhoC inhibited it (166).  Expression in the same metastatic A375M cells of a p190RhoGAP-
RhoC chimera, to selectively target the GAP activity to downregulate RhoC, reduced their 
migratory and invasive phenotypes, whereas chimeras made with RhoA and RhoB did not 
(167).  Furthermore, RhoC expression increases as cells become more metastatic (168).  In 
contrast to RhoC, RhoB overexpression has been shown to inhibit migration and invasion 
(164).  Thus, a simplistic summary suggests that the primary functions of these closely 
related isoforms are motility and migration for RhoA, growth suppressing activity for RhoB, 
and invasion and metastasis for RhoC.  Additional evidence suggesting greater complexity 
will be discussed below.    
  
RhoA: effectors, downstream signaling and biological consequences 
 Throughout evolution, nature has increased the number of Rho proteins as organisms 
become more complex.  Although the three members of the RhoA/B/C subfamily are highly 
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similar (~85% identical), it is clear that they are not functionally redundant.  Their sequence 
divergence is thought to give these highly related proteins the diversity needed to perform 
distinct cellular functions, either by differential signaling to common effectors or by 
affording access to specialized subcellular locations for interaction with distinct effector 
proteins. 
      
     RhoA effectors 
The small GTPase RhoA has been shown to be important in a wide array of cellular 
processes such as actin cytoskeletal organization, gene expression, cell cycle progression and 
transformation (5, 9, 169). This wide range of functions is made possible by preferential 
interaction of the GTP-bound form of RhoA with a multitude of specific effectors (59).  In 
contrast to Ras, in which the effector binding domain consists simply of a core region 
representing residues 32-40 (Switch I), plus flanking residues from ~25-45, the picture in 
Rho is more complicated.   By the use of chimeric proteins between RhoA and H-Ras, and 
between RhoA and Rac1, Hall and colleagues showed that, unlike Ras, the “effector binding 
region” of RhoA must require residues well outside the core effector domain of Switch I 
(170, 171).  Rho family proteins contain an “insert domain” (residues ~123-137) not found in 
other Ras superfamily GTPases, and this insert region is required for the activation of 
specific RhoA effectors even if not for their binding (172).  Finally, residues in loop 6 of Rho 
proteins (~75-92) are also required for the specificity of RhoA effector interactions (173, 
174). 
 There are well over a dozen proteins known to interact with RhoA in a GTP-
dependent manner (59, 60, 142) and that are therefore candidates to be true effector targets 
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(Figure 1.7). These include the Rho kinases, ROCK I and ROCK II (elaborated further on 
page 25) (175-179), the protein kinase N (PKN)-related kinases (180-183), the myosin-
binding subunit of myosin light chain (MLC) phosphatase (MLCP) (184), Citron kinase 
(185), Rhophilin (182), Rhophilin-2 (186), Rhotekin (187), Kinectin (188, 189), p116RIP 
(190), phospholipase D (PLD) (191) and the diaphanous-related formins mDia1 and mDia2 
(189, 192). 
 Sequence divergence in and around the Switch I effector binding region (Figure 1.6) 
adds to the diversity and selectivity of effector proteins for specific Rho isoforms.  Most 
RhoA effectors are known to also interact with RhoB and/or RhoC, although their interaction 
intensities vary.  For example, in interaction studies, the Rho effectors ROCK and Citron 
kinase both display a higher affinity for RhoC over RhoA (193). Furthermore, in vivo, RhoC 
has a greater ability to activate ROCK as compared to RhoA (194).  These studies grew out 
of intensive efforts to understand the ways in which Rho proteins regulate the cytoskeleton in 
normal function and in disease states, especially oncogenesis. 
 
     RhoA signaling and downstream consequences:  cytoskeletal organization 
 Initial studies with Rho proteins had hinted at a possible role in cytoskeletal control. 
In these studies, it was noted that p21 Rho protein was ADP-ribosylated by C3 exoenzyme in 
vitro and that this in vitro ADP-ribosylated Rho protein corresponded to the dominant C3 
substrate of eukaryotic cells.  It was also noted that treatment of cells with C3 exoenzyme 
caused the loss of microfilaments and rounding of cells (195).  In another study, ADP-
ribosylated Rho protein was microinjected into fibroblast cells and rounding up of the 
injected cells was noted (196). The authors from both studies suggested that the biological 
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Figure 1.7: RhoA effectors and cellular processes. Well over a dozen proteins are 
known to interact with RhoA in a GTP-dependent manner, leading to a wide array of 
cellular processes such as actin cytoskeletal organization, gene expression, cell cycle 
progression and transformation. 
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role of Rho was to control some aspect of cytoskeletal organization.  The connection between 
RhoA, extracellular signaling and cytoskeletal control was not directly made until the 
publication of a seminal paper from Anne Ridley and Alan Hall in 1992 (70). It was in this 
paper, the authors established that stress fibers and focal adhesions were regulated by RhoA. 
Stress fibers (197) are axial bundles of F-actin and myosin that traverse the cytoplasm and 
terminate at focal adhesions (198), which are cellular structures that link the extracellular 
matrix (ECM) on the outside of the cell, through integrin receptors, to the actin cytoskeleton 
inside the cell.  It is thought that strong adhesions to the substratum mediated by integrin 
receptors and stimulation of contractility by soluble serum factors generate tension, resulting 
in alignment and bundling of actin filaments to form stress fibers, and resulting in clustering 
of integrins and associated proteins to form focal adhesions (198). Ridley and Hall found that 
lysophosphatidic acid (LPA) in serum induced the formation of these structures and that 
treatment with C3 exoezyme blocked their formation. They also established that RhoA lies in 
a signaling pathway downstream from growth factor receptors located on the cell surface 
(169).   
 At least two effectors, ROCK and mDia, appear to be required for Rho-induced 
assembly of stress fibers and subsequent focal adhesion formation (59) (Figure 1.8).  The 
ROCK serine/threonine kinases, also called Rho kinases, were the first effectors of Rho to be 
discovered (199).  Two ROCK isoforms have been identified (175, 176, 178, 200):  ROCK I 
(also known as ROCK 1, ROKβ and p160ROCK) and ROCK II (also known as ROCK 2, 
ROKα and Rho kinase).  Phosphorylation of three downstream targets have been shown to 
be important for the formation of stress fibers in cells.  ROCK has been shown to 
phosphorylate the myosin-binding subunit of MLC phosphatase (184, 201, 202). MLC 
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Figure 1.8: RhoA-GTP signal transduction pathways leading to stress fiber and 
focal adhesion formation.  Active RhoA signals to the effector ROCK leading to 
phosphorylation of MLC phosphatase, which increases MLC phosphorylation. ROCK 
also phosphorylates MLC directly. The increased phosphorylation of MLC stimulates 
the ATPase activity of myosin II, which leads to actomyosin assembly and contractility.  
ROCK also phosphorylates and activates LIM kinases which, in turn, phosphorylate and 
inactivate the actin severing protein cofilin, leading to actin filament stabilization.  
Active RhoA also signals to the effector mDia who, through binding with the G-actin-
binding protein Profilin, leads to increased actin polymerization. The final outcome of 
these signaling pathways results in stress fiber and focal adhesion formation. Adapted 
from Bishop and Hall, 2000, Biochem. J., 348: 241-255. 
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phosphatase is inhibited by phosphorylation and this inhibition indirectly leads to an increase 
in phosphorylation of MLC itself (59).  ROCK has also been shown to directly phosphorylate 
MLC (203, 204).  Phosphorylation of MLC occurs at serine 19 and this phosphorylation 
stimulates the actin-activating ATPase activity of myosin II and promotes the assembly of 
actomyosin filaments (59).  The third downstream target of ROCK involved in the formation 
of stress fibers is LIM kinase (LIMK1 and LIMK2).  ROCK was shown to phosphorylate 
LIMK1 at threonine 508 (205) and LIMK2 at threonine 505 (206).  Phosphorylation of both 
LIM kinases was shown to enhance their ability to phosphorylate cofilin (207).  Cofilin is an 
actin severing protein, and phosphorylation on serine 3 by either LIM kinase inhibits its actin 
severing/depolymerization activity (208-210).  
 Expression of constitutively active ROCK does not induce correctly organized stress 
fibers (176, 179).  Yet, inhibition of ROCK by Y-27632, a ROCK inhibitor (211), causes loss 
of serum- and activated Rho-induced stress fibers (212).  These data suggest that ROCK is 
necessary, but not sufficient, for Rho-induced stress fiber assembly.  A second RhoA 
effector, mDia, was shown to complement the activity of ROCK in stress fiber formation 
(213).  mDia1 and 2 isoforms are mammalian homologs of the Drosophila diaphanous 
protein and are members of the formin-homology family of proteins involved in actin 
nucleation (214).  Expression of activated forms of mDia promoted the assembly of thin 
stress fibers that appeared to be less bundled than those produced by activation of RhoA or 
by expression of an activated form of ROCK. Experimental titration of activated forms of 
both ROCK and mDia induced the formation of stress fibers that better resembled those 
found when RhoA is activated normally (213).   
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The exact role that mDia plays in cooperation with ROCK to form proper stress fibers 
has yet to be determined.  Possible roles include its effects on microtubules (215) or by its 
interaction with profilin, which promotes actin polymerization (192). The sum effect of the 
actions of ROCK and mDia is to increase acto-myosin contractility.  Increased Rho-
stimulated acto-myosin contractility has been shown to lead to formation of stress fibers and 
subsequent focal adhesions (198, 216). 
 
     RhoA signaling and downstream consequences:  cell cycle progression 
In addition to its role in cytoskeletal organization, RhoA has also been shown to be 
functionally required for the G1-S phase transition in fibroblast cells.  In one study, addition 
of C3 exoenzyme, an ADP-ribosyltransferase that inactivates Rho proteins (217), prevented 
serum starved Swiss 3T3 cells from entering S phase.  The authors identified RhoA as the 
single protein that was ADP-ribosylated in the cells when C3 exoenzyme was added and 
clearly show that RhoA plays a critical role in the G1-S phase progression (218).  In another 
study, the authors microinjected constitutively activated mutants of RhoA, Rac1 and Cdc42 
into quiescent fibroblasts and observed cell cycle progression through G1 into S phase.  They 
observed that microinjection of dominant negative forms of these Rho proteins or C3 
exoenzyme into quiescent fibroblasts prevented serum-induced S phase entrance (219).    
 The requirement for RhoA in cell cycle progression may be due to two specific 
actions: regulation of gene transcription (specifically cyclin D1) and downregulation of 
cyclin dependent kinase inhibitors (220). Two main pathways have been described in support 
of RhoA involvement in gene transcription. First, RhoA (along with Rac1 and Cdc42) was 
shown to activate transcriptional activation by SRF.  Serum response factor (SRF) is a 
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transcription factor, which regulates many immediate-early genes (221).  Functional RhoA 
was shown to be required for serum- and LPA-induced activation of SRF.  It was also shown 
that activated RhoA can activate SRF in the absence of external stimuli (222).  Also, it was 
shown that RhoA can activate the SRF-related transcription factor MEF2C (223).  This 
RhoA-dependent activation of MEF2C involves the RhoA effector PKN and activation of 
ERK6 (p38γ) (224), a member of the MAPK superfamily. The authors also provide evidence 
that activation of the ERK6 (p38γ) pathway is required for the ability of RhoA to subvert 
normal cell growth and induce cellular transformation (223).  The SRF and MEF2C 
transcription factors lead to increased transcription of c-Fos and c-Jun, respectively (222, 
223). c-Jun and c-Fos, along with related proteins, form the AP-1 transcription factor (225).  
AP-1 binds to palindromic DNA sequence termed the TRE, which is present in the regulatory 
regions of many genes, thus controlling their expression.  Expression of c-Jun and c-Fos, to 
form the AP-1 transcription factor, play an important role in cell proliferation (226).   
Second, it was shown that RhoA (along with Rac1 and Cdc42) efficiently induces the 
transcriptional activity of nuclear factor kappaB (NF-kappaB) by a mechanism that involves 
both phosphorylation of Ikappa Balpha and translocation of p50/p50 and p50/p65 dimers to 
the nucleus.  The authors showed, through use of dominant negative mutants, that activation 
of NF-kappaB by TNFα depends on both RhoA and Cdc42 (227).  The same authors, in an 
additional paper, show that the NF-kappaB and C/EBPβ transcription factors are accessory 
proteins for RhoA-linked regulation of the activity of SRF (228). The transcription of cyclin 
D1 has been shown to be controlled by the AP-1 (229) and NF-kappaB (230) transcription 
factors. Cyclin D1 has been shown to be crucial for cell proliferation and tumorigenesis as its 
expression increases as the cell enters the cell cycle and it has been shown to be 
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overexpressed in a variety of cancers (231).  Thus, one example of how RhoA may contol 
cell cycle progression, and hence increased proliferation, would be regulation of cyclin-D1 
expression through control of AP-1 and NF-kappaB.   
 Another example of how RhoA may control cell cycle progression is through the 
downregulation of cyclin-dependent kinase inhibitors p21-CIP1 and p27-KIP1 (232).  p21-
CIP1 (233) and p27-KIP1 (234) are cyclin-dependent kinase inhibitors that control cell cycle 
progression through G1 phase into S phase, a major checkpoint for proliferating cells.  
Downregulation of p21-CIP1 by active RhoA has been shown to be crucial for oncogenic 
Ras to promote cell cycle entry (235).  Furthermore, it was shown that Ras-transformed cells 
contain high levels of RhoA-GTP, which functions to inhibit the expression of p21-CIP1.  
Further, the actions of RhoA-GTP are uncoupled from ROCK and stress fiber formation, as 
inhibition of ROCK by the inhibitor Y-27632 did not affect the levels of p21-CIP1 (236).  
Currently, the only clue as to how RhoA might regulate p21-CIP1 levels was provided by a 
report which showed that RhoA activity affects the phosphorylation of the SP1 transcription 
factors, which regulate the transcription from the p21-CIP1 promoter.  The authors show that 
treatment with a GGTI upregulated levels of p21-CIP1. Furthermore, they show that both 
treatment with C3 exoenzyme and expression of a dominant negative RhoA increased the 
levels and activity of p21-CIP1 (237).  Furthermore, it has also been shown, through the use 
of both dominant negative RhoA and C3 exoenzyme treatment, that RhoA activity is required 
for growth factor-dependent downregulation of p27-KIP1 and progression from G1 to S 
phase (238, 239).   
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 Finally, several RhoGEFs, including Ect2 and GEF-H1, have been demonstrated to be 
critical for cytokinesis (240-242).  Taken together, all of these results indicate that RhoA 
activity is required for proper cell proliferation. 
 
     RhoA signaling and downstream consequences:  oncogenic transformation 
 Perhaps not surprisingly, given its roles in cytoskeletal organization and cell cycle 
control, there is also evidence that RhoA is involved in both morphological and growth 
transformation.  In one study, using focus forming assays as the read-out , coexpression of an 
activated form of RhoA along with a weakly transforming Raf-1 mutant greatly enhanced 
transformation.  Furthermore, coexpression of a dominant negative mutant of RhoA reduced 
oncogenic Ras transformation. The authors also showed that activated RhoA further 
enhanced oncogenic Ras-triggered morphologic transformation, as well as growth in soft 
agar and cell motility (159).  In a different study, it was shown that activated RhoA strongly 
cooperates with constitutively active Raf in focus formation assays in NIH 3T3 cells. The 
authors showed that a dominant negative RhoA inhibited focus formation by both activated 
Ras and Raf.  Furthermore, the authors showed that stable coexpression of dominant negative 
RhoA and activated Ras in Rat1 fibroblast cells reverted Ras transformation (160). 
 The central role of RhoA in regulating processes critical to cell morphology and 
growth suggests that, in addition to the proximal regulation of RhoA activity by GEFs, GAPs 
and GDIs, upstream signaling that impinges upon RhoA activity levels will also provide 
critical inputs to both cytoskeletal organization and cellular proliferation.  One such upstream 
signal is represented by the atypical Rho-related protein, Rnd3, as described in the next 
section. 
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Rnd proteins: atypical Rho GTPases 
     Similarities to / differences from classical Rho GTPases  
 The Rnd proteins represent a subfamily of the Rho family of small GTPases. These 
proteins show a high degree of sequence similarity to RhoA (45-49%) but display distinct 
biochemical and functional properties (4, 12). The Rnd family consists of three members, 
which are ~90% identical in their GTPase domains: Rnd1/RhoS/Rho6/ARHS (chromosome 
location 12q12-q13), Rnd2/RhoN/Rho7/ARHN (chromosome location 17q21) and 
Rnd3/RhoE/Rho8/ARHE (chromosome location 2q23.3). Rnd proteins are found only in 
vertebrates and thus arose late in evolution (~500 million years ago).  Rnd1 is expressed in 
the brain and liver, while Rnd2 is expressed in the brain, liver and testes. Although Rnd3 
mRNA is ubiquitously expressed, Rnd3 protein is found basally at low levels but is induced 
by specific signaling as discussed later. All three Rnd proteins possess unique C-terminal 
extensions and both Rnd1 and Rnd3 possess novel N-terminal extensions, of 8 and 18 amino 
acids, respectively.  These novel N-terminal extensions have been shown to be important for 
proper membrane localization.  Addition of these N- and C-terminal extensions increase the 
size of the Rnd proteins (27-30 kD), as compared to other well studied members of the Rho 
family (21 kD).  Therefore, Rnd proteins are migrate at a slower mobility when examined by 
SDS-PAGE.  Furthermore, Rnd proteins have basic isoelectric points, in contrast to RhoA, 
which has an acidic isoelectric point (12), suggesting distinct microenvironments and 
signaling partners. 
 Rnd proteins display several unusual biochemical properties compared to other Rho 
proteins.  First, the CAAX motifs of all three Rnd proteins terminate in a methionine, and are 
thus classified as potential substrates for prenylation by farnesyl transferase (99, 102). In 
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contrast to the classical Rho family proteins, which are geranylgeranylated, Rnd proteins 
have been shown to be farnesylated (15, 16, 106). In the case of Rnd3, farnesylation is 
required for membrane localization and for its ability to alter cytoskeletal organization (Singh 
et al., unpublished data).  
 In contrast to most Ras and Rho family proteins, which cycle through binding GDP 
and GTP, Rnd proteins are GTPase-deficient, resistant to GAP activity, and display a higher 
affinity for GTP over GDP (15, 16, 243). Thus, Rnd proteins are found predominantly bound 
to GTP in cells and are considered to be constitutively active. Although their core structure is 
very similar to that of GTP-bound RhoA, Rnd proteins contain natural substitutions at the 
Ras amino acid positions Gly12, Ala59 and Gln61 (Figure 1.9).  Mutations of these residues 
in Ras result in an activated version that is unable to hydrolyze GTP, and is thus 
constitutively active and transforming. In Rnd3, residues 32, 79 and 81 (equivalent to Ras 
positions Gly12, Ala59 and Gln61; RhoA positions Gly14, Ala61 and Gln63) are all serines.  
Mutating serines 79 and 81 to the corresponding residues in WT RhoA resulted in a version 
of Rnd3 that was able to hydrolyze GTP at a level equal to WT RhoA.  Mutating all three 
Rnd3 serines to the appropriate WT RhoA residues resulted in GTPase activity greater than 
that of WT RhoA (16).   
The crystal structure of the core GTPase domain of Rnd3 has been solved (244, 245).  
From these studies, it was noted that the primary loss of GTPase activity is due to the 
replacement of the catalytically competent glutamine with a serine (Ser81).  Glutamine 
lowers the energy of the transition state, thus enhancing the rate of hydrolysis (244).  The 
side chain of serine 81, which corresponds to the catalytically active glutamine 63 in RhoA, 
is rotated away from the γ-phosphate and is unable to stabilize a nucleophilic water molecule 
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Figure 1.9: Sequence alignment of the Rnd family proteins.  Highlighted are the core 
effector domain (orange), the Rho insert domain (Red) and CAAX prenylation motif (cyan). 
Residue substitutions involved in Rnd protein GTPase deficiency are highlighted in green. 
"*" indicates that the residues in that column are identical in all sequences in the alignment. 
":" indicates that conserved substitutions have been observed. "." indicates that semi-
conserved substitutions are observed. Accession numbers: NP_055285 (Rnd1), NP_005431 
(Rnd2) and NP_005159 (Rnd3). 
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for an in-line attack of the γ-phosphate (245).  Multiple amino acid residue differences in the 
Rnd3 Switch I and Switch II regions compared to other small GTPases contribute to its 
stability in the GTP-bound state and its apparent inability to transition to a GDP-bound state 
(244).  Further, it was noted that the presence of the serine residue at position 32 would cause 
a steric clash with the RhoGAP arginine finger (245).  From these studies it was also shown 
that four of the six residues of RhoA that are involved in an extensive hydrogen-bonding 
network with RhoGAP deviate in Rnd3.  Thus, these structural differences make a Rnd3-
RhoGAP interaction unlikely (245).  Given that Rnd proteins do not hydrolyze GTP and are 
resistant to GTPase activity and that the concentration of GTP in the cell is ten-fold higher 
than that of GDP, it also seems very unlikely that Rnd3 requires interaction with RhoGEFs in 
order to become GTP-bound and active (245).  Taken together, all of these properties suggest 
that the activity of Rnd3 must be regulated in a manner distinct from GDP/GTP cycling. 
      
      Regulation of expression / activity of Rnd proteins 
 Since Rnd proteins do not GDP/GTP cycle, they are thought to be regulated in part at 
the level of expression. A wide variety of signals have been shown to induce the expression 
of Rnd proteins, including cytokines, growth factors, sex steroid hormones, neurotransmitters 
and genotoxic stressors. In the case of Rnd1, expression has been shown to be induced by 
promoter hypomethylation in gastric cancer (246) and upon inflammation in endothelial cells 
(247). Furthermore, Rnd1 expression was also increased in rat smooth muscle by the sex 
hormone steroids estradiol and progesterone (248). Rnd2 expression can be induced in 
monocytes activated by lipopolysaccharides (249).  Rnd3 expression is induced in MDCK 
cells by the Ras/Raf/MEK/ERK pathway (250).  In both Swiss 3T3 fibroblasts and bone 
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marrow-derived mesenchymal stem cells, Rnd3 expression was shown to be induced by 
platelet-derived growth factor (PDGF) (14, 251). Binding of factor VIIa to tissue factor on 
keratinocytes also induces Rnd3 expression (252). Furthermore, stress agents such as 
ultraviolet-B irradiation (253, 254) and the DNA-damaging agents cisplatin, mitomycin C, 
etoposide and camptothecin have also been shown to increase Rnd3 expression (255, 256), as 
does ethanol exposure in astrocytes (257).   
Like Rnd1, Rnd3 expression is also regulated by sex hormones.  For example, Rnd3 
expression is increased in breast tissue of parous women as compared to nulliparous women 
(258). Several studies have shown that the expression of Rnd proteins is increased in the 
myometrium during pregnancy.  Pregnancy-induced increases of Rnd1 in rat myometrium 
(259) and Rnd3 in rabbit myometrium (260) and an increase in Rnd1, Rnd2, and Rnd3 in both 
rat and human myometrium (261) have been documented.  Studies of human myometrial 
samples in another study also showed an increase in Rnd2 and Rnd3 expression, but only a 
non-significant increase in Rnd1 expression was noted (262).  
Exposure of mice to the drugs cocaine and MDMA (ecstasy) led to upregulation of 
Rnd3 message in the hippocampus, striatum and prefrontal cortex regions of the mouse brain 
(263, 264).  Meanwhile, Rnd2 message was upregulated only in the prefrontal cortex after 
exposure to cocaine, whereas Rnd1 message was not affected after treatment with either drug 
(264).    
Finally, in Xenopus laevis Rnd1 (XRnd1) was isolated in a screen for genes that 
perturbed secondary axis formation in Xenopus embryos. XRnd1 was shown to be transiently 
expressed during the time that certain tissues were undergoing morphogenic remodeling 
(265).  These examples illustrate that Rnd protein expression is modulated by many different 
36
  
cellular events.  However, these expression changes are unlikely to be modulated rapidly 
enough to allow temporal regulation of Rnd protein activity in a manner appropriate to most 
normal signal transduction events. 
In addition to regulation of Rnd activity by changes in expression, Rnd proteins may 
also be regulated by post-translational modifications that directly or indirectly alter its 
abundance and/or its localization.  While this work was in progress, Ridley and colleagues 
demonstrated that Rnd3 binds to and becomes phosphorylated by the serine/threonine kinase 
and Rho effector, ROCK I (266).  Coexpression of constitutively active ROCK I increased 
the half-life of Rnd3 by increasing protein stability, supporting the notion that 
phosphorylation can contribute to Rnd3 activity by modulating its expression.   
 
     Effectors and biological activities of Rnd proteins 
 Rnd proteins are largely known, indeed named, for their effects on the cytoskeleton.  
Expression of Rnd1 and Rnd3 but not Rnd2 in fibroblast and epithelial cells causes a loss of 
stress fibers and focal adhesions leading to rounding-up of cells (15, 243) (Figure 1.10).  
Because the phenotype resulting from Rnd activity (stress fiber disassembly) is the opposite 
of that seen with active RhoA (stress fiber assembly), Rnd proteins are thought to elicit these 
morphological changes by abrogating signaling from RhoA.  Two possible models to explain 
mechanisms by which Rnd proteins may antagonize RhoA signaling have been put forth, and 
evidence has been provided in support of each model (Figure 1.11).  In the one model, Rnd 
proteins (Rnd1 and Rnd3) bind and activate p190RhoGAP, which decreases the levels of 
active GTP-bound RhoA.  In the other model, Rnd3, but not Rnd1, binds and sequesters 
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Figure 1.10: Effects of Rnd3 expression on the actin cytoskeleton. Expression of 
exogenous Rnd3 in NIH 3T3 cells results in a loss of stress fibers and focal adhesions, 
leading to rounding of the cell. Hence “Rnd” for rounding. 
38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Rnd3 antagonizes the RhoA-ROCK I signaling pathway at two 
separate levels. Rnd3 has been shown to bind to and activate p190RhoGAP leading to 
reduced levels of RhoA-GTP. Rnd3 has also been shown to bind and inhibit the RhoA 
effector ROCK I. Overexpression of exogenous Rnd3 leads to loss of stress fibers and 
focal adhesions, leading to cell rounding. 
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ROCK I, a downstream effector necessary for stress fiber and focal adhesion formation.  
These models may not be mutually exclusive, however. 
 Rnd3 was first identified in a yeast two-hybrid screen using p190ARhoGAP as bait 
and called RhoE (16). Overexpression of either Rnd1 or Rnd3 in fibroblasts causes cell 
rounding due to stress fiber disassembly and focal adhesion turnover (15, 243), very similar 
to the effect seen with overexpression of p190RhoGAP (267). Therefore, a logical study 
would be to see if Rnd proteins function with p190RhoGAP to elicit cytoskeletal 
reorganization through downregulation of RhoA.  
In support of the first model, Rnd proteins have been shown to bind to p190RhoGAP 
by yeast two-hybrid screen (13).  In this report, the authors showed that the cellular effects of 
Rnd proteins are mediated through p190RhoGAP, the most abundant GAP for RhoA in cells 
(268). They further showed that a region of Rnd3 found within amino acids 16-93 is 
sufficient for interacting with p190RhoGAP.  This region of Rnd3 contains the P loop along 
with both switch I and switch II. They also showed that two specific mutants of Rnd3 were 
unable to bind to p190RhoGAP. The first mutant was Rnd3(T37N), which is analogous to the 
persistently GDP-bound RhoA(T19N) mutant. The second mutant was Rnd3(T55A), which 
is analogous to the RhoA(T37A) mutant that shows impaired effector binding.  Furthermore, 
they showed that both of these mutants had no effects on cell morphology, such as cell 
rounding.  Using knockout 3T3 fibroblasts, it was shown that the rounding effects of Rnd1 
and Rnd3 were substantially attenuated in both p190A-/- and p190B-/- cells, as compared to 
control WT 3T3 cells. The authors went on to show that, in in vitro GAP assays, addition of 
all three Rnd proteins increased p190A- and p190B-dependent GAP activity toward RhoA-
GTP by approximately 2-fold. Furthermore, the Rnd3(T55A) mutant did not affect p190-
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dependent GAP activity toward RhoA-GTP.  Using Rhotekin RBD assays (269) and Tat-
mediated protein transduction, the authors went on to show that in control 3T3 fibroblasts, 
transduction of WT Rnd3, but not Rnd3(T55A), substantially reduced RhoA-GTP levels.  
The authors in this study concluded that Rnd proteins inhibit RhoA signaling by increasing 
the GAP activity of p190RhoGAP towards RhoA-GTP. 
 In the second model, a study has shown that Rnd3 binds to and sequesters ROCK I, a 
downstream effector of RhoA (14).  To determine how Rnd3 inhibits stress fiber formation, 
the authors investigated whether Rnd3 was able to bind to known RhoA targets involved in 
stress fiber formation.  In a GST pull down experiment, GST-tagged Rnd3 selectively pulled 
down ROCK I from cells. Using truncation mutants of ROCK I in GST-Rnd3 pulldown 
experiments, the authors determined that Rnd3 binds to the N-terminus of ROCK I.  They 
also determined that Rnd3 does not bind to the related ROCK II. They determined that the 
minimal region for Rnd3 binding is amino acids 1-420 of ROCK I, a region that includes the 
kinase domain. This region of ROCK I is different from the region that binds RhoA, which 
binds in the RBD found near the C-terminal end of ROCK I (amino acids 934-1015).  The 
authors determined that the kinase activity of ROCK I was not needed for Rnd3 binding, as a 
kinase dead form of ROCK I was still able to interact with Rnd3.  Using immunostaining, 
they determined that endogenous Rnd3 localized to the Golgi complex and the plasma 
membrane of COS-7 cells.  Using co-staining with ROCK I and Rnd3 antibodies, the authors 
noted a significant degree of overlap of the two proteins in cells, especially the trans-Golgi 
network. The authors went on to show, through coimmunoprecipitation experiments, that 
exogenous Rnd3 and ROCK I directly interact. They further showed that the endogenous 
proteins also directly interact.  Using a coexpression/GST-pull down assay in COS-7 cells, 
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the authors showed that Rnd3 and RhoA cannot bind to ROCK I simultaneously, even 
though they bind to different regions of ROCK I.  
To test whether Rnd3 had any effect on the ability of ROCK I to phosphorylate 
downstream effectors, the authors investigated the effect of Rnd3 expression on 
phosphorylation of MLC phosphatase (MLCP), a major downstream target of ROCK I (199). 
Coexpression of Rnd3 in COS-7 cells reduced MLCP phosphorylation induced by both 
constitutively active and WT ROCK I, as well as reducing the background level of MLCP 
phosphorylation in the absence of exogenous ROCK I.  These results indicate that Rnd3 
inhibits stress fiber formation by preventing ROCK I from phosphorylating MLCP.  Finally, 
the authors went on to show that cytoskeletal changes, mainly cell rounding, caused by 
treatment with a high concentration of PDGF coincided with increased Rnd3 protein 
expression. These results correlate well with the role of Rnd3 in negatively regulating stress 
fiber formation.  The kinase domain of ROCK is highly inaccessible, as the C-terminal 
region can bind to the N-terminal region to form an autoinhibited structure (270, 271).  The 
authors speculated that in this inactive conformation the Rnd3-binding site near the kinase 
domain would be masked.  They went on to state that RhoA-GTP binding to ROCK I induces 
an open conformation and Rnd3 can bind once RhoA has dissociated. 
 It is quite obvious from all of the research to date that Rnd1 and Rnd3 affect RhoA-
mediated cytoskeleton organization.  Yet, the question remains whether either of the two 
models presented above is more physiologically relevant. I hypothesize that the effects of 
Rnd1 and Rnd3 on the actin cytoskeleton are largely attributable to p190RhoGAP-mediated 
activity, based on three lines of evidence.  First, Rnd effects on the actin cytoskeleton are 
much less pronounced in p190RhoGAP -/- cells (13).  Second, Rnd3 has been shown to bind 
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to only ROCK I (14) and not ROCK II (266).  To date, no differences in function have been 
reported for these two highly related proteins (199), suggesting that ROCK II activity would 
compensate for loss of ROCK I.  Third and most importantly, Rnd1 does not bind (or binds 
poorly) to ROCK I, but is quite efficient at inducing loss of stress fibers and focal adhesions 
(15).  Therefore, I support the p190RhoGAP model.  Naturally, this does not preclude a 
contribution from the ROCK model, or from additional unknown mechanisms. 
The Rnd3-ROCK I model may still play a role in cellular activities. In Ras-
transformed cells, there is a loss of stress fibers and focal adhesions, similar to what is seen 
in cells overexpressing Rnd3 (15, 243).  Nevertheless, despite this, Ras-transformed cells 
often show an upregulation of active RhoA, which might be predicted to lead to an increase, 
not a decrease, in stress fiber formation.  Raf activation in MDCK cells leads to both an 
increase in Rnd3 expression and to loss of stress fibers and focal adhesion (250).  However, 
Ras-transformed cells still need upregulation of active RhoA for cell proliferation (236).  
Perhaps increased Rnd3 expression in Ras-transformed cells is involved in the uncoupling of 
active RhoA from ROCK signaling by sequestering away ROCK I, leading to promotion of 
proliferation but loss of stress fibers and focal adhesions.  In this way, Rnd3 might contribute 
to the transformed phenotype and increased motility seen in Ras transformed cells.  
 A few other Rnd protein effectors have been described in addition to ROCK and 
p190RhoGAP (Figure 1.12).  One example is the protein Socius (Latin for “partner”).  Socius 
was pulled out of a yeast two-hybrid screen of a rat brain cDNA library using Rnd1 as bait 
(272).  The report describing the cloning of Socius shows that it has an open reading frame 
that encodes a protein of 485 amino acids and has a predicted molecular mass of 54.7 kD. 
Analysis of the predicted amino acid sequence of Socius revealed a UBX domain in the C-
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Figure 1.12: Effectors of Rnd proteins. Rnd proteins share similar effectors implying 
some conservation of function. Differential binding to other effectors dictates distinct 
biological functions. 
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terminal region. The UBX domain is an ~80 amino acid module of unknown function, 
structurally related to ubiquitin (273). Socius can bind to all three Rnd proteins.  
Furthermore, by using pulldown assays, the authors showed that Myc-tagged Socius 
expressed in COS-7 cells bound to Rnd1 but was unable to bind to GST-tagged RhoA, Rac1 
or Cdc42, whether loaded with GTP-γS or GDP.  In pulldown experiments, Rnd1(T27N), a 
putatively dominant negative mutant (equivalent to RhoA(T19N)) was unable to bind to 
GST-Socius, and a Rnd1(T45A) effector domain mutant (equivalent to RhoA(T37A)) was 
binding-impaired.  The function of Socius is unknown, but it was shown to bind Rnd proteins 
through its C-terminal region and to colocalize with both Rnd1 and Rnd3 at the plasma 
membrane.  In COS-7 cells, the authors showed that expression of either Rnd1 or Rnd3 
caused the translocation of Socius to the cell periphery. Although expression of WT Socius 
in fibroblasts had little effect on the actin cytoskeleton, a constitutively membrane-targeted 
form of Socius with an artificial CAAX motif attached was shown to induce the disassembly 
of stress fibers but did not cause a branching phenotype.  This suggests that the Rnd protein-
induced disassembly of stress fibers and the Rnd branching phenotype are differentially 
regulated by at least two distict signaling pathways, and that Socius is involved only in the 
pathway leading to disassembly of stress fibers.  The authors suggested that Socius may 
serve as an adapter or scaffold protein, linking Rnd proteins to cytoskeletal regulatory 
molecules that might bind to the UBX domain. 
Rnd1 has also been shown to bind to the Grb7 adapter protein (274) and to 
phosphodiesterase 6D (275).  The interaction between Rnd1 and Grb7 was shown by yeast 
two-hybrid, by in vitro binding and by pull down assays (274).  Grb7 (276) belongs to the 
Grb7/10/14 family of adapter proteins (277), which are related to the prototypic Grb2 adapter 
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protein involved in Ras activation (278). The interaction between Rnd1 and Grb7 involved 
the switch II region of Rnd1 and an SH2 phosphotyrosine recognition domain of Grb7, 
although no tyrosine phosphorylation of Rnd1 was detectable.  This interaction could be 
involved in stress fiber inhibition in lamellipodia, where Grb7 partially localizes (12).   
The interaction of Rnd1 and phosphodiesterase 6D (PDE 6D) was shown by yeast 
two-hybrid assay (275).  In this report, the authors showed that PDE 6D (279) (also referred 
to as the δ subunit of retinal rod phosphodiesterase) was able to extract Ras and Rap family 
members from the membranes of HeLa cells, an activity reminiscent of the well-
characterized RhoGDIs (280) and RabGDIs (281). It should be noted that Rnd proteins do 
not associate with RhoGDI (15) and it was shown that RhoGDI does not extract Rnd3 from 
membranes (282).  Although it was not determined in this report whether Rnd1 was extracted 
from membranes (275), given the structural similarities (279) between PDE6D and 
RhoGDIs, I speculate that perhaps PDE 6D regulates Rnd1 protein (along with Rnd2 and 
Rnd3) activity in a way similar to the manner in which RhoGDIs regulate canonical Rho 
GTPases (89-91).  
 Rnd2 binds a distinct set of putative effector proteins, including Rapostlin (283), 
Vacuolar protein sorting protein 4-A (284), Pragmin (285), MgcRacGAP (286), and 
Mesenchyme homeobox 2 protein (287). The same group that identified Socius (272) also 
identified three novel proteins using Rnd2 as bait in yeast two-hybrid screens.  The first 
protein was Rapostlin (named for “apostle of Rnd2”), also known as forming binding protein 
1 (FBP1) (283).  In in vitro binding assays, Rapostlin specifically bound to Rnd2 among the 
Rho family of GTPases and did so in a GTP-dependent manner.  The authors showed that 
Rapostlin binds to microtubules and that, in PC12 neuronal cells, Rapostlin induced neurite 
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branching in response to Rnd2. In a follow-up paper, the authors described numerous splice 
variants of Rapostlin and showed that all are able to bind to Rnd2 in a GTP-dependent 
manner, along with binding to the neural Wiskott-Aldrich syndrome protein (N-WASP) 
(288).  In immunoprecipitation experiments, Rnd2 reduced the interaction of full length 
Rapostlin with N-WASP, but had no effect on the interaction of N-WASP with Rapostlin 
splice variants.  
The second protein found to interact with Rnd2 was Vps4-A or Vacuolar protein 
sorting 4-A (284), a member of the AAA ATPase family and a central regulator of early 
endosomal trafficking. The authors showed interaction by in vitro binding and 
coimmunoprecipitation assays, with Vps4-A binding to both GTP- and GDP-loaded forms of 
Rnd2.  When Rnd2 was co-expressed with an ATPase-deficient mutant of Vps4-A in HeLa 
cells, it was recruited to Vps4-A-bound early endosomes.  The authors suggested that Rnd2 is 
involved in regulation of endosomal trafficking via direct binding to Vps4-A.  
The third protein found to interact with Rnd2, via a yeast two-hybrid screen, was 
Pragmin (285). The authors showed through in vitro and in vivo binding assays that Pragmin 
specifically bound to Rnd2 and did so in a GTP-dependent manner. Surprisingly, Rnd2-
bound Pragmin significantly stimulated RhoA activity and induced cell contraction through 
the RhoA-ROCK pathway in HeLa cells.  In PC12 neural cells, Pragmin expression inhibited 
NGF-induced neurite outgrowth in response to Rnd2, whereas knockdown of Pragmin by 
siRNA enhanced neurite elongation.  The authors suggested that Rnd2 regulates neurite 
outgrowth by functioning as a RhoA activator through Pragmin, in contrast to Rnd1 and 
Rnd3 which inhibit RhoA signaling.  These results could also give clarification to why Rnd2 
does not induce loss of stress fibers and focal adhesions when expressed in fibroblasts (15).  
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In a study using male germ cells, MgcRacGAP was shown to physically interact with 
Rnd2 by both GST-pulldown and by co-immunoprecipitation. Furthermore, these two 
proteins were shown to colocalize (286). MgcRacGAP is a RhoA-specific GAP that was 
shown to localize to the mitotic spindle in metaphase and to be condensed at the midbody 
during cytokinesis. Furthermore, using a GAP-inactive mutant, the GAP activity of 
MgcRacGAP was shown to be required for cytokinesis (289, 290). It was later shown that 
MgcRacGAP initiates cytokinesis through the controlled assembly of the contractile ring 
(291). The authors suggested that MgcRacGAP, and quite possibly other RhoGAPs, may 
participate in signaling pathways involving Rnd family proteins (286).  Using a stringent, 
high-throughput yeast two-hybrid system, Rnd2 was shown to interact with the mesenchyme 
homeobox 2 protein (MEOX2) (287). The expression of the gene encoding MEOX2 was 
shown to be downregulated in vascular smooth muscle cells when quiescent cells were 
stimulated by mitogens to reenter the cell cycle.  Conversely, this gene was shown to be 
upregulated when proliferating cells were starved of serum.  Thus, MEOX2 may play a 
regulatory role in the cell cycle (292).  What role the interaction of Rnd2 and MEOX2 may 
play in the cell is currently unknown. 
 Rnd2, like Rnd1 and Rnd3, also interacts with proteins important for axon growth.  
Axon guidance occurs by directional protrusion of a growth cone. Neurite extensions on the 
growth cone sense the environment in several directions. The neurite retracts in the respone 
to a repulsive signal and the cytoskeleton rearranges to orient the growth cone in another 
direction, so as to detect an attractive signal.  Plexins are the receptors for the semaphorins, 
which are transmembrane or secreted proteins that guide cell migration or axon pathfinding.  
Semaphorin recognition leads to plexin activation and the retraction and collapse of the 
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growth cone due to RhoA-dependent actin contraction (12, 293). All three Rnd proteins have 
been shown to bind to plexin B1 (294). In one study, the authors examined the binding ability 
of the three Rnd proteins.  They showed that all three Rnd proteins directly interact with the 
cytoplasmic domain of Plexin-B1. The main emphasis of the study was centered on Rnd1 
and its direct interaction with Plexin-B1. The authors showed that, in COS-7 cells, 
coexpression of Rnd1 and Plexin-B1 induced cell contraction in response to semaphorin 4D, 
and the interaction between these proteins was required. Semaphorin 4D-induced contraction 
in Plexin-B1/Rnd1-expressing COS-7 cells was suppressed by dominant negative RhoA, a 
Rho-associated kinase inhibitor, a dominant negative form of PDZ-RhoGEF, or deletion of 
the carboxyl-terminal PDZ-RhoGEF-binding region of Plexin-B1, indicating that the PDZ-
RhoGEF/RhoA/Rho-associated kinase pathway was involved in this morphological effect. 
They also found that Rnd1 promoted the interaction between Plexin-B1 and PDZ-RhoGEF 
and thereby dramatically potentiated the Plexin-B1-mediated RhoA activation. The authors 
suggested that Rnd1 plays an important role in the regulation of Plexin-B1 signaling, leading 
to RhoA activation during axon guidance and cell migration.  
In an additional paper from the same group, they showed that Plexin-B1 directly 
stimulates the intrinsic GTPase activity of R-Ras (295). The authors showed that the GAP 
activity of Plexin-B1 required the interaction of Rnd1 and that down-regulation of R-Ras 
activity by the Plexin-B1-Rnd3 complex was essential for the Semaphorin 4D-induced 
growth cone collapse in hippocampal neurons. The authors speculated, and then 
demonstrated, that Plexin-B1 mediates Semaphorin 4D-induced repulsive axon guidance 
signaling by acting as a GAP for R-Ras. Rnd1 binding to Plexin-B1 opens the two R-Ras 
GAP domains of Plexin-B1 to allow full GAP activity towards R-Ras (296). The full role of 
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either Rnd2 or Rnd3 involvement in regulation of PDZ-RhoGEF-mediated Rho activation by 
Plexin-B1 or Plexin-B1-mediated R-Ras GAP activity remains to be determined. 
 In addition to its relatively well-studied effects on the cytoskeleton, there is evidence 
that Rnd3 may also be involved in regulation of the cell cycle.  G1 cell cycle progression is 
controlled by the D-type and E-type cyclins (297).  Past studies have shown that inhibition of 
RhoA blocks G1 progression (218, 219). RhoA was shown to be required for sustained ERK 
signaling which is associated with expression of cyclin D1 during mid-G1 phase (298).  
Furthermore, it was shown that cyclin D1 expression is controlled by RhoA/ROCK signaling 
through stress fiber-mediated integrin signaling that sustains ERK activation (299).  
Meanwhile, a recent report indicates that ectopic overexpression of Rnd3 blocks cell-cycle 
progression at G1 phase (255). The authors demonstrated that increased ectopic Rnd3 
expression in fibroblast cells inhibited cell proliferation and prevented serum starved cells 
from entering the cell cycle in response to growth factor stimulation.  This inhibition of cell 
proliferation was due to a lack of cyclin D1, a protein known to be important in cell cycle 
progression.  Further, the authors demonstrated that increased Rnd3 expression negatively 
affected the translation of cyclin D1 mRNA and that expression of cyclin D1 could not 
rescue the growth arrest induced by Rnd3.  They suggested that Rnd3 may also affect the 
translation of other mRNAs.  With this in mind, perhaps Rnd3 physically interacts with 
components of the translational machinery, such as eIF4E (300).   
In agreement with these findings, another study has found that expression of Rnd3, 
along with disrupting the actin cytoskeleton, inhibited U87 glioblastoma cell proliferation 
(301). In this study, the authors showed that Rnd3 expressing U87 cells showed a reduction 
in Rb phosphorylation and in cyclin D1 expression.  Induction of cyclin D1 is one event 
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required for Rb phosphorylation (inactivation), leading to cell cycle progression (297).  They 
further showed that Rnd3 expression in these cells inhibits ERK activation following serum 
stimulation in quiescent cells.  The authors proposed that Rnd3 inhibits ERK activation, 
thereby decreasing cyclin D1 expression and leading to a reduction in Rb inactivation. They 
speculated that this mechanism is involved in the Rnd3-induced cell growth inhibition.  They 
further went on to show that Rnd3 expression induced apoptosis in U87 cells along with 
colon carcinaoma and melanoma cells and stated that their results indicate that Rnd3 plays an 
important role in the regulation of cell proliferation and survival. They suggested that Rnd3 
may be considered an “oncosuppressor” since it is able to induce apoptosis in several tumor 
cell lines. Furthermore, another study found that forced overexpression of Rnd3 in prostate 
cancer cells, devoid of Rnd3, resulted in G2/M cell cycle arrest. These authors found that the 
cell cycle arrest was due to the inhibition of expression of Cdc2 and cyclin B1, two proteins 
essential for G2/M phase transition.  The authors suggested that Rnd3 is a tumor suppressor 
gene, which is downregulated early in the development of prostate cancer (302). 
 Rnd3 has also been shown to have pro-survival activities in response to genotoxic 
stress.  Rnd3 has been shown to be a direct p53 transcriptional target gene (256).  In this 
report, the authors showed that genotoxic stress triggered actin depolymerization, resulting in 
actin stress fiber disassembly through p53-dependent Rnd3 induction.  They found that Rnd3 
inhibited ROCK I activity during genotoxic stress and thereby suppressed apoptosis.  Rnd3-
specific knockdown resulted in stress fiber maintenance and a striking increase in apoptosis.  
The authors demonstrated that p53-mediated induction of Rnd3, in response to DNA damage, 
favors cell survival partly through inhibition of ROCK I-mediated apoptosis.  In another 
report from the same group, they showed that Rnd3 protein levels increased upon exposure to 
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UVB in human keratinocyte cells (254).  The authors showed that knockdown of Rnd3 by 
siRNA resulted in a significant increase in apoptosis and a reduction in protein levels of the 
pro-survival targets p21, JNK, p38 and cyclin D1, as well as an increase in reactive oxygen 
species levels.  The authors suggested that Rnd3 is a pro-survival factor acting upstream of 
p21, JNK, p38 and cyclin D1. Through the use of siRNA to p53, the authors showed that 
Rnd3 functions independently of its known associates, p53 and ROCK I.  The authors noted 
that targeted expression of Rnd3 in the epidermis of mice resulted in a significant reduction 
of the number of apoptotic cells following UVB irradiation.  The authors stated that Rnd3 
induction counteracts UVB-induced apoptosis and may serve as a novel target for the 
prevention of UVB-induced photodamage regardless of p53 status. 
 Rnd3 has also been shown to participate in the stimulation of the inflammatory 
response induced by ethanol in astrocytes (257).  Expression of exogenous Rnd3 in 
astrocytes resulted in a disruption of the actin cytoskeleton and a decrease in the protein 
levels of RhoA and Rac1, along with a decrease in the phosphorylation of the RhoA/ROCK 
downstream target MLC phosphatase.  The authors also showed that treatment of astrocytes 
with ethanol resulted in an increase in endogenous Rnd3 protein levels.  Overexpression of 
Rnd3 in astrocytes also resulted in stimulation of the inflammatory response as seen by 
induction of the IRAK/ERK/NF-kappaB pathway and COX-2 expression.  The authors 
showed that treatment of astrocytes resulted in the induction of the IRAK/ERK/NF-kappaB 
pathway and COX-2 expression, which coincided with increased Rnd3 protein expression.  
The authors stated that the above results strongly support the conclusion that Rnd3 has a role 
in the stimulation of the inflammatory pathway induced by alcohol. 
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 One report has given evidence that Rnd3 is a key regulator of apical junction 
dynamics (303).  In this report, the authors showed that, in rat mammary epithelial tumor 
cells, exogenously expressed Rnd3 colocalized with actin at cell periphery and induced the 
localization of the adherens junction protein β-catenin and the tight junction protein ZO-1 to 
sites of cell-cell contact. Tight junctions regulate the diffusion of solutes on the basis of size 
and charge through a paracellular pathway and restrict the lateral diffusion of lipids and 
membrane proteins between the apical and basolateral regions (304, 305). Adherens 
junctions are responsible for intercellular adhesion between neighboring cells (306).  
Furthermore, this expression of Rnd3 led to the formation of highly sealed tight junctions. 
Also, the authors showed that expression of Rnd3 was able to rescue the disruptive effects of 
constitutively active RhoA on apical junction organization.  The authors suggested that the 
antagonism between RhoA and Rnd3 in mammary epithelial tumor cells plays a fundamental 
role in controlling apical junction architecture and the formation of tight junctions. 
 
     Rnd proteins and cancer 
 There is strong evidence that Rnd3 is dysregulated in human cancer, especially when 
the Raf pathway is activated.  For example, increased Rnd3 expression has been found in 
pancreatic tumors (307), colon cancer cell lines (308) and melanomas (309, 310).  Recently, 
using immunochemistry on tissue microarrays from 115 patients with non-small cell lung 
cancer, it was shown that patients with Rnd3-negative tumors had a substantially longer 
cancer-related survival than did patients with Rnd3-positive tumors (311).  Rnd3 expression 
in prostate cancer is controversial. One report, using immunoblot analysis, showed that Rnd3 
protein expression was seen in benign prostate cancer cells, but not in cancer cells, with a 
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similar distribution of both mRNA and protein in patient tissues (302).  However, another 
report has shown that levels of Rnd3 expression are far higher in prostate cancer cell lines 
with high metastatic potential compared with those of low metastatic potential (312).  
Perhaps, prostate cancer progression requires initially low levels of Rnd3 for increased 
proliferation and then high levels of Rnd3 for increased metastatic invasiveness.  
There are also conflicting results regarding Ras transformation and Rnd3.  One group 
has shown that Rnd3 negatively regulates Ras- and Raf-induced fibroblast transformation. 
Yet, others have shown that Rnd3 acts in concert with Raf (250) and Ras (Singh et al., 
unpublished).  Perhaps, like many signaling pathways, Rnd3 is regulated in a tissue-specific 
manner, to signal to different effectors and perform different tasks. Similarly, the stage of the 
tumor may influence whether Rnd3 is up- or downregulated.  Currently there is insufficient 
information to determine whether this is the case.  
 In contrast to Rnd3, there is currently little information regarding Rnd1 and Rnd2 in 
human cancer.  The gene encoding Rnd2 is the centromeric neighbor of the breast/ovarian 
cancer susceptibility gene encoding BRCA1, although in the opposite orientation; however, 
there is currently no information available regarding Rnd2 and breast and ovarian cancers. 
In cancers, chronic upregulation of Rnd3 may serve to selectively regulate its 
downstream targets.  In normal cells, however, the activity of Rnd3 must be tightly regulated.  
I have hypothesized that Rnd3 activity is regulated by PKC-mediated phosphorylation, and 
this work is discussed in detail in Chapter 2.  Below I set forth my rationale for this 
hypothesis. 
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Dynamic membrane association by an electrostatic switch 
 Numerous examples exist in the literature in which phosphorylation of membrane-
associated proteins results in loss of affinity for membranes.  One example is ARNO, a GEF 
for the Arf family of small GTPases (313). Binding of ARNO to the plasma membrane is 
mediated by dual action of its pleckstrin homology (PH) domain, which binds to 
phosphoinositides, and its polybasic domain, which interacts with acidic membrane 
phospholipids (314, 315).  ARNO is phosphorylated on serine 392 located within its C-
terminal polybasic region (316).  Introduction of a negative charge to this region reduces 
interaction of ARNO with the plasma membrane and has the functional consequence of 
inhibiting guanine nucleotide exchange.  This phosphorylation-mediated regulation of 
nucleotide exchange is the result of a process termed a “PH domain-electrostatic switch” 
(317).   
The regulation of ARNO by the PH domain-electrostatic switch is analogous to the 
regulation of the MARCKS (myristoylated alanine-rich C kinase substrate) protein by a 
“myristoyl-electrostatic switch”.  MARCKS association with the plasma membrane requires 
a myristoyl fatty acid moiety as well as electrostatic interaction of its basic effector domain 
with acidic phospholipids (318).  Phosphorylation of serines in the basic effector domain of 
MARCKS neutralizes its electrostatic interaction with the plasma membrane and causes its 
displacement from the plasma membrane (319).   
 K-Ras4B was shown to be a substrate for PKC phosphorylation in its C-terminal 
polybasic region (320), and our lab has shown recently, in collaboration with Mark Philips 
and colleagues, that this phosphorylation influences both its subcellular localization and 
function (321).  It has been postulated that the C-terminal phosphorylation combines with the 
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C-terminal farnesyl isoprenoid modification to create a “farnesyl-phosphate switch” to 
regulate K-Ras4B membrane association and function.  Previous studies have demonstrated 
that proper K-Ras4B membrane interactions require both hydrophobic interaction of the 
farnesyl group with the lipid bilayer and electrostatic interaction of the polybasic region with 
acidic phospholipids (136, 138). 
 
C-terminal phosphorylation of Ras-related proteins and regulation of function 
  In addition to regulation by GDP/GTP cycling, there is growing evidence for 
regulation of GTPase function via stimulus-mediated posttranslational modifications.  
Several members of the Ras and Rho family of small GTPases have been shown to be 
substrates for phosphorylation at their C-terminal regions immediately upstream of the 
CAAX-containing membrane targeting motif (Figure 1.13).  Furthermore, these 
phosphorylation events have been shown to have functional consequences.  Rap1 was 
documented to be phosphorylated on serine 180, close to its C-terminus, by protein kinase A 
(PKA).  This phosphorylation was shown to regulate its subcellular localization and 
association with effector molecules (322-324).  Furthermore, RhoA was also documented to 
be phosphorylated close to its C-terminus on serine 188 by PKA (325).  This phosphorylation 
event was shown to negatively regulate RhoA activity by translocation away from 
membranes, through enhanced interaction with RhoGDI (282, 326). Recently, it was shown 
that nerve growth factor (NGF) elicits PKA-dependent phosphorylation on serine 188 in 
PC12 neuronal cells (327). This phosphorylation event renders RhoA unable to bind to 
ROCK, which interacts with the C-terminus of RhoA.  The authors suggested that 
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Protein Phosph. site Sequence (human) Kinase 
K-Ras4B Serine 181 KKKKKKSKTK-----CVIM PKC 
Rap1-A Serine 180 KKPKKKS--------CLLL PKA 
RhoA Serine 188 RRGKKKSG-------CLVL PKA 
RalA Serine 194 KKKKRKSLAKRIRERCCIL Aurora-A 
Rnd3 Serine 240 RKDKAKS--------CTVM ROCK, PKC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: C-terminal phosphorylation of small GTPases. Several small GTPases 
have been shown to be phosphorylated in their C-terminal region located within the 
polybasic region, just upstream of the CAAX motif. These phosphorylation events have 
been shown to have biological consequences and are believed to reduce the affinity of the 
proteins for the plasma membrane.  
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phosphorylation at serine 188 “may serve as a novel secondary switch of RhoA, capable of 
overriding GTP-binding-elicited effector activation to a subset of effector targets” (327).   
As mentioned above, our group has recently shown that the previously appreciated 
phosphorylation of K-Ras4B (320) is directed by protein kinase C (PKC) at the C-terminal 
serine 181 (321).  This phosphorylation event causes K-Ras4B to translocate from the plasma 
membrane to the mitochondria, resulting in enhanced apoptosis. Additionally, our group 
along with Chris Counter and colleagues has determined that Aurora-A kinase-mediated 
phosphorylation of the Ras-related small GTPase RalA (328) leads to loss of RalA plasma 
membrane localization and translocation to the cytosol and internal membranes (Lim et al., 
under revision). 
 I hypothesize that stimulus-mediated phosphorylation of Ras-related small GTPases 
may be a more common mode of regulation, distinct from GDP/GTP cycling, than has been 
appreciated.  Rnd3 contains a putative PKC site at its extreme C-terminus at serine 240, and 
may therefore be regulated in a manner similar to those documented above for other Ras-
related small GTPases (Figure 1.14).  What effect PKC-mediated phosphorylation at serine 
240 has on Rnd3 localization, and hence its function, has been a major area of my 
dissertation research and will be discussed further in detail in Chapter 2 below. 
 
The protein kinase C (PKC) family of serine/threonine kinases 
 The PKC family of serine/threonine kinases is divided into three classes, grouped 
together on the basis of their sequence homology and modes of action (329) (Figure 1.15).  
Members of the conventional class of PKCs (α, βI, βII and γ) are Ca2+-dependent and are 
activated by both phosphatidylserine (PS) and diacylglycerol (DAG).  Members of the novel 
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Figure 1.14: The proposed Rnd3 electrostatic switch. Rnd3 is associated with the 
plasma membrane due to hydrophobic interaction with the lipid bilayer and electrostatic 
interaction of the polybasic region with acidic phospholipids. Introduction of negative 
charges by phosphorylation reduces interaction of Rnd3 with the plasma membrane and 
causes its displacement from the plasma membrane. 
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Conventional PKCs Novel PKCs Atypical PKCs 
α, βI, βII, γ δ, ε, η, θ δ, ι, λ 
Ca2+-dependent Ca2+-independent Ca2+-independent 
Activated by PS and 
DAG 
Activated by PS and DAG Activated by PS, but not 
DAG 
 
 
 
Figure 1.15: The PKC family of serine/threonine kinases. The PKC family of kinases 
is divided into three groups: conventional, novel and atypical. This grouping is based upon 
their sequence homology and modes of activation: PS is phosphatidylserine and DAG is 
diacylglycerol. 
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class of PKCs (δ, ε, η and θ) are Ca2+-independent but are still activated by both PS and 
DAG.  The atypical class of PKCs (ζ, ι and λ) is both Ca2+- and DAG-independent.  PKC is 
thought to reside in the cytosol in an inactive conformation and to translocate to the plasma 
membrane upon activation, where it regulates numerous cellular functions through its 
phosphorylation of target substrates (330, 331).  Through the use of specific PKC inhibitors 
and genetically ablated mouse embryo fibroblasts, I have implicated PKCα, a conventional 
PKC, in the phosphorylation of Rnd3. I show, in Chapter 2 below, that PKCα-mediated 
phosphorylation of Rnd3 has an effect on Rnd3 localization and hence, on its function.  I also 
demonstrate, in Chapter 3, that Rnd3 is subject to post-prenyl processing by Rce1 and Icmt, 
and that these post-translational modifications also regulate Rnd3 activity.  Together, my 
dissertation research presents evidence for novel regulatory mechanisms for this atypical and 
interesting small GTPase of the Rho family.  
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CHAPTER 2 
REGULATION OF RND3 LOCALIZATION AND FUNCTION BY 
PKCα-MEDIATED PHOSHORYLATION 
 
Abstract 
 The Rnd proteins (Rnd1, Rnd2 and Rnd3/RhoE) form a distinct branch of the Rho family 
of small GTPases. Rnd3 decreases RhoA activity and regulates cytoskeletal organization and 
cell cycle progression. Since Rnd3 is a constitutively-activated GTPase, how Rnd3 itself is 
regulated to cause these changes is still under investigation. I have shown that, upon PKC 
agonist stimulation, Rnd3 undergoes an electrophoretic mobility shift and becomes 
metabolically labeled with 32P, and its subcellular localization becomes enriched at internal 
membranes. These changes are blocked by inhibition of conventional, but not novel, PKC 
isoforms and do not occur in PKCα-null cells or with a nonphosphorylatable mutant Rnd3. I 
provide evidence that integrin engagement regulates downstream signaling functions of Rnd3 
by inducing PKCα-mediated phosphorylation.  This results in increased downstream 
signaling to Rho-ROCK pathway targets such as cofilin and myosin light chain (MLC).  
Thus, integrin engagement is a physiological regulator of Rnd3 posttranslational 
modification by PKCα, and this modification in turn is a mediator of Rnd3 subcellular 
  
localization and downstream signaling. These results add a new mechanism of Rnd3 
regulation, and clarify how Rnd3 modulates Rho signaling to alter cytoskeletal organization. 
 
Introduction 
 Members of the Rho family of small GTPases are involved in the regulation of cell 
growth and survival as well as organization of the actin cytoskeleton to control cell shape and 
cell motility (5, 59, 332).  These proteins act as molecular switches by cycling between an 
inactive GDP bound form and an active GTP bound form, the latter of which is then able to 
interact preferentially with effector molecules (1).  This molecular switching is regulated by 
two classes of regulatory proteins: guanine nucleotide exchange factors (GEFs), that 
accelerates the intrinsic GDP-GTP exchange activity to favor formation of the active GTP-
bound protein (81, 83), and GTPase activating proteins (GAPs), that inactivate G-proteins by 
enhancing their intrinsic GTPase activity to increase GTP hydrolysis and formation of the 
inactive GDP-bound form (87, 88).  The most thoroughly characterized proteins of this 
family of small GTPases are RhoA, Rac1 and Cdc42 (4, 9, 10).  Activation of RhoA leads to 
formation of stress fibers and focal adhesions (70), while activation of Rac1 and Cdc42 lead 
to the formation of lamellipodia and filopodia, respectively (71, 72).   
 The Rnd family of proteins (Rnd1, Rnd2 and Rnd3/RhoE, also known as Rho6, Rho7 and 
Rho8, respectively) form a unique branch of the Rho family (12).  One striking difference 
between Rnd proteins and other members of the Rho family is their effect on the actin 
cytoskeleton.  In contrast to RhoA, which upregulates stress fibers and focal adhesions in 
both epithelial cells and fibroblasts, expression of either Rnd1 or Rnd3 causes a decrease in 
stress fibers and the disappearance of focal adhesions, leading to cell rounding (hence “Rnd” 
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for rounding) (15, 243).  Recently, multiple mechanisms by which Rnd proteins counteract 
the effects of RhoA have been brought to light.  First, Rnd proteins were found to bind and 
activate p190RhoGAP, increasing its GAP activity toward GTP-bound RhoA.  Expression of 
Rnd3 led to reduced cellular levels of GTP-bound RhoA by a p190RhoGAP-dependent 
mechanism (13).  Second, Rnd3 was shown to bind directly to the RhoA effector ROCK1.  
Overexpression of Rnd3 inhibited ROCK1-induced stress fiber formation and 
phosphorylation of the ROCK1 target myosin light chain phosphatase (MLC-P) (14).  Thus, 
Rnd proteins antagonize the effects of RhoA by multiple mechanisms. 
 Another striking difference from most other members of the Rho family is that Rnd 
proteins lack intrinsic GTPase activity (15) and their activity is not controlled by GEFs or 
GAPs.  Because they are GTPase-deficient, Rnd proteins are bound to GTP in vivo and are 
constitutively in an “active” state (16) due to sequence divergence at highly conserved 
positions critical for normal GTP hydrolysis (15, 16).  These results suggest that the activity 
of Rnd proteins is regulated not by GTP/GDP cycling, but at the level of expression and/or 
by post-translational modifications.  Indeed, Rnd3 protein expression is induced upon growth 
factor addition (14), stress signaling (254, 256) and upon transformation by active Ras or Raf 
(250) and (Singh et al., unpublished).  Rnd3 expression is also deregulated in human cancers 
(302, 307, 310-312).  These changes in protein levels are mediated largely at the level of 
transcription, but may also be mediated at the level of translation or protein stability (255).  
 A majority of Ras and Rho family GTPases, including Rnd proteins, terminate in C-
terminal CAAX tetrapeptide motifs (where C = cysteine, A = aliphatic residue and X = any 
amino acid) (95).  The CAAX motif is a crucial signal needed for these proteins to be post-
translationally modified by isoprenylation, proteolytic removal of the AAX residues, and 
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carboxylmethylation of the prenylated cysteine. The CAAX-signaled modifications are 
necessary but not sufficient for the correct subcellular localization, membrane association 
and biological activity of Rho GTPases (97, 333, 334). Additional C-terminal sequence 
elements, palmitoylated cysteines or polybasic residues, are also required to serve as a 
second subcellular targeting signal (136). Rnd3 terminates in a methionine in the “X” 
position and is thus farnesylated like Ras family proteins (16).  Farnesylation of Rnd3 is 
required for membrane localization and for its ability to alter the cytoskeleton (Singh et al., 
unpublished data). 
 In addition to regulation by GDP/GTP cycling, there is growing evidence for 
posttranslational modification of Ras family GTPase function upon stimulus-mediated 
phosphorylation.  Several small GTPases of the Ras and Rho families have been shown to be 
substrates for phosphorylation on serine residues at their C-terminal regions immediately 
upstream of the CAAX motif, and these phosphorylation events have been demonstrated to 
have functional consequences.  Phosphorylation of Rap1 by protein kinase A (PKA) on 
S180, close to its C-terminus, has been shown to regulate its subcellular localization and its 
association with other proteins (322-324).  Also, phosphorylation of RhoA by PKA on S188 
close to its C-terminus has been shown to negatively regulate its activity by translocating 
RhoA from membranes, through enhanced interaction of RhoA with Rho-GDI (282, 325).  
Furthermore, we have shown recently that the previously appreciated phosphorylation of K-
Ras4B (320) is directed by protein kinase C (PKC) at S181 of the C-terminus (321).  This 
phosphorylation causes K-Ras4B to translocate from the plasma membrane to the 
mitochondria, resulting in the biological consequence of enhanced apoptosis (321).  We 
reasoned that the location and function of Rnd proteins might also be regulated in a similar 
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manner by phosphorylation of a C-terminal serine residue (Figure 1.14).  Studies undertaken 
to explore the role of phosphorylation in the regulation of localization, and hence function, 
are described in this chapter. 
 
Materials and Methods 
Antibodies and reagents 
 Anti-hemagglutinin (HA) (HA.11 clone 16B12) and -Myc (clone 9E10) antibodies 
were from Covance. Antibodies directed against β-actin (clone AC-74) and the FLAG 
epitope (M2), and the PKC agonist phorbol myristic acid (PMA), were from Sigma. Anti-
green fluorescent protein (GFP) antibody (clone 3E6) was from Molecular Probes. Anti-
PKCα antibody (clone 3) was from BD Biosciences. Anti-Rnd3 mouse monoclonal antibody 
(clone 4) was from Upstate Biotechnologies-Millipore. A rabbit polyclonal antibody directed 
against the N-terminus of Rnd3 has been described previously (250) and was kindly provided 
by Steen Hansen.  Antibodies directed against total cofilin, phospho-cofilin (Ser 3), total 
MLC2, phospho-MLC2 (Ser 19), phospho-MARCKS (Ser152/156) and phospho-(Ser) PKC 
substrate were all from Cell Signaling Technology. Ionomycin and Y-27632 were from 
Calbiochem. Bryostatin-1, Gö-6976 and Rottlerin were from BIOMOL Research 
Laboratories.  Calf intestinal phosphatase (CIP) was from New England Biolabs. 
 
Molecular constructs 
 Mammalian expression constructs encoding HA-Rnd3 and GFP-Rnd3 were generated 
by inserting the full length human Rnd3 cDNA into the BamHI sites of pCGN-hygro (335) 
and pEGFP-C1 (Clontech), respectively.  Site-directed mutagenesis to produce cDNA 
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sequences encoding the Rnd3-S240A, Rnd3-S240E, Rnd3-S7,11A and Rnd3-S7,11,240A 
mutant proteins was performed using the QuickChange Mutagenesis Kit (Stratagene), 
according to the manufacturer's instructions.  Full length wild type and kinase-deficient 
(K368R) rat PKCα cDNAs (a generous gift from William Davis, University of North 
Carolina at Chapel Hill [UNC-CH]) were PCR-amplified and inserted into the XhoI and 
HindIII sites of both pEGFP-C1 and pCMV-3b, to generate GFP-PKCα and Myc-PKCα 
expression constructs, respectively. The FLAG-Rnd3 expression construct was generated by 
inserting full length human wild type Rnd3 cDNA into the EcoRI and XhoI sites of pHIT-
FLAG3 (a generous gift from Yanping Zhang, UNC-CH). Generation of FLAG-Rnd3-S7A, 
S11A, S210A, T214A, S218A, S222A, S240A (a seven amino acid, phosphodeficient Rnd3; 
henceforth termed “Rnd3-All A”) has been described previously (266).  To generate the 
GFP-Rnd3-All A expression construct, the open reading frame from FLAG-Rnd3-All A was 
PCR amplified using a 5’ primer containing a HindIII site and a 3’ primer containing a SalI 
site. The PCR product was cut with HindIII and SalI restriction enzymes and ligated into the 
HindIII and SalI sites of pEGFP-C3. The tandem affinity purification (TAP) expression 
constructs were generated by inserting a DNA cassette encoding two protein-A modules, a 
tobacco etch virus (TEV) protease cleavage site and a FLAG tag in-frame into the BamHI 
and EcoRI sites of the plasmid pcDNA3.1(+) (Invitrogen) to produce a new vector termed 
pTAP-Go. A stop codon was inserted after the FLAG tag to produce pTAP-Stop. pTAP-
Rnd3 was produced by inserting human Rnd3 cDNA into the EcoRI and XhoI sites in-frame 
behind the TAP tag cassette found in pTAP-Go.  All sequences were verified by the Genome 
Analysis Facility at UNC-CH. 
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Cell culture and transfections 
 NIH 3T3 mouse fibroblasts were maintained in high glucose Dulbecco’s modified 
Eagle medium (DMEM-H) (GIBCO-Invitrogen) containing 10% calf serum (Invitrogen) and 
penicillin-streptomycin (P/S, Invitrogen) at 37°C in a humidified atmosphere of 10% CO2.  
Isolation of PKCα +/+ and -/- mouse embryonic fibroblasts has been described previously 
(336).  These cells were cultured in DMEM-H without sodium pyruvate (Sigma) containing 
10% fetal calf serum (FCS), glutamine and P/S (Invitrogen), and maintained at 37°C in a 
humidified atmosphere of 5% CO2.  HEK-293 cells were cultured in DMEM-H media 
containing 10% FCS and P/S, and maintained at 37°C in a humidified atmosphere of 5% 
CO2. Expression vectors were transfected into NIH 3T3 and HEK-293 cells using TransIT-
LT1 transfection reagent (Mirus) according to the manufacturer’s instructions.  Expression 
vectors were transfected into PKCα mouse embryo fibroblast cells using Lipofectamine and 
Plus reagents (Invitrogen) according to the manufacturer’s instructions. 
 
Calf intestinal phosphatase treatment assay 
 Equal amounts of lysate (devoid of phosphatase inhibitors) from NIH 3T3 cells 
expressing HA-Rnd3 (treated with or without 100 nM PMA for 10 min) were incubated in 
phosphatase buffer (100 mM NaCl, Tris-HCl pH 7.9, 10 mM MgCl2 and 1 mM DTT) with or 
without  20 units of calf intestinal phosphatase at 37° C for 1 h. Lysates were resolved on 
12% SDS-PAGE, transferred to Immobilon PVDF (Millipore) and immunoblotted with anti-
HA antibody. 
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Fibronectin engagement assay 
 FN (20 µg/ml) was immobilized onto tissue culture dishes in PBS overnight at 4°C.  
Dishes were then rinsed twice with PBS and blocked with 0.5% delipidated bovine serum 
albumin (BSA) (Sigma) in DMEM for 1 h at 37°C. NIH 3T3 cells were serum-starved in 
DMEM containing 0.5% delipidated BSA for 6 h. Cells were then trypsinized with trypsin-
EDTA (Cellgro) and neutralized in an equal amount of Trypsin Neutralizing Solution 
(Cambrex Bio Science). Cells were centrifuged, then resuspended in DMEM containing 
0.5% delipidated BSA and kept in suspension on tissue culture plates coated with 1% agarose 
for 1 h at 37°C. After 1 h in suspension, cells were plated onto FN-coated tissue culture 
dishes for various times, onto plastic for 2 h, or kept in suspension for an additional 2 h 
before being lysed. Cell lysate proteins were precipitated in 12.5% trichloroacetic acid 
(TCA), washed twice with ice-cold acetone, dried and resuspended in Laemmli sample 
buffer. Samples were resolved on 12% SDS-PAGE, transferred to Immobilon PVDF 
(Millipore) and immunoblotted with appropriate antibodies. 
 
Live cell imaging 
 To visualize the effects of PKC activation on Rnd3 localization in real time, NIH 3T3 
cells were transiently transfected with GFP-Rnd3. After 24 h, cells were treated with either 
bryostatin-1 (100 nM) or PMA (100 nM) and ionomycin (500 µg/ml).  Live cell images were 
captured on a Zeiss 510 LSM confocal microscope at 20X magnification and analyzed using 
LSM 5 Image browser software (Zeiss).  To evaluate a role for different PKC isoforms in 
modulating Rnd3 localization, NIH 3T3 cells were transiently transfected with an expression 
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vector encoding GFP-Rnd3 as described above.  After 24 h, cells were incubated with either 
DMSO vehicle or the PKC inhibitors Gö-6976 (2.5 µM) or Rottlerin (10 µM).  After 3 h, 
cells were treated with PKC agonists PMA (100 nM) and ionomycin (500 µg/mL), and live 
cell images were captured by confocal microscopy at five min intervals as described above. 
 
Western blot analysis 
 Cells were washed with PBS, lysed in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate and supplemented with 
Complete Protease Inhibitor Cocktail tablets (Roche) along with phenyl-methyl sulfonyl 
fluoride (PMSF) and sodium pervanadate) and centrifuged to remove insoluble material.  2X 
Laemmli sample buffer was added to equivalent amounts of cellular lysates which were then 
resolved on 12% SDS-PAGE and transferred to Immobilon PVDF membranes.  Membranes 
were blocked in 5% nonfat dry milk in TBS-Tween-20 and probed with appropriate primary 
antibodies, followed by anti-mouse or -rabbit IgG-horseradish peroxidase (HRP)-conjugated 
secondary antibody (Amersham Biosciences).  Membranes were then incubated in 
SuperSignal West Dura Extended Duration substrate (Pierce) and the signal developed on 
HyBlot CL autoradiography film (Denville Scientific Inc.). 
 
Results 
 Rnd3 subcellular localization is altered upon PKC activation. Our inspection of Rnd 
protein sequences revealed a consensus PKC site at serine 240 in the C-terminal 
hypervariable membrane targeting domain immediately upstream of the CAAX prenylation 
motif, similar to the arrangement seen in the C-terminus of K-Ras4B  (Figure 2.1).  We 
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Figure 2.1: Amino acid sequence alignment of the C-terminal hypervariable 
membrane targeting regions of Ras superfamily small GTPases. Rnd proteins 
contain a conserved potentially phosphorylatable serine residue immediately upstream 
of the CAAX motif. 
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reasoned that the subcellular localization of Rnd3, like that of K-Ras4B, Rap1 and RhoA, 
might also be regulated by a combination of prenylation and C-terminal phosphorylation.  
We therefore used PKC agonists to test the effects of PKC activation on Rnd3 subcellular 
localization.  To visualize these effects in living cells, we treated NIH 3T3 mouse fibroblast 
cells, transiently expressing GFP-tagged Rnd3, with the non-phorbol, PKC-specific agonist 
bryostatin-1.   Live cell images were taken before and 10 min after treatment.  As shown in 
Figure 2.2A, treatment with bryostatin-1 caused rapid loss of Rnd3 from the plasma 
membrane and enrichment in cytosol and internal membranes.  To determine whether this 
response was unique to bryostatin-1 or a reproducible consequence of activating PKC, we 
also treated cells with PMA and ionomycin.  PMA is a phorbol ester that specifically 
activates PKC, whereas ionomycin is a calcium ionophore that acts as a mobile ion carrier 
and activates the conventional forms of PKC by raising the intracellular levels of Ca2+.  NIH 
3T3 cells expressing GFP-Rnd3 were treated with PMA + ionomycin, and live cell images 
were taken at 5-min increments.  As shown in Figure 2.2B, concurrent treatment with PMA 
and ionomycin, like bryostatin-1, also caused loss of Rnd3 from the plasma membrane and 
enrichment at cytosol and internal membranes.  The change in Rnd3 subcellular localization 
after treatment with distinct types of PKC agonists indicates that PKC activity is inversely 
correlated with Rnd3 plasma membrane binding. 
 The PKC family of serine/threonine kinases is divided into three classes, grouped 
together on the basis of their sequence homology and modes of activation (329). Most PKC 
family members are thought to reside in the cytosol in an inactive conformation and to 
translocate to the plasma membrane upon activation, where they regulate numerous cellular 
functions through phosphorylation of target substrates (330, 331).  To begin to elucidate the 
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Figure 2.2: Activation of conventional, but not novel, PKCs causes Rnd3 
translocation from the plasma membrane. A, PKC agonist bryostatin-1 causes loss of 
Rnd3 from the plasma membrane.  NIH 3T3 cells transiently expressing GFP-Rnd3 
were treated with bryostatin-1 (100 nM).  Representative live images of two individual 
cells before (left panel) and 10 min after (right panel) addition of agonist are shown. B, 
Activation of PKC by using PMA + ionomycin also causes loss of Rnd3 from the 
plasma membrane. NIH 3T3 cells transiently expressing GFP-Rnd3 were treated with 
PMA (100 nM) + ionomycin (500 µg/ml).  Live images are shown of a single cell 
visualized at 5 min increments. C, Inhibitor of conventional, but not novel, PKCs blocks 
Rnd3 translocation.  NIH 3T3 cells transiently expressing GFP-Rnd3 were treated with 
DMSO vehicle, Gö-6976 (2.5 µM) to inhibit conventional PKCs, or Rottlerin (10 µM) 
to inhibit novel PKCδ, for 3 h prior to stimulation with PMA + ionomycin. Live images 
are shown of single cells visualized at 5 min increments.  All images shown are 
representative of at least three independent experiments in which at least 50 cells were 
visualized. 
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identity of the specific PKC family member(s) responsible for the change in Rnd3 subcellular 
localization after stimulation with broad-based PKC activators, we employed the use of 
class-specific PKC inhibitors.  First, we used Gö6976, an indocarbazole compound that has 
been shown to discriminate clearly between conventional and novel PKCs, selectively 
inhibiting conventional but not novel PKCs (337).  In addition, we used Rottlerin, a naturally 
derived product that selectively inhibits the novel PKC isoform PKCδ (338).  NIH 3T3 cells 
expressing GFP-Rnd3 as above were treated with either Gö6976, Rottlerin or DMSO vehicle 
alone for 3 h prior to stimulation with PMA + ionomycin.  As shown in Figure 2.2C, the 
conventional PKC inhibitor Gö6976 but not the PKCδ-specific inhibitor Rottlerin or vehicle 
control blocked alterations in Rnd3 localization.  This result indicates that at least one 
conventional PKC isoform is involved in the regulation of the subcellular location of Rnd3.  
Because NIH 3T3 cells express only the alpha isoform of conventional PKCs (339), it is 
likely that PKCα is the major isoform responsible for the effects seen on Rnd3 in these cells. 
 
 Rnd3 is phosphorylated upon PKC activation. To evaluate the possible direct 
involvement of Rnd3 phosphorylation in modulating its location, we wished to determine 
whether Rnd3 itself becomes phosphorylated upon activation of PKC.  NIH 3T3 cells 
transiently expressing HA-tagged Rnd3 were treated with PKC agonists as in Figure 2.2C.  
Cell lysates were collected, resolved on SDS-PAGE and immunoblotted with anti-HA 
antibody.  As shown in Figure 2.3A, a slightly slower migrating band consistent with post-
translationally modified HA-Rnd3 appeared in lysates of cells stimulated with PMA + 
ionomycin, but not with DMSO vehicle.  This result is consistent with phosphorylation of 
Rnd3 upon PKC activation.  Furthermore, Gö6976, but not Rottlerin, blocked this mobility 
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Figure 2.3: Activation of conventional, but not novel, PKCs causes phosphorylation-
dependent mobility shift of Rnd3 and incorporation of labeled phosphate. A, NIH 3T3 
cells transiently expressing HA-Rnd3 were treated with PKC agonist and inhibitors as 
indicated.  Cell lysates were resolved on SDS-PAGE and immunoblotted with anti-HA 
antibody.  The slower migrating Rnd3 band is seen only in PKC agonist-stimulated cell 
lysates and is blocked by the PKC inhibitor Gö-6976. B, Pretreatment with the ROCK 
inhibitor, Y-27632, does not prevent the electrophoretic mobility shift of Rnd3.  NIH 3T3 
cells expressing HA-Rnd3 were pretreated for 3 h with either DMSO vehicle, Y-27632 (10 
µM ) or Gö-6976 (2.5 µM). Cells were then treated with PMA for 10 min as above, and cell 
lysates were resolved on SDS-PAGE. C, Calf intestinal phosphatase (CIP) treatment causes 
disappearance of the slower migrating band of Rnd3.  NIH 3T3 cells transiently expressing 
HA-Rnd3 expression vector were treated with PMA + ionomycin.  CIP was added to the cell 
lysate to reverse phosphorylation. Cell lysates were resolved on SDS-PAGE and 
immunoblotted with anti-HA antibody. D, Inducible but not basal Rnd3 phosphorylation is 
sensitive to inhibition of conventional PKCs.  NIH 3T3 cells transiently expressing HA-Rnd3 
were serum starved for 12 h, then cultured in phosphate-free media and metabolically labeled 
with 32P-orthophosphate prior to treatment with PMA and/or Gö-6976.  Anti-HA-
immunoprecipitated proteins were resolved on SDS-PAGE and developed by 
autoradiography. Small portions of the immunoprecipitates were run on a duplicate gel, 
transferred to membrane and probed with anti-HA antibody to confirm equal amounts of 
immunoprecipitated proteins. 
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shift, suggesting that it is mediated by a conventional PKC.  Recently, our collaborator, Anne 
Ridley, showed that Rnd3 is subject to ROCK-mediated phosphorylation (266). ROCK and 
PKCs share a common phosphorylation recognition sequence (340) and results from recent 
publications have demonstrated that the two families of kinases directly phosphorylate 
identical residues found on a number of protein substrates (341). We therefore investigated 
whether ROCK-mediated Rnd3 phosphorylation was stimulated by treatment with PMA.  As 
seen in Figure 2.3B (lane 2), pretreatment of NIH 3T3 cells with the ROCK-specific inhibitor 
Y-27632 failed to prevent a mobility shift of HA-tagged Rnd3 when cells were treated with 
PMA.  Once again, pretreatment with the conventional PKC inhibitor Gö6976 prevented the 
mobility shift of HA-tagged Rnd3 normally seen upon PMA treatment (lane 3). The results 
seen in Figure 2.3B suggest that the effects seen on Rnd3 when cells are treated with PMA 
(plasma membrane translocation and gel mobility shift) are due specifically to activation of 
PKC and not ROCK.   
 Next, to confirm that the slower migrating band represents a phosphorylation event, 
we treated cells with a PKC agonist followed by calf intestinal phosphatase (CIP) and 
immunoblotted with anti-HA antibody as before.  CIP treatment (Figure 2.3C, lane 3) 
abrogated the appearance of the slower migrating band present in the cells treated with PKC 
agonist alone (Figure 2.3C, lane 2).  Lastly, NIH 3T3 cells transiently expressing HA-Rnd3 
were metabolically labeled with 32P-orthophosphate and treated with PMA or DMSO vehicle. 
HA-tagged Rnd3 was then immunoprecipitated and resolved by SDS-PAGE. To confirm that 
equal amounts of HA-Rnd3 were present regardless of treatment, small portions of the HA 
immunoprecipitations were run on a separate gel and immunoblotted with anti-HA antibody.  
As shown in Figure 2.3D, the shifted form of HA-Rnd3 seen in the agonist-treated cells (lane 
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2) incorporated the radioactive phosphate label, indicating that the shifted form represents 
phosphorylated protein.  Furthermore, pre-treatment with the conventional PKC inhibitor 
Gö6976 blocked the appearance of the radioactively labeled, slower migrating band (lane 3). 
Interestingly, Rnd3 is also basally phosphorylated, as shown by the incorporation of 32P into 
the lower band regardless of PKC activation status. Taken together, these results are 
consistent with inducible phosphorylation of Rnd3 by activation of a conventional PKC. 
 
 Mutation of Rnd3 C-terminal S240 alone does not alter cell morphology, Rnd3 PKC 
sensitivity or Rnd3 localization. We had identified serine 240, just upstream of the CAAX 
motif, as a potential PKC phosphorylation site similar to those found in some other small 
GTPases that regulate their localization and function.  To determine if phosphorylation of 
serine 240 is required for Rnd3 function, we used site-directed mutagenesis to mutate the 
serine to a nonphosphorylatable alanine residue, thereby generating a putatively phospho-
deficient Rnd3 protein, termed S240A.  After sequence confirmation, we transiently 
expressed both GFP-Rnd3-WT and GFP-Rnd3S240A in NIH 3T3 cells (Figure 2.4A). As 
anticipated, cells expressing empty GFP vector were flat and well spread, whereas cells 
expressing GFP-Rnd3-WT were rounded.  Most of the GFP-Rnd3 was located at the plasma 
membrane, with additional cytosolic and perinuclear staining observed (Figure 2.4A).  
Surprisingly, the morphology of cells expressing either the putatively phospho-deficient 
S240A mutant or the phospho-mimetic S240E was indistinguishable from that of cells 
expressing GFP-Rnd3-WT, and GFP-Rnd3-S240A and GFP-Rnd3-S240E were localized 
similarly to that of GFP-Rnd3-WT (Figure 2.4A).  In addition, staining with Texas Red 
phalloidin revealed no change in stress fibers in cells expressing the three different Rnd3 
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 Figure 2.4: Phosphorylatable serine at residue 240 is not required for effects of 
PKC activation on Rnd3. A, Similar morphology of cells expressing GFP-Rnd3-WT, 
GFP-Rnd3-S240A and GFP-Rnd3-S240E. NIH 3T3 cells were transiently transfected 
with either GFP-vector, GFP-Rnd3-WT, GFP-Rnd3-S240A or GFP-Rnd3-S240E 
expression constructs. B, The phosphodeficient S240A mutant still displays a mobility 
shift.  NIH 3T3 cells transiently expressing HA-Rnd3 proteins were treated with PMA 
for 10 min.  Cell lysates were resolved on SDS-PAGE and immunoblotted with anti-HA 
antibody. 
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proteins (data not shown).  These surprising results indicate that phosphorylation of S240 is 
not required for the ability of Rnd3 to cause cytoskeletal changes and cell rounding, and 
suggests that at least one other site in Rnd3 is also targeted by PKC.  
 To determine whether the S240A mutation rendered Rnd3 PKC-insensitive, we evaluated 
whether it retained or lost the PKC-induced mobility shift on SDS-PAGE.  Contrary to our 
initial hypothesis, but consistent with the cell morphology data, both the WT and the S240A 
mutant forms of Rnd3 displayed the same mobility on SDS-PAGE in the absence or presence 
of PKC activation (Figure 2.4B).  Taken together, we concluded that phosphorylation of 
Rnd3 at serine 240 alone is not sufficient to regulate Rnd3 subcellular localization or to 
produce the mobility-shifted form of Rnd3. 
 
 Additional sites of PKC-mediated phosphorylation in Rnd3. In optimizing the SDS-
PAGE gel mobility-shift experiments using HA-tagged Rnd3, we employed a rabbit 
polyclonal antibody produced against the N-terminus of Rnd3 (250). Surprisingly, this 
antibody did not detect the mobility shift of HA-Rnd3 in lysates from NIH 3T3 cells that had 
been treated with PMA. Yet, this shift was seen reproducibly when immunoblotting with 
either an antibody directed against the HA epitope tag or a mouse monoclonal antibody 
directed against the entire Rnd3/RhoE protein (Figure 2.5A).  We therefore postulated that 
the site or sites of phosphorylation responsible for the shifted form of Rnd3 must be located 
in the first 15 amino acids that were used in producing the Rnd3 polyclonal antibody.  Visual 
inspection of the Rnd3 sequence, and the phosphorylation prediction program NetPhos 2.0 
(342), revealed two additional consensus PKC phosphorylation sites at serines 7 and 11. 
Together with the previous data demonstrating a correlation between alteration of Rnd3 
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Figure 2.5: Multiple residues of Rnd3 are involved in its PKC-dependent translocation 
and electrophoretic mobility shift. A, An N-terminal peptide polyclonal antibody (aa 1-15) 
does not recognize the mobility-shifted form of Rnd3.  NIH 3T3 cells transiently expressing 
HA-Rnd3 or empty vector were treated with either DMSO vehicle or PMA for 10 min +/- 
CIP treatment.  Cell lysates were resolved on SDS-PAGE and immunoblotted initially with 
anti-HA antibody.  The blot was then stripped and blotted sequentially with a specific anti-
Rnd3/RhoE antibody and anti-Rnd3 antiserum. B, GFP-Rnd3 multiple phosphorylation 
mutants still translocate from the plasma membrane after PKC activation. NIH 3T3 cells 
were transiently transfected with either GFP-Rnd3-WT or GFP-Rnd3 phosphorylation 
mutants and treated with either vehicle or PMA for the indicated times.  Live images were 
taken on a confocal microscope. C, GFP-Rnd3-WT, but not GFP-Rnd3-All A, translocate 
from the plasma membrane after PKC activation. NIH 3T3 cells were transiently transfected 
with either GFP-vector, GFP-Rnd3-WT or GFP-Rnd3-All A. Cells were treated with either 
vehicle or PMA for 10 min. Live cell images were taken on a confocal microscope. PMA 
treatment caused loss of GFP-WT-Rnd3 from the plasma membrane along with a 
corresponding flattened phenotype. A similar event was not seen in GFP-Rnd3-All A 
expressing cells. D, FLAG-Rnd3-WT, but not FLAG-Rnd3-All-A, displays an 
electrophoretic mobility shift after PKC activation. NIH 3T3 cells were transiently 
transfected with either FLAG-Rnd3-WT or FLAG-Rnd3-All-A and treated with either 
vehicle or PMA for 10 min. Lysates were resolved on SDS-PAGE and blotted with anti-
FLAG antibody to visualize FLAG-tagged Rnd3 protein. 
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subcellular localization and the presence of a mobility-shifted form of Rnd3 on SDS-PAGE, 
we hypothesized that phosphorylation of Rnd3 within this unique N-terminal extension, 
which would introduce negative charges, could be responsible for the effects on Rnd3 seen 
after treatment with PKC agonist.  We reasoned that phosphorylation of Rnd3 at serines 7 
and 11 in the N-terminal extension, with or without phosphorylation at serine 240, may 
disrupt the polar interactions of Rnd3 with the plasma membrane.  Site-directed mutagenesis 
was then used to generate GFP-tagged versions of Rnd3 that contained alanine substitutions 
at serines 7 and 11 along with serine 240, and these mutant GFP-Rnd3 constructs were 
expressed transiently in NIH 3T3 cells.  However, as with GFP-Rnd3-S240A, the subcellular 
localization of both the double and triple serine mutants, GFP-Rnd3-S7,11A and GFP-Rnd3-
S7,11,240A were also altered indistinguishably from that of GFP-Rnd3-WT after treatment 
with PMA (Figure 2.5B).   
 Possible explanations for the lack of effect of the triple mutant S7A, S11A, S240A is that 
phosphorylation at one or more other site(s) is the primary target of PKC or that Rnd3 can be 
phosphorylated on additional sites when the preffered sites are absent.  To explore this 
possibility, numerous serine residues and a threonine (S7, S11, S210, T214, S220, S222 and 
S240) in Rnd3 were mutated to the corresponding phospho-deficient alanines to generate a 
nonphosphorylatable form of Rnd3 (Rnd3-All A).  This nonphosphorylatable mutant was 
used in a PMA treatment translocation assay.  As seen in Figure 2.5C, stimulation of NIH 
3T3 cells with PMA caused the loss of GFP-tagged Rnd3 WT from the plasma membrane.   
Consistent with a requirement for Rnd3 to become phosphorylated in order for it to 
translocate upon PKC activation, PMA stimulation did not cause the loss of the 
nonphosphorylatable “All A” mutant Rnd3 from the plasma membrane.  Furthermore, a 
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FLAG-tagged version of Rnd3-All A did not display a gel mobility shift when expressed in 
NIH 3T3 cells stimulated with PMA, as was seen with FLAG-Rnd3-WT (Figure 2.5D). 
Thus, while further work will be needed to identify the minimal number of PKC 
phosphorylation sites needed for membrane translocation, both the mobility shift and the 
translocation seen upon PKC activation require that Rnd3 itself be able to become 
phosphorylated. 
 
 PKCα is the isoform responsible for Rnd3 phosphorylation. While the specific target 
residue(s) have not yet been determined, the exact identity of the PKC isoform(s) responsible 
for the phosphorylation and altered localization of Rnd3 upon PKC activation also remained 
to be uncovered.  Based on the PKC inhibitor data shown previously (Figures 2.2C, 2.3A and 
2.3B) and the fact that NIH 3T3 cells express only the alpha isoform of conventional PKCs 
(339), we hypothesized that PKCα was the isoform involved.   Therefore, we performed 
additional studies in mouse embryo fibroblasts (MEFs) in which PKCα had been genetically 
ablated (336).  Cell lysates from PKCα -/- and matched control WT MEFs were separated on 
SDS-PAGE and immunoblotted with an isoform-specific anti-PKCα antibody.  As shown in 
Figure 2.6A, PKCα protein was undetectable in the -/- MEFs whereas it was easily 
detectable in the wild type matched control MEFs.  We then tested whether PKCα is required 
for the electrophoretic mobility shift of Rnd3 seen upon stimulation with PKC agonists.  
PKCα -/- MEFs and WT control cells transiently expressing HA-Rnd3 were treated with the 
PKC agonist PMA.  Lysates from these cells were resolved on SDS-PAGE and 
immunoblotted with anti-HA antibody.  As shown in Figure 2.6B, the slower migrating band 
of Rnd3 was seen only in the WT MEF cells and not in the PKCα -/- MEF cells, 
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Figure 2.6: PKCα is the PKC isozyme responsible for Rnd3 phosphorylation. A, PKCα 
null MEF cells do not express any detectable PKCα protein. Cell lysates from PKCα -/- 
MEFs and matched WT control MEFs were separated by SDS-PAGE and probed with an 
anti-PKCα antibody. B, PMA stimulation causes a gel mobility-shift of Rnd3 in WT but not 
in matched PKCα null MEFs.  Cells transiently expressing HA-Rnd3 were treated with PKC 
agonist PMA for 10 min. Cell lysates were resolved on SDS-PAGE and blotted with anti-HA 
antibody. C, Reintroduction of PKCα-WT, but not of dominant negative (DN) PKCα-DN, 
into PKCα null MEFS causes a mobility shift of Rnd3 when cells are treated with PKC 
agonist PMA. Cells transiently expressing HA-Rnd3 along with either pCMV-vector, Myc-
PKCα-WT or Myc-PKCα-DN were treated with PKC agonist PMA for 10 min. Cell lysates 
were resolved on SDS-PAGE and probed with anti-HA antibody. D, Rnd3 and PKCα 
interact in vivo. HEK 293 cells, stably expressing either empty pTAP2 vector only or Rnd3 
fused to the TAP tag, were transiently transfected with a GFP-PKCα expression construct 
and were treated with PMA for 10 min. Lysates from these cells were immunoprecipitated 
with FLAG antibody.   Immunoprecipitates, along with cell lysate inputs, were resolved on 
SDS-PAGE and probed with anti-GFP and anti-FLAG antibodies (* = IgG heavy chain). E, 
PMA stimulation causes loss of GFP-Rnd3 from the plasma membrane in  matched WT 
control MEFs, but not in PKCα -/- MEFs. Cells transiently expressing either GFP vector 
only or GFP-Rnd3 were treated with PKC agonist PMA for 10 min. Images were taken 
before and after PMA treatment. 
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demonstrating that the PKCα isoform is required for the mobility-shifted form that we 
confirmed previously to represent PKC-mediated phosphorylated Rnd3.  To confirm that the 
kinase activity of PKCα is required for its effects on Rnd3 phosphorylation, we reintroduced 
either WT or kinase-deficient (KD) PKCα into PKCα -/- MEFs and looked for restoration of 
the appearance of the slower migrating form.  The K368R PKCα mutant is considered 
kinase-deficient as it abolishes ATP binding ability (343). PKCα -/- MEFs, transiently 
expressing HA-Rnd3 along with either empty Myc-vector only, Myc-PKCα-WT or Myc-
PKCα-KD were treated with the PKC agonist PMA, and cell lysates were resolved on SDS-
PAGE and immunoblotted with anti-HA antibody.  As shown in Figure 2.6C, an 
electrophoretic mobility shift of HA-Rnd3 was seen only upon reintroduction of PKCα-WT 
but not kinase-deficient PKCα.  Thus, the kinase activity of PKCα is required for Rnd3 
phosphorylation. 
  
 Rnd3 and PKCα physically interact. We next investigated the possibility of a direct 
physical interaction between Rnd3 and PKCα in vivo.  To this end, HEK-293 cells stably 
expressing either Rnd3 fused to a tandem affinity purification (TAP) tag (pTAP-Rnd3) or the 
pTAP2 tag-only empty vector negative control (pTAP-Stop) were transfected along with a 
GFP-PKCα expression construct. The TAP tag used in this experiment employs two Protein-
A modules fused in frame upstream of a FLAG tag (see Materials and Methods). Cells were 
stimulated with PMA, lysates were collected and TAP-tagged Rnd3 was immunoprecipitated 
using FLAG antibody and then resolved on SDS-PAGE.  As seen in Figure 2.6D, GFP-
tagged PKCα was co-immunoprecipitated in lysates where TAP-tagged Rnd3 was expressed 
and not in the TAP-tag only control lysates. GFP-PKCα did not co-immunoprecipitate with 
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TAP-Rnd3 in the absence of the PKC agonist PMA (data not shown). The data in Figure 
2.6D thus point to a direct interaction of Rnd3 with PKCα in cells that have been stimulated 
to activate PKCα, and further bolster the results of previous experiments where both the 
PMA-mediated translocation and electrophoretic mobility shift of Rnd3 were abrogated by 
the presence of the conventional PKC inhibitor Gö6976 (Figures 2.2C, 2.3A and 2.3B). 
 
 Rnd3 does not translocate from the plasma membrane in PKCα null MEFs after 
PKC activation. Next, we transiently expressed GFP vector only and GFP-Rnd3 in both 
PKCα -/- and matched control WT MEFs. Cells were treated with the PKC agonist PMA and 
images were taken before and after treatment. As seen in Figure 2.6E, PMA treatment has no 
effect on the cellular localization of GFP alone in either PKCα -/- or the matched control WT 
MEFs. However, PMA treatment in WT MEFs caused the loss of GFP-Rnd3 from the plasma 
membrane. In contrast, PMA treatment did not cause the loss of GFP-Rnd3 from the plasma 
membrane in PKCα -/- MEFs.  Thus, the data presented (the use of a specific conventional 
PKC inhibitor and PKCα -/- MEFs, along with the direct interaction between Rnd3 and 
PKCα) suggests that PKCα is the isoform responsible for Rnd3 phosphorylation. 
 
      Fibronectin engagement results in PKCα-mediated phosphorylation of Rnd3. We 
speculated that physiologically important pathways involving both alterations in cytoskeletal 
organization and activation of PKCα may lead to phosphorylation of Rnd3.  PKCα was one 
of the first signaling molecules detected within focal adhesions (344), and evidence now 
suggests that integrins and the transmembrane heparan sulphate proteoglycan syndecan-4 can 
act cooperatively to activate PKCα, to then generate the adhesion-mediated signals necessary 
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for the assembly of stress fibers and focal adhesions (345).  Consistent with this, 
pharmacological inhibitors of PKCα and transient expression of DN PKCα suppress focal 
adhesion formation and cell migration mediated by α5β1 integrins in cells plated on FN 
(346).  In addition, the RhoA-selective activator p115RhoGEF is a substrate for and is 
stimulated by PKCα (347).  Finally, RhoGDI is a direct phosphorylation target of PKCα, 
leading to disruption of RhoGDI-RhoA binding, increased RhoA membrane association, and 
upregulation of RhoA signaling (348).  Taken together, we envisioned a model in which 
inhibiting restraints placed on RhoA by Rnd3 could be eliminated by FN engagement-
mediated phosphorylation and cytoplasmic sequestration of Rnd3 by PKCα.  In this scenario, 
outlined in the model presented in Figure 2.7, Rnd3 is a key mediator of this cascade.  
 We therefore investigated the effects of fibronectin engagement on cell spreading and 
PKCα-mediated phosphorylation of Rnd3.  To this end, NIH 3T3 cells were serum-starved 
for 6 h in culture medium containing 0.5% delipidated-BSA, to avoid signals from normal 
serum lipids such as lysophosphatidic acid (LPA) that are known to stimulate Rho activity.  
After serum starvation, cells were kept in suspension for 1 h and then either plated on FN-
coated tissue culture plates for various times or kept in suspension for a further 2 h, as 
decribed in Experimental Procedures.  Serum-starved cells attached and spread within 20 min 
when plated on FN, but attached poorly and did not spread even at 120 min when plated on 
plastic (Figure 2.8A).  
 We then investigated whether FN engagement-mediated activation of PKCα leads to 
phosphorylation of Rnd3. Lysates from cells transiently expressing FLAG-Rnd3, treated as 
indicated above, were probed with anti-FLAG antibody to confirm that equal amounts of 
FLAG-Rnd3 protein were present in each sample.  Surprisingly, despite the unequivocal 
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Figure 2.7: Model: Cellular engagement of fibronectin causes activation of PKCα 
through α5β1 integrin – syndecan-4 and leads to signaling through the Rho-ROCK 
pathway. 
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 Figure 2.8: Fibronectin engagement results in PKCα-mediated phosphorylation of 
Rnd3. A, Serum-starved cells attached and spread within 20 min when plated on FN, 
but attached poorly and did not spread even at 120 min when plated on plastic. NIH 3T3 
cells were serum-starved in 0.5% delipidated BSA and plated on FN for various times, 
held in suspension or plated on plastic, as decribed in Materials and Methods, then 
visualized by using a light microscope.  B, Fibronectin engagement leads to increased 
phosphorylation of exogenous FLAG-tagged Rnd3.  Cells transiently expressing FLAG-
Rnd3 were treated as above. Cell lysates were separated by SDS-PAGE and probed with 
anti-FLAG antibody to detect the presence of exogenous Rnd3 protein. The blot was 
then stripped and re-probed with an anti-phospho-serine PKC substrate antibody. 
Lysates were also probed with anti-P-MARCKS antibody to detect PKCα-dependent 
phosphorylation, and with anti-P-cofilin and anti-P-MLC antibodies to detect activity of 
the Rho-ROCK signaling pathway. 
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activation of PKCα as shown by increased levels of phosphorylated MARCKS protein, no 
electrophoretic mobility shift of Rnd3 was seen in lysates from cells plated on FN.  
Phosphorylation of MARCKS (myristoylated alanine-rich C kinase substrate) is a reliable 
marker for activation of PKCα (349-352).  We then considered the possibility that activation 
of PKC upon integrin engagement might produce a weaker signal than that produced upon 
stimulation with the PKC agonists bryostatin-1 or PMA, the latter of which could lead to 
phosphorylation of additional sites responsible for the mobility-shifted form of Rnd3.  We 
therefore probed the same blot with an antibody that specifically detects phosphorylated 
serines in PKC substrate proteins (353).  Using this antibody, phosphorylated FLAG-Rnd3 
protein was easily detectable in cells plated on FN, but not in cells kept in suspension (Figure 
2.8B).  Thus, FN engagement leads to phosphorylation of FLAG-Rnd3, which coincides with 
phosphorylation of MARCKS protein.   
 Further, under the same conditions, engagement of FN led to an increase in phospho-
cofilin and phospho-MLC.  Phosphorylation of the actin-severing protein cofilin is a readout 
for the activity of ROCK, an immediate downstream effector of RhoA (207, 208), 
specifically when α5β1 integrins are engaged with the ECM protein fibronectin (354). MLC, 
which is a downstream target of the Rho-ROCK signaling pathway (via LIM kinase) 
involved in actomyosin contractility (184, 203, 204), is also phosphorylated in response to 
plating of cells onto FN (269).  Our results are therefore consistent with the model proposed 
in Figure 2.7 in which FN engagement signals through a linear pathway of PKCα to Rnd3, 
leading to its translocation from the plasma membrane and thus preventing disruption of 
signals from the Rho-ROCK pathway leading to changes in the actin cytoskeleton. 
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 PKCα-dependent Rnd3 phosphorylation downregulates Rnd3 inhibitory activity 
and leads to increased signaling through the Rho-ROCK pathway.  As mentioned earlier, 
Rnd3 exerts its biological activity at least in part by counteracting the effects of RhoA 
signaling.  Because our model predicts that PKC-mediated phosphorylation decreases Rnd3 
activity, we investigated whether Rnd3 phosphorylation leads to an increase in signaling 
through the Rho-ROCK pathway.  To this end, NIH 3T3 cells were transiently transfected 
with either GFP only, GFP-Rnd3-WT or GFP-Rnd3-All A expression constructs.  
Transfected cells were treated with either DMSO vehicle or PMA and then fixed and stained 
with Rhodamine-conjugated phalloidin to mark actin.  As seen in Figure 2.9A, PMA 
treatment caused not only translocation of GFP-Rnd3-WT from the plasma membrane but 
also the restoration of stress fibers, along with greater spreading and a flattened appearance 
of the cells.  None of these changes were seen when cells were treated with only DMSO 
vehicle.  In direct opposition to the results seen with GFP-Rnd-WT, PMA treatment had no 
effect on the plasma membrane localization of the PKC-insensitive mutant GFP-Rnd3-All A; 
stress fibers were not restored, and the cells did not flatten and spread. Thus, phosphorylation 
of Rnd3 is required for the reappearance of stress fibers upon PMA treatment, and the non-
phosphorylated All A mutant can act as a dominant negative to overcome the ability of 
endogenous Rnd3 to restore stress fibers. 
 To uncover a possible molecular mechanism for the restoration of stress fibers and cell 
spreading in PMA-treated cells expressing Rnd3-WT but not Rnd3-All A, lysates from 
PMA-treated cells were resolved on SDS-PAGE and immunoblotted for phospho-MLC. As 
seen in Figure 2.9B, in Rnd3-WT expressing cells, the levels of phospho-MLC were higher 
after treatment with PMA, as compared to treatment with DMSO vehicle only.  In contrast, 
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Figure 2.9: PKCα-dependent Rnd3 phosphorylation downregulates Rnd3 inhibitory 
activity and leads to increased signaling through the Rho-ROCK pathway. A, Treatment 
with PMA causes re-formation of stress fibers in GFP-Rnd3-WT but not in GFP-Rnd3-All 
A-expressing cells. NIH 3T3 cells were transiently transfected with either GFP-vector, GFP-
Rnd3-WT or the nonphosphorylatable GFP-Rnd3-All A mutant and then treated with either 
DMSO vehicle or PMA for 10 min.  Live images were taken on a confocal microscope.  
Actin structures were visualized with Texas Red-phalloidin. B, PKCα-dependent 
phosphorylation leads to increased signaling through the Rho-ROCK pathway. Cells were 
transfected and treated as above. Lysates were separated by SDS-PAGE and probed with 
anti-GFP-antibody to visualize equal expression of the GFP-fusion proteins. Additionally, 
lysates were probed with anti-P-MLC antibody to detect signaling from the Rho-ROCK 
pathway. 
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Rnd3-All A effectively acted as a dominant negative in this pathway, abrogating the ability 
of PKC activation to increase phospho-MLC.  The data are thus consistent with a model in 
which Rnd3 located at the plasma membrane is able to disrupt signals from the Rho-ROCK 
pathway that are involved in stress fiber formation/maintenance.  We envision that, when 
Rnd3 becomes phosphorylated after PKC activation (PMA treatment, FN engagement) and is 
translocated from the plasma membrane, it is no longer able to disrupt the Rho-ROCK 
signaling pathway.  The Rnd3-All A mutant, which is no longer subject to PKC-mediated 
phosphorylation, is still located on the plasma membrane, even after PKC activation. Hence, 
in Rnd3-All A expressing cells, signals coming from the Rho-ROCK pathway at the plasma 
membrane can still be disrupted by this PKC-insensitive mutant Rnd3. These results 
demonstrate that PKCα phosphorylation of Rnd3 represents an important negative feedback 
loop that may be critical to restoration of signaling through Rho-ROCK following transient 
activity of the GTPase-insensitive Rho family protein Rnd3. 
 
Discussion 
 It has long been appreciated that Rnd3/RhoE is constitutively GTP-bound (16), and 
therefore that its activity must be regulated by means other than GTP-GDP cycling.  Rnd3 
protein expression is known to be tightly regulated and responsive to both internal and 
external cues.  Although Rnd3 protein is found in low abundance at steady state, its mRNA is 
ubiquitously expressed (15).  Previous studies have shown that Ras or Raf activation caused 
upregulated Rnd3 gene and protein expression in MDCK and other epithelial cells (250) 
(Singh et al., unpublished data). Also, platelet-derived growth factor (PDGF) stimulation of 
Swiss 3T3 fibroblasts caused cell rounding and branching, which coincided with 
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upregulation of Rnd3 protein expression (255).  Recently, our collaborators found that Rnd3 
gene transcription was also associated with ERK MAPK activation in melanomas (310).  
However, modulation of expression is a relatively slow process compared to many signaling 
activities mediated by small GTPases. Rapid modulation of Rnd3 activity by other means 
might be required to regulate dynamic signaling processes.  We recently showed that 
Rnd3/RhoE is a direct target of the serine/threonine kinase ROCK, altering Rnd3 protein 
degradation (266).  Here we have presented evidence that post-translational regulation of 
Rnd3 activity can also be accomplished via differential subcellular localization due to PKCα-
mediated phosphorylation.  Our results thus add an additional mechanism of regulation to 
those documented previously, and clarify how Rnd3 modulates Rho signaling to alter 
cytoskeletal organization. 
 Several closely related proteins have been shown previously to be substrates for 
phosphorylation by PKC.  In particular, K-Ras4B was shown to be a substrate for PKC 
phosphorylation in its C-terminal polybasic region (320, 355, 356), and we have shown 
recently that this phosphorylation influences both its subcellular localization and its function, 
in part by altering effector interactions due to this differential localization (321). We 
reasoned that Rnd3, which is also a farnesylated protein with a polybasic domain, might be 
regulated in a manner similar to that of K-Ras4B. 
  Our inspection of the Rnd3 amino acid sequence revealed a potential PKC 
phosphorylation site at residue S240, just upstream of the CAAX motif in the C-terminal 
hypervariable membrane-targeting domain.  Here we demonstrate that Rnd3 is 
phosphorylated upon PKC activation, and that inhibition of conventional PKC isoforms 
abrogates this phosphorylation.  However, we have determined that phosphorylation at S240 
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was not solely responsible for the effects seen on Rnd3 due to PKC activation. Rather, 
multiple additional residues may be necessary.  
 Both Rnd3 and Rnd1 can induce inhibition of actin stress fibers and focal adhesions upon 
transfection into fibroblasts (15). Both of these Rnd proteins contain an extra N-terminal 
extension that is not found in other Rho proteins, including in Rnd2, which does not induce 
disruption of actin stress fibers.  Furthermore, these extensions are needed for proper plasma 
membrane localization and function (15). When the first 6 amino acids were deleted from 
Rnd1, this N-terminal truncation mutant failed to localize correctly and was unable to block 
stress fiber formation (15). Whether Rnd1 is also a target of PKC-mediated phosphorylation 
is presently unknown.  Similarly to the effects of Rnd1 N-terminal truncation, the original 
clone of Rnd3, which was missing the first 15 N-terminal residues, also lacked the ability to 
down regulate stress fibers (16).  It could be envisioned that phosphorylation of residues 
located in both the N- and C-terminal extensions would reduce plasma membrane affinity.  
Further, when the crystal structure of Rnd3 was solved, only the core GTP-binding domain 
was amenable to crystallization, as the N- and C-terminal extensions were subject to 
proteolysis (244, 245).  These N- and C-terminal extensions are highly disorganized and 
attempts have been made unsuccessfully to plot their possible structure by current protein 
structure computer programs.  Thus, although it seems likely that these extensions are 
involved in Rnd3 membrane interactions, structural information on these extensions is 
lacking. Therefore, it is currently impossible to predict potential effects of phosphorylation of 
these residues on Rnd3 secondary structure that may influence such interactions.  
The exact phosphorylation sites contained within these extensions necessary for loss of 
Rnd3 from the plasma membrane and translocation to the cytosol still remain to be 
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deciphered.  We concluded that phosphorylation of Rnd3 at serine 240 alone is not sufficient 
to regulate Rnd3 subcellular localization or to produce the mobility-shifted form of Rnd3.  
Our preliminary mutagenesis analyses of other candidate phosphorylation sites suggests that 
multiple PKC sites are likely to be involved. 
We have also shown in this report that the phosphorylation state of Rnd3 has direct 
consequences on its cellular location, with phosphorylation causing loss of plasma membrane 
localization and translocation to the cytosol.  We have also determined that Aurora-A-
mediated phosphorylation of the small GTPase RalA (328) leads to loss of plasma membrane 
localization and translocation to the cytosol (Lim et al., under revision). Previous studies on 
the localization and functional consequences of PKA-mediated phosphorylation of Rap and 
RhoA (324, 326, 357), as well as our lab’s recent observations on PKC-mediated 
phosphorylation of K-Ras4B (321), indicate that these posttranslational modifications are 
important modulators of both localization and biological function.  Taken together, we 
suggest that stimulus-mediated phosphorylation of Ras family small GTPases may be a more 
common mechanism of their regulation, distinct from GTP/GDP cycling, than has been 
appreciated.  Indeed, as similar results have been documented for the ARF nucleotide 
exchange factor ARNO (314, 316, 317), even GTP/GDP cycling itself may be regulated in a 
similar manner under some circumstances. 
 After demonstrating, through several lines of evidence, that the conventional PKC 
responsible for Rnd3 phosphorylation is PKCα, we sought out an extracellular stimulus-
mediated mechanism of PKCα activation and regulation of Rnd3 (358). Our observations 
support a mechanism wherein fibronectin-mediated integrin activation, of PKCα results in 
PKCα-mediated phosphorylation of Rnd3. Initial studies in fibroblasts revealed that 
106
  
engagement of the α5β1 integrin by the cell-binding domain of fibronectin (FN) was 
insufficient for cells to form focal adhesions (359).  It was later discovered that an additional 
interaction composed of the heparin sulfate proteoglycan syndecan-4 binding to the heparin-
binding domain of FN was necessary to trigger focal adhesion formation (360).  However, 
this requirement could be bypassed by activation of PKCα (361), demonstrating not only that 
PKCα is present in focal adhesions, but that its activity contributes to their formation.  In a 
series of studies by Oh, Couchman and colleagues, it was revealed that a ternary complex is 
formed, at sites of focal adhesion assembly, consisting of the cytoplasmic domain of 
syndecan-4 interacting with the catalytic subunit of PKCα in combination with PIP2 to yield 
a sustained, higher level of PKCα activity (362-364).  Use of pharmacological inhibitors of 
PKCα and transient expression of dominant negative PKCα suppressed focal adhesion 
formation and cell migration mediated by α5β1 integrins in melanoma cells, which also 
express syndecan-4, when plated on FN (346). It has also been shown that PKCα can be 
activated in cells by adhesion to FN (352). Previous studies have shown that RhoA is 
activated in cells when plated on FN (269) and that syndecan-4 acts cooperatively with 
integrins in a Rho-dependent fashion in the assembly of focal adhesions and actin stress 
fibers (345), although the mechanism was not delineated. We have presented evidence here 
that PKCα-mediated phosphorylation of Rnd3 leads to increased signaling through the Rho-
ROCK signaling pathway.  
 We suggest that phosphorylation of Rnd3 leads to relocalization away from plasma 
membrane sites where it can antagonize signaling from the Rho-ROCK pathway, thus 
leading to remodeling of the actin cytoskeleton. Such a model would be consistent with a 
study from Larsson and colleagues, who demonstrated that the Rnd3 target p190RhoGAP 
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was present in membrane ruffles and neurite outgrowths, where it was modulated by, but did 
not interact directly with, the epsilon isoform of PKC (365).  During the course of our 
studies, Couchman and colleagues described observations that further support our model 
(366). They described a mechanism where cell attachment on FN through syndecan-4 led to 
PKCα-dependent activation of Rho for the formation and maintenance of stress fibers. We 
offer here compelling evidence that Rnd3 may represent an important link directly 
connecting PKCα with the Rho-ROCK pathway and the myriad of cell responses they 
control through cytoskeletal organization via actomyosin contractility.  Determining exactly 
how PKCα-mediated alterations in Rnd3 localization affect its ability to modulate Rho-
ROCK will likely require a fuller characterization of Rnd3-interacting proteins. 
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CHAPTER 3 
ROLE OF POST-PRENYL PROCESSING IN 
RND3 LOCALIZATION AND FUNCTION 
(Some material appearing in Roberts, PJ et al., 2008, JBC) 
 
Abstract 
 The Rho GTPases comprise a major branch of the Ras superfamily of small GTPases. 
Studies have demonstrated that distinct functions of the different Rho GTPases are dependent 
upon proper subcellular localization to diverse compartments where they are able to interact 
with discrete upstream regulators and downstream effectors. These studies have 
demonstrated that proper subcellular localization, and hence biological activity, is dependent 
upon a series of post-translational modifications governed by the C-terminal CAAX motif. 
These modifications involve prenylation of the CAAX motif followed by two post-prenyl 
processing steps.  A recent study (94) found that, unlike farnesylated members of the Ras 
GTPases, the geranylgeranylated classical members of the Rho GTPases are not dependent 
upon post-prenyl processing for proper membrane association and hence biological activity. 
Rnd3/RhoE, a member of the Rnd subfamily of Rho GTPase, is subject to prenylation by a 
farnesyl isoprenoid.  Hence, studies were undertaken to determine if Rnd3 is dependent upon 
post-prenyl processing for proper membrane association and biological function.  Specific 
  
structural mutations in the CAAX motif of Rnd3, along with the use of mouse embryonic 
fibroblasts genetically ablated for each of the two enzymes involved in post-prenyl 
processing, allowed us to determine that post-prenyl processing is necessary for proper 
membrane localization of Rnd3 and its biological function in stress fiber disassembly. 
 
Introduction 
 The Rho family of small GTPases represents a major branch of the Ras superfamily of 
small GTPases (4, 5, 19, 59).  These proteins act as molecular switches by cycling between 
an inactive GDP-bound form and an active GTP-bound form, the latter of which is then able 
to interact preferentially with effector molecules (1).  This molecular switching is made 
possible by two classes of enzymes: guanine nucleotide exchange factors (GEFs), which 
activate G-proteins by catalyzing GDP-GTP exchange (81, 83), and GTPase activating 
proteins (GAPs), that inactivate G-proteins by hydrolyzing GTP to GDP (87, 88).  The most 
thoroughly characterized members of this family are RhoA, Rac1 and Cdc42 (4, 9, 10).  A 
major function of the Rho proteins is their regulation of the actin cytoskeleton (332, 367).  
Activation of Rho leads to stress fiber and focal adhesion formation (70), while activation of 
Rac1 and Cdc42 lead to lamellipodia and filopodia formation, respectively (71, 72). In 
addition to their effects on actin cytoskeleton organization, Rho proteins are involved in 
many critical processes necessary for numerous signal transduction pathways as well as 
transcriptional regulation and growth control (5).  
 Essentially all members of the Rho family, along with the Ras family, terminate in a 
CA1A2X motif (where C=cysteine, A=aliphatic residue and X=any amino acid) (95).  This 
motif is a crucial signal needed for these proteins to be post-translationally modified by 
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prenylation, a permanent post-translational modification required for correct subcellular 
localization and for biological activity (97).  Proper localization of prenylated, membrane 
associated proteins relies on an ordered cascade of enzymatic reactions (116).  The first 
reaction in this enzymatic cascade is stimulated by either of two cytosolic prenyl transferase 
enzymes: farnesyl transferase (FTase) or geranylgeranyl tranferase I (GGTase I) (98).  The 
“X” in the CAAX motif determines the prenylation specificity of that protein (99, 100, 102, 
103).  A large number of Rho proteins terminate in X = L and are therefore substrates for 
GGTase I, which adds a C20 geranylgeranyl isoprenoid group to the cysteine of the CAAX 
motif, while Ras proteins (X = S or M) are substrates for FTase, which adds a C15 farnesyl 
isoprenoid group (95). 
 Prenylation by either a C15 farnesyl or C20 geranylgeranyl isoprenoid group is not 
sufficient to complete the CAAX-signaled modifications; two further processing steps, 
termed post-prenyl processing, are needed (116, 117).  The first step involves the proteolytic 
cleavage of the –AAX residues from the prenylated cysteine by an endoplasmic reticulum 
(ER)-localized protease termed Ras converting enzyme 1 (Rce1).  The second step involves 
the methylation of the now-terminal prenylated cysteine residue catalyzed by another ER-
localized enzyme termed Isoprenylcysteine carboxyl methyltransferase (Icmt).  It is crucial to 
note that prenylation is an obligate prior step for both Rce1 and Icmt.  The end result of this 
enzymatic cascade, involving both prenylation and post-prenyl processing, is thought to 
make the carboxy-terminal domain of CAAX motif-containing proteins more hydrophobic 
(121).  Furthermore, a second signal, beyond CAAX-signaled prenylation and the two post-
prenyl processing steps, is needed for proper membrane association.  This second signal is 
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either palmitoylation of one or two cysteine residues or the presence of a polybasic region in 
the hypervariable domain immediately upstream of the CAAX motif (136, 138).  
 Much of the information we have on the Rho proteins has been gleaned from studies 
involving the three classical members of this family (RhoA, Rac1 and Cdc42) (9, 10, 332).  
Recent work has revealed that other members of this family have diverse cellular functions 
beyond those of the classical Rho family members (4, 11).  It is believed that these varied 
cellular functions are made possible in part due to their localization to distinct subcellular 
compartments (94, 368).  The Rnd family of proteins (Rnd1, Rnd2 and Rnd3/RhoE) form a 
unique branch of the Rho family (12).  Unlike the other members of the Rho family that 
switch between an active and inactive state regulated by their GTP-binding status, Rnd 
proteins lack the ability to hydrolyze GTP and are resistant to GAP activity (15, 16).  They 
are predominantly found bound to GTP in vivo and are constitutively in an “active” state (16) 
due to amino acid substitutions at highly conserved positions critical for normal GTP 
hydrolysis (15, 16).  A distinctive action of the Rnd proteins is their effect on the actin 
cytoskeleton.  In contrast to RhoA, which upregulates stress fibers and focal adhesions in 
both epithelial cells and fibroblasts, ectopic expression of either Rnd1 and Rnd3 causes stress 
fiber disassembly and the disappearance of focal adhesions, leading to cell rounding (hence 
“Rnd” for round) (15, 243).  The CAAX motif of Rnd3 ends in a methionine and thus is 
predicted to be farnesylated.  In vivo, Rnd3 was indeed shown to be a substrate for 
farnesylation (16).  Furthermore, Rnd3 has been shown to be effectively mislocalized in cells 
after treatment with FTI (Singh et al., unpublished data).  Additionally, Rnd3 contains a 
polybasic region just upstream of the CAAX motif, similar to the Ras protein K-Ras4B 
(140).  Previous studies have shown that K-Ras4B activity is partially dependent upon post-
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prenyl processing (369).  Given that Rnd3 is both farnesylated and contains a polybasic 
region, this atypical Rho family small GTPase may also depend upon post-prenyl processing 
for proper membrane association and thus, for biological activity. Studies aimed at 
determining the role of post-prenyl processing in the regulation of Rnd3 localization and 
function are presented here in this chapter. 
 
Materials and Methods 
Molecular constructs 
 GFP-Rnd3 expression plasmids were generated by inserting the full length human 
Rnd3 cDNA into the BamHI site of pEGFP-C1 (Clontech).  To generate GFP-Rnd3-
(STVM), -(CTYM) and -(CTVR),  mutagenic 3’ primers were used in a PCR reaction to 
change the corresponding CAAX motif residues.  GFP-Rnd3 (WT) vector was used as the 
template in these PCR reactions.  Multiple bacterial colonies were screened and sequenced to 
confirm proper mutagenesis had occurred. The FLAG-Rnd3 WT expression construct was 
generated by inserting full length human wild type Rnd3 cDNA into the EcoRI and XhoI 
sites of pHIT-FLAG3 (a generous gift from Yanping Zhang, UNC-CH). Generation of 
FLAG-Rnd3-S7A, S11A, S210A, T214A, S218A, S222A, S240A (a seven amino acid, 
phosphodeficient Rnd3; henceforth termed “Rnd3-All A”) has been described previously 
(266) and was a generous gift from Anne Ridley (King’s College London).  To generate the 
GFP-Rnd3-All A expression construct, the open reading frame from FLAG-Rnd3-All A was 
PCR amplified using a 5’ primer containing a HindIII site and a 3’ primer containing a SalI 
site. The PCR product was cut with HindIII and SalI restriction enzymes and ligated into the 
HindIII and SalI sites of pEGFP-C3.   To generate the GFP-Rnd3-All A expression construct, 
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the open reading frame from FLAG-Rnd3-All A was inserted into the HindIII and SalI sites 
of pEGFP-C3.  To generate GFP-Rnd3-All A-(STVM) and -(CTYM), mutagenic 3’ primers 
were used in a PCR reaction to change the corresponding CAAX motif residues.  GFP-Rnd3-
All A vector was used in these PCR reactions as the template. Multiple bacterial colonies 
were screened and sequenced to confirm proper mutagenesis had occurred. All sequences 
were verified by the Genome Analysis Facility at UNC-CH. 
 
Antibodies and reagents 
 FLAG tag antibody (M2) was from Sigma. Texas Red-phalloidin was from 
Invitrogen. 
 
Cell culture 
 NIH 3T3 mouse fibroblasts were maintained in high glucose Dulbecco’s modified 
Eagle medium (DMEM-H) (GIBCO-Invitrogen) containing 10% calf serum (Invitrogen) and 
penicillin-streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 10% CO2.   
Spontaneously immortalized mouse embryo fibroblasts (MEFs) were originally prepared 
from Rce1-/- and Icmt-/- mouse embryos (133), along with control fibroblasts (Rce1+/+ and 
Icmt+/+) from littermate embryos, and were kindly provided by Stephen G. Young 
(University of California at Los Angeles).  These MEFs were maintained in DMEM-H 
(GIBCO-Invitrogen) containing 15% fetal bovine serum (FBS) along with penicillin-
streptomycin, nonessential amino acids and L-glutamine at 37°C in a humidified atmosphere 
of 5% CO2. 
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Transfections, immunofluorescence and live cell microscopy 
Expression vectors were transfected into NIH 3T3 cells using TransIT-LT1 
transfection reagent (Mirus) according to the manufacturer’s instructions.   Expression 
vectors were transfected into MEFs using Lipofectamine and Plus reagents (Invitrogen) 
according to the manufacturer’s instructions. 
 For immunofluorescence, NIH-3T3 cells were transiently transfected with GFP-
tagged Rnd3 fusion constructs. Cells were either imaged live or fixed 24 hours later with 
3.7% formaldehyde, permeabilized with Triton X-100, stained with Texas Red-phalloidin 
and mounted with Vectashield containing 4',6-diamidino-2-phenylindole (DAPI). Cells were 
visualized and imaged with a Zeiss Axioskop fluorescent microscope equipped with both 
FITC and TRITC filters. MetaMorph imaging software (Universal Imaging) was used for the 
manipulation and capture of images. Brightness and contrast of the JPEG images were 
adjusted using Adobe Photoshop software.  
 For live cell microscopy of MEFs, cells were plated, transfected with expression 
vectors for GFP-tagged proteins, and imaged in a 35-mm culture dish that was coated with 
poly-D-lysine and incorporated a No. 1.5 glass coverslip (MatTek, Ashland, MA).  Cells 
were viewed using an inverted laser scanning confocal microscope (Zeiss 510 LSM) 
equipped with an oil immersion 63X NA 1.4 objective.  Images were captured by scanning 
with the 488 nM spectral line of an argon-ion laser using the LP 505 emission filter.  
Brightness and contrast of the JPEG images were adjusted using Adobe Photoshop software. 
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Western blot analysis 
 Cells were washed with PBS, lysed in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate and supplemented with 
Complete Protease Inhibitor Cocktail tablets (Roche) along with phenyl-methyl sulfonyl 
fluoride (PMSF) and sodium pervanadate) and centrifuged to remove insoluble material. 
Laemmli sample buffer (2X) was added to equivalent volumes of cellular lysates which were 
then resolved on 12% SDS-PAGE and transferred to Immobilon PVDF membranes.  
Membranes were blocked in 5% nonfat dry milk in TBS-Tween-20 and probed with 
appropriate primary antibodies, followed by anti-mouse or -rabbit IgG-horseradish 
peroxidase (HRP)-conjugated secondary antibody (Amersham Biosciences). Membranes 
were then incubated in SuperSignal West Dura Extended Duration substrate (Pierce) and the 
signal was developed on HyBlot CL autoradiography film (Denville Scientific Inc.). 
 
Results 
 Specific CAAX motif mutations result in misprocessed Rnd3 proteins. To study 
the effect of abrogating post-prenyl processing on the localization and function of Rnd3, 
three different mutations were made in the Rnd3 CAAX motif. The first CAAX mutant 
changed the cysteine residue of the wild type CAAX motif, CVTM, to a serine residue 
(CTVM → STVM). This SAAX mutation is commonly used to generate a completely 
unprocessed protein, as the cysteine residue needed for farnesylation is lacking.  The second 
CAAX mutant made changed the X residue from a methionine to an arginine (CTVM → 
CTVR).  Farnesyltransferase does not utilize substrate proteins terminating in X = R (103); 
the specificity pockets of both FTase and GGTase discriminate against bulky amino acids 
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and arginine cannot be accommodated without disrupting the extended conformation of the 
CAAX motif.  Therefore, this mutant protein will not be farnesylated and will therefore also 
not undergo any post-prenyl processing step.  The third CAAX mutant made changed the A2 
residue from a valine to a tyrosine (CTVM → CTYM). Previous work has shown that this 
mutation in the CAAX motif of K-Ras4B results in a protein that is still farnesylated, but 
does not undergo either –AAX proteolysis or carboxy methylation (369).   
 FLAG-tagged Rnd3 CAAX motif mutants mentioned above, along with WT Rnd3, 
were transiently expressed in NIH 3T3 cells.  Cell lysates were collected, resolved on SDS-
PAGE and immunoblotted with anti-FLAG antibody. Previous studies have shown that 
unprocessed and partially-processed CAAX motif-containing proteins, including K-Ras4B, 
have slower apparent mobilities on SDS-PAGE, as compared to WT protein (369).  As seen 
in Figure 3.1, all three Rnd3 CAAX motif mutants migrated at a slower mobility on SDS-
PAGE as compared to WT Rnd3, which is indicative of improperly processed forms of Rnd3. 
 Expression of GFP-tagged versions of Rho GTPases has been used extensively to 
monitor their lipid modification status, because the localization of these proteins reflects their 
CAAX-signaled processing (65, 370-372).  GFP contains a putative nuclear localization 
signal (NLS), and expression of GFP alone results in a diffuse cytoplasmic and nuclear 
accumulation pattern (373).  Attachment of the GFP tag to either a Ras or Rho small GTPase 
sequence results in its nuclear exclusion (374), whereas complete inhibition of the lipid 
modifications of these GTPases results in a subcellular localization similar to that of GFP 
alone (65, 374). The localization of these GFP-small GTPase fusion proteins has been shown 
to reflect accurately the subcellular localization of the endogenous protein (94).  
117
 
 
 
 
 
 
 
Figure 3.1: Rnd3 CAAX motif mutants are misprocessed as compared to WT 
Rnd3. Lysates from NIH 3T3 cells transiently expressing FLAG-tagged Rnd3 CAAX 
mutants or WT Rnd3 were resolved on SDS-PAGE and blotted with anti-FLAG 
antibody. Rnd3 proteins with CAAX motif mutations run at a slower mobility as 
compared to WT Rnd3 protein, which is fully processed. 
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Therefore, to visualize whether disrupting Rnd3 post-prenyl processing also disrupted 
its subcellular localization in living cells, GFP-tagged Rnd3 CAAX mutants were expressed 
in NIH-3T3 cells, along with GFP vector only and GFP-Rnd3 WT. As seen in Figure 3.2, 
GFP-tagged Rnd3 WT was found localized on the plasma membrane and perinuclear 
structures, while GFP alone was cytosolic with nuclear accumulation.  Both the SAAX and 
the CTVR mutants displayed a localization that is very similar to GFP alone, consistent with 
the localization of completely unprocessed GTPases.  In contrast, the A2 mutant CTYM 
retained some plasma membrane localization, consistent with the prediction that this A2 
mutant is farnesylated, but neither –AAX proteolyzed nor carboxymethylated. 
Morphologically, cells expressing GFP-Rnd3 WT were rounded and poorly spread compared 
to cells expressing empty vector or to cells expressing all three Rnd3 CAAX motif mutants, 
which had the same flat and spread appearance.  These results are consistent with a 
requirement for full CAAX-signaled processing in order for Rnd3 to be able to promote 
stress fiber disassembly. 
 
 Both membrane localization and function of Rnd3 depend on Rce1- and Icmt-
mediated processing. To confirm that both post-prenyl processing steps are necessary for 
proper localization and function of Rnd3, these properties were examined in mouse 
embryonic fibroblasts (MEFs) genetically ablated for either Rce1 and Icmt (133).  First, 
FLAG-tagged Rnd3 WT was ectopically expressed in both Rce1-/- and Icmt-/- MEFs, or in 
matched control WT MEFs, and its expression was confirmed by western blotting for the 
FLAG tag.  As seen in Figure 3.3, FLAG-tagged Rnd3 expressed in either Rce1-/- or Icmt-/- 
MEFs displayed a slower electrophoretic mobility on SDS-PAGE as compared to expression 
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Figure 3.2: Misprocessing of GFP-tagged Rnd3 CAAX motif mutants results in 
Rnd3 cytosolic and nuclear accumulation. NIH 3T3 cells transiently expressing 
GFP vector only, GFP-Rnd3 WT or GFP-Rnd3 with CAAX motif mutations were 
visualized using fluorescent microscopy. Rnd3 proteins with CAAX motif mutations 
are localized to the cytosol and nucleus, similar to GFP alone. WT Rnd3 is found on 
the plasma membrane and endomembranes. 
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Figure 3.3: Rnd3 is misprocessed in both Rce1-/- and Icmt-/- MEFs. A, Lysates from 
Rce1+/+ and Rce1-/- and B, Icmt+/+ and Icmt-/- MEFS expressing FLAG-tagged Rnd3 
were resolved on SDS-PAGE and blotted with anti-FLAG antibody. FLAG-Rnd3 
protein from Rce1-/- and Icmt-/- MEF lysates runs at a slower mobility, as compared to 
the WT matched control MEFs, owing to misprocessing due to loss of –AAX 
proteolysis and prenylated terminal cysteine methylation, respectively. 
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in their matched control WT MEFs.  This indicates that lack of either Rce1 or Icmt result in a 
processing defect of Rnd3.  We next investigated whether Rnd3 is also mislocalized in these 
cells.  As seen in Figure 3.4, GFP-tagged Rnd3 was mislocalized away from the plasma 
membrane in both Rce1-/- and Icmt-/- cells, as compared to their matched control WT MEFs.  
Furthermore, the rounding phenotype seen in WT MEFs expressing GFP-tagged Rnd3 was 
lost in both Rce1-/- and Icmt-/- cells.  The rounding phenotype was only seen when GFP-
tagged Rnd3 was found on the plasma membrane, indicating that Rnd3 disruption of RhoA-
mediated stress fiber assembly requires that specific subcellular localization. 
 
 Specific CAAX motif mutations abrogate the gain-of-function phenotype of the 
All A mutant of Rnd3. As shown previously in Chapter 2, the “All A” phosphodeficient 
mutant of Rnd3 was found predominantly on the plasma membrane and, as expected, was 
resistant to translocation upon treatment with PKC agonists (Figures 2.5C and 2.9A). This 
All A mutant showed a gain-of-function phenotype as compared to WT Rnd3. Cells 
expressing this All A mutant were rounded, due to lack of stress fibers, even after treatment 
with PMA (Figure 2.9). To test whether post-prenyl processing is also required in the context 
of this PKC-resistant phosphodeficient Rnd3, similar CAAX motif mutants were constructed 
in the All A background.  As seen in Figure 3.5, GFP-Rnd3-All A, with a WT CAAX motif, 
was localized on the plasma membrane as expected.  The completely unprocessed SAAX 
mutant was localized to the cytoplasm and accumulated in the nucleus.  While a large 
majority of the prenylated but not clipped or methylated Rnd3-All A-CTYM mutant was 
similarly localized, some was retained on the plasma membrane.  This result indicates that 
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Figure 3.4: Rnd3 is mislocalized in both Rce1-/- and Icmt-/- MEFs. Live Rce1-/- 
and Icmt-/- MEFs, along with WT matched control MEFs, transiently expressing 
GFP-Rnd3, were visualized using confocal microscopy. In Rce1-/- MEFs, GFP-Rnd3 
showed a significant decrease in plasma membrane localization, accompanied by 
substantial cytosolic distribution and some nuclear accumulation. In Icmt-/- MEFs, 
GFP-Rnd3 exhibited a complete loss of plasma membrane and endomembrane 
localization that was accompanied by increased cytosolic, but not nuclear, localization. 
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Figure 3.5: CAAX motif mutants abrogate the dominant phenotype of the 
nonphosphorylatable Rnd3-All A mutant. NIH 3T3 cells expressing GFP only, GFP-
Rnd3-All A or GFP-Rnd3-All with CAAX motif mutants were fixed and labeled with 
Texas Red phalloidin to mark stress fibers. Cells were visualized by fluorescent 
microscopy. Expression of GFP-Rnd3-All A resulted in cell rounding and a complete loss 
of stress fibers. Both CAAX motif mutants displayed localization similar to GFP only. 
Cells expressing these mutants were flat, similar to cells expressing GFP only. The STVM 
mutant expressing cells displayed levels of stress fibers similar to cells expressing GFP 
only. Cells expressing the CTYM mutant had fewer stress fibers as compared to cells 
expressing GFP only.  
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the processing status of Rnd3 affects its localization, but that the PKC-sensitivity status of 
Rnd3 does not affect its location in the absence of PKC stimulation.  
To test the functional capabilities of these mutants, cells expressing them were 
labeled with Texas Red-phalloidin to visualize stress fibers.  As seen in Figure 3.5, many 
stress fibers were present in control cells expressing GFP vector only.  In direct opposition to 
this, there were no stress fibers present in cells expressing GFP-Rnd3-All A with a WT 
CAAX motif.  There were many stress fibers present in the completely unprocessed “SAAX” 
mutant of GFP-Rnd3-All A, highlighting biological consequences of its inability to localize 
correctly, while an intermediate number of stress fibers was present in the prenylated but not 
clipped or methylated CTYM CAAX motif mutant.  This observation is consistent with the 
hypothesis that only Rnd3 localized on the plasma membrane is able to signal properly to 
downregulate Rho-ROCK signaling. Hence, proper post-prenyl processing is required for 
both Rnd3 localization and functional activity. 
 
Discussion 
 In this chapter, I have used several approaches to study the role of post-prenyl 
processing in the regulation of localization and function of the novel Rho family member 
Rnd3.  In contrast to the classical Rho family members, I have found that post-prenyl 
processing dictated by the CAAX motif, including the steps of proteolysis by Rce1 and 
carboxymethylation of the prenylated cysteine by Icmt, is necessary for proper Rnd3 
localization and function.  Interference with proper post-prenyl processing (either by CAAX 
motif mutations or expression in Rce1 or Icmt null MEFs) resulted in a slower mobility of 
Rnd3 protein on SDS-PAGE, consistent with its partial processing.  In addition, CAAX motif 
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mutations of Rnd3 that interfered with post-prenyl processing resulted in mislocalization of 
GFP-Rnd3 away from the plasma membrane and accumulation in the cytoplasm and nucleus 
in NIH 3T3 cells.  GFP-tagged Rnd3 WT was similarly mislocalized when expressed in 
Rce1-/- and Icmt-/- MEFs in which post-prenyl processing does not occur due to the lack of 
relevant processing enzymes.  
In the course of this study, I observed that mislocalized Rnd3 is also impaired in 
function.  Not only was GFP-tagged Rnd3 mislocalized in Rce1-/- and Icmt-/- MEFs, but it 
also produced consistently less rounding in these cells as compared to matched WT control 
cells.  Furthermore, I observed that the GFP-Rnd3-All A CTYM CAAX motif mutant, which 
undergoes prenylation but not post-prenyl processing, was not completely restricted from 
plasma membrane association and resulted in an amount of stress fibers intermediate between 
that of completely processed Rnd3 WT and the completely unprocessed Rnd3 SAAX mutant.  
Thus, while overwhelmingly mislocalized, the small pool of this partially processed form of 
Rnd3 (CTYM) may still provide sufficient signal from the plasma membrane to cause some 
stress fiber disassembly. I speculate that, when Rnd3 is mislocalized, it is unable to engage 
downstream effectors such as p190RhoGAP or ROCK I to abrogate the effects of RhoA-
ROCK signaling.  With the increasing evidence that Rnd3 is overexpressed in cancers with 
increased metastatic potential (307, 310, 311), Rnd3 may be a target of drugs that block 
either prenylation (108) or post-prenyl processing (116).  It would be interesting to determine 
the role of Rnd3 in the observed cellular effects of FTIs and of current and future inhibitors 
of Rce1 and Icmt. 
 A recent study suggested that members of the classical Rho family of small GTPases 
are not dependent on post-prenyl processing for proper localization (126).  The grand scope 
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of a larger overall study by our lab in collaboration with Channing Der’s lab (for which some 
of the Rnd3 data was collected) (106) was to examine the dependency of post-prenyl 
processing of all Rho family GTPase members.  We have found, in opposition to the 
aforementioned study, that the majority of Rho family members, including 
geranylgeranylated members, are differentially dependent upon post-prenyl processing 
through Rce1 and Icmt for proper localization and/or function.  Past work has demonstated 
that both H-Ras and K-Ras-mediated transformation is impaired when either Rce1 or Icmt are 
disrupted (127, 135).  It was also noted that transformation by B-Raf was inhibited by loss of 
Icmt activity, even though B-Raf itself is not an Icmt substrate.  Therefore, some other target 
or targets of Icmt activity must be responsible for the Icmt deficiency-induced inhibition of 
Raf.   
With the information gained in this study, it is plausible that Icmt deficiency-induced 
inhibition of Rho proteins could be responsible for the effects seen with Icmt functional loss. 
With this in mind, RhoA may represent one possible target of Icmt inhibitors. In the study   
mentioned above (106), we found that RhoA subcellular localization was sensitive to loss of 
Icmt function.  A previous report noted that nonmethylated RhoA is less stable than the 
methylated form (375).  In support of this, Bergo and colleagues have shown that the steady-
state levels of GTP-bound RhoA and total RhoA were decreased in Icmt targeted fibroblasts 
transformed with K-Ras, due to accelerated protein turnover (135). Surprisingly, the authors 
saw an increase in the stability of Ras proteins in these cells.  They also noted an 
upregulation in the level of p21-CIP1, a cyclin-dependent kinase inhibitor which blocks cell 
cycle progression.  Past studies have shown p21-CIP1 levels are upregulated by activated Ras 
and that this upregulation can be antagonized by RhoA (235, 236).  To test whether p21-
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CIP1 was important for the effects seen with loss of Icmt function, Bergo and colleagues 
inactivated Icmt in K-Ras-transformed cells deleted for the gene encoding p21-CIP1.  The 
authors observed that the Icmt inactivation in these cells had no measurable effect on cell 
growth on plastic plates or on the growth of colonies in soft agar.  They concluded that the 
effect of Icmt inactivation on K-Ras transformation may have been a consequence of its 
effects on Rho and p21-CIP1, rather than being due to a direct effect on the intrinsic 
properties of K-Ras itself.  In support of a role for RhoA in the effects seen with inhibition of 
Icmt function, Lu and colleagues have noted that an Icmt inhibitor decreased both RhoA 
methylation and activity along with endothelial monolayer permeability, a RhoA-dependent 
property (376). Furthermore, a change in the organization of intercellular junctions was 
noted.  The authors suggest that carboxymethylation of RhoA may be critical for its ability to 
modulate endothelial barrier function.  In a follow-up experiment the same authors noted that 
treatment of endothelial cells with an Icmt inhibitor decreased levels of RhoA protein (377). 
This decrease in RhoA protein levels coincided with a loss of GRP94, a protein that is a 
component of the unfolded protein response. The decrease in GRP94 protein levels caused 
apoptosis, possibly through dysfunction in the unfolded protein response. The authors 
suggest a novel link between RhoA and the unfolded protein response.  With its documented 
role in cellular processes such as actin cytoskeletal organization, gene expression, cell cycle 
progression and transformation (169), perhaps RhoA may be a functionally important target 
for Icmt-dependent inhibitors.  
 Icmt knock out mice died earlier in development as compared to Rce1 knock out 
mice, despite the fact that prior Rce1-mediated cleavage is necessary for Icmt-mediated 
processing to take place at the now-terminal farnesylated cysteine of its substrate proteins.  
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Several explanations could be offered for this observed disparity in phenotypes. First, there 
may be additional proteins in the cell that are reliant on Icmt function, but are not reliant on 
Rce1 function.  Second, perhaps prenylated proteins are more affected by the presence of the 
exposed C-terminal cysteine than by the presence of the –AAX extension (378, 379).  
Finally, with the observations mentioned above regarding protein stability in Icmt-targeted 
cells, perhaps loss of Icmt function has a differential effect on the ability of proteins to avoid 
degradation in the cell. 
 Development of inhibitors of both Rce1 and Icmt is still currently in its infancy. In 
contrast to FTIs and GTIs, there is limited documentation in the literature of studies based on 
inhibiting the two post-prenyl processing enzymes.  One example of an Icmt-specific 
inhibitory compound is the indole-based small molecule cysmethynil.  Casey and colleagues 
have documented that cysmethynil treatment results in inhibition of cell growth in an Icmt-
dependent fashion. They showed that treatment of cancer cells with cysmethynil resulted in 
mislocalization of Ras, impairment of EGF signaling and blockage of anchorage-independent 
growth, which could be reversed by overexpression of Icmt (380).  Furthermore, inhibition of 
Icmt function has been shown to be a critical component of the antiproliferative effect of the 
antifolate methotrexate, a drug commonly used in chemotherapy (381). Recently, the first 
natural product inhibitor of Icmt named spermatinamine was described.  This product, from 
the Australian marine sponge, was discovered in a natural product high-throughput screening 
of conducted to discover Icmt inhibitors (382).  In addition, compound libraries are being 
screened and both peptidic and non-peptidic compounds are being designed and tested for 
use as Rce1-specific inhibitors (383-385).  
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 While development of inhibitors of post-prenyl processing has been limited (116), 
perhaps the information gained here regarding sensitivity of a large number of Rho proteins 
to loss of post-prenyl processing will spur further interest in development of Rce1- and Icmt-
specific inhibitors.  It should be noted that while inhibitors of farnesyl transferase (FTIs) 
were initially designed as “anti-Ras” drugs; it is now generally accepted that Ras proteins are 
not the only targets of FTIs (107).  Numerous Rho family proteins are currently being 
investigated as possible targets of FTIs and thus responsible for some of the effects seen with 
FTI treatment (113). It could be envisioned that, in the future, certain cancers that are 
dependent upon post-prenylated proteins (not only Ras family proteins, but also Rho family 
proteins) could possibly be treated with either Rce1 or Icmt inhibitors (80). 
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CHAPTER 4 
CONCLUDING REMARKS, FUTURE DIRECTIONS AND SUMMARY 
 
Concluding Remarks 
Rho proteins act as molecular switches, cycling between an inactive GDP-bound form and an 
active GTP-bound form. This activated GTP-bound form is capable of interacting with 
downstream effectors, resulting in a myriad of cellular outcomes.  Rnd3 is a member of the 
Rnd family of proteins, which form a distinct branch of the Rho family of small GTPases.  
Rnd3 has been shown to be GTPase-deficient and constitutively bound to GTP, and is 
considered to be constitutively active (15, 16).  Rnd3 is largely known for its role in 
counteracting signaling from the RhoA-ROCK signaling pathway (13-15, 243). Because it 
does not undergo GDP/GTP cycling, other modes of regulation for Rnd3 have been proposed 
(12, 17). Regulation by expression has been suggested and numerous reports have indeed 
provided evidence that Rnd3 expression is modulated by various biological stimuli (14, 250, 
254, 256). Because regulation by expression is a relatively slow process, more rapid and 
efficient modes of regulation for Rnd3 must exist. To this end, I decided to explore the 
possibility that Rnd3 may be regulated in a more dynamic fashion through post-translational 
mechanisms.  Several Ras-related small GTPases have been shown to be phosphorylated at 
sites within the polybasic regions of their C-terminal hypervariable domains, just upstream of 
the CAAX membrane-targeting motif (282, 321, 323-325, 328).  These phosphorylation 
  
events have been shown to have biological consequences and are believed to reduce the 
affinity of these proteins for the plasma membrane, a subcellular location important for 
effector signaling.  Inspection of Rnd protein sequences revealed a potentially 
phosphorylatable serine residue at position 240 in the hypervariable region, located between 
the polybasic region and the CAAX motif. This serine fits the consensus PKC 
phosphorylation motif. Therefore, I sought to determine if PKC-dependent phosphorylation 
at serine 240 occurred, and if so, whether it had any effect on Rnd3 localization and function.  
Through my research outlined in Chapter 2, I found that upon PKC activation, Rnd3 became 
phosphorylated and its subcellular localization was altered.  I found that PKC activation 
caused rapid loss of Rnd3 from the plasma membrane and enrichment in the cytosol and on 
internal membranes.  I also found that serine 240 alone is not responsible for the effects of 
PKC activation on Rnd3.  Rather, through the use of specific mutants including a 
nonphosphorylatable mutant of Rnd3, I found that multiple sites of phosphorylation exist in 
Rnd3. By use of both pharmacologic and genetic analyses, I demonstrated a requirement for 
PKCα.  I also provided evidence that integrin engagement regulates downstream signaling 
functions of Rnd3 by inducing PKCα-mediated phosphorylation. Furthermore, I have 
presented evidence that PKCα-mediated signaling, through phosphorylation of Rnd3, leads 
to increased signaling through the RhoA-ROCK signaling pathway. A recent study described 
a mechanism where FN engagement led to PKCα-dependent activation for the formation and 
maintenance of stress fibers; although no direct connection between PKCα and RhoA was 
shown (366). My observations support a mechanism wherein FN-mediated integrin 
activation of PKCα results in PKCα-mediated phosphorylation of Rnd3. I have offered 
compelling evidence that Rnd3 may represent an important link directly connecting PKCα 
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with the RhoA-ROCK signaling pathway. The increase in Rnd3 expression in metastatic 
cancers (307, 310, 312, 386) suggests that Rnd3 might be selected for due its role in 
counteracting signaling from the RhoA-ROCK pathway. Rnd3 function may contribute to the 
more motile phenotype seen in metastatic cancers and phosphorylation may represent one 
mode of regulation to keep its signaling functions in check. The results I have presented 
further suggest that stimulus-mediated phosphorylation of Ras-related small GTPases may be 
a more common mode of regulation, distinct from GDP/GTP cycling, than has been 
appreciated. 
 In the other major aspect of my work, I investigated a role for other post-translational 
mechanisms of regulation of Rnd3.  Proper plasma membrane localization of Ras-related 
small GTPases is mediated by a three-step enzymatic pathway involving prenylation of the 
cysteine found in the CAAX motif by either 15 carbon farnesyl or 20 carbon geranylgeranyl 
isoprenoids followed by two post-prenyl processing steps: -AAX proteolysis and methylation 
of the terminal prenylated cysteine (96, 97, 105, 116). The end result of this enzymatic 
cascade, involving both prenylation and post-prenyl processing, is thought to make the C-
terminal domain of CAAX motif-containing proteins more hydrophobic, to better facilitate 
proper interactions with membranes (121). Although the classical Rho proteins such as 
RhoA, Rac1 and Cdc42 have been well studied (4, 9), little is known about the less-studied 
Rho proteins, especially the importance of CAAX-mediated signaling modifications for their 
subcellular locations and functions (95). A recent study found that, while farnesylated Ras 
proteins require full post-prenyl processing for proper membrane localization, 
geranylgeranylated Rho proteins do not (126).  As discussed in Chapter 3, I investigated 
Rnd3 as part of a large collaborative effort evaluating the importance of Rce1- and Icmt-
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mediated post-prenyl processing for the membrane association and function of nonclassical 
Rho proteins.  Through the use of CAAX-specific mutations I found that full processing 
(prenylation, along with –AAX cleavage and carboxyl methylation) is required for both 
proper membrane localization and function of Rnd3.  I have also provided evidence that there 
is a direct correlation between Rnd3 plasma membrane localization and the ability to disrupt 
stress fiber formation/maintenance.  Further, Rnd3 requires Rce1-mediated -AAX proteolysis 
and Icmt-mediated carboxyl methylation of the isoprenylcysteine for proper subcellular 
localization, as shown by the use of Rce1-/-, Icmt-/- and WT control MEFs.  In contrast to 
control WT MEFs where GFP-Rnd3 was mainly plasma membrane localized along with 
some endomembrane localization, GFP-Rnd3 expressed in Rce1-/- MEFs showed a 
significant decrease in plasma membrane association, accompanied by substantial cytosolic 
distribution and some nuclear accumulation.  GFP-Rnd3 expressed in Icmt-/- MEFs exhibited 
a complete loss of plasma membrane and endomembrane localization that was accompanied 
by increased cytosolic, but not nuclear, localization. My colleagues also showed that 
alternative prenylation in Rho proteins is a rare event, implying that most Rho GTPase 
targets of FTIs will likely be sensitive to FTI alone. Rnd3 in particular is solely farnesylated 
and thus may represent an important Rho target of FTIs.  Further, we showed that, in contrast 
to the aforementioned study (126), RhoA was highly sensitive to Icmt loss and RhoB was 
highly sensitive to Rce1 loss.  Also, we showed that the majority of Rho proteins were 
dependent on both Rce1 and Icmt for proper subcellular localization and/or function.  These 
results provide further validation for continued work on developing pharmacological 
inhibitors of these two enzymes for use as possible cancer therapeutics. 
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Future Directions: Identifying novel interacting proteins of Rnd3. 
  Signal transduction pathways rely on an ordered cascade of protein-protein 
interactions.  When, where and with what partners a specific protein interacts have particular 
significance for the biological functions of that protein. As previously mentioned, several 
known interaction partners have been identified for Rnd3, but how its activity is regulated, 
the specific signaling pathways in which it participates, and the full range of effectors it uses 
to achieve its biological effects remain poorly understood.  Indeed, the normal roles of Rnd3 
remain incompletely characterized. As described above, there is currently some evidence for 
the involvement of Rnd3 in at least three biological processes:  regulation of cytoskeletal 
organization, cell cycle progression, and tumor suppressor activity.  Screens for additional 
interacting partners that identify proteins with roles in each of these activities may provide 
support for the physiological relevance of these pathways to Rnd3 function.  Identification 
of additional interacting partners would facilitate understanding of these and other processes. 
Several yeast two-hybrid assay screens to identify Rnd3 effectors have been 
performed by others.  In addition, a tandem affinity purification technique called TAP-tag 
has been applied for unbiased biochemical identification of interacting proteins. However, it 
is clear that more work remains to be done.  A logical future direction for my studies is to 
identify and validate novel interacting protein partners for Rnd3, both to enhance 
understanding of effector targets and to uncover additional biological processes for which 
Rnd3 may be important. 
Interactions of Rnd3 with both p190RhoGAP and ROCK I (13, 14) have been shown 
to facilitate the mechanisms by which Rnd proteins counteract the effects of RhoA on the 
actin cytoskeleton.  A third protein shown to bind to Rnd3 is Socius, (272).  The normal 
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function of Socius is unknown, but a membrane-targeted mutant of Socius disrupts the actin 
cytoskeleton similarly to the Rnd proteins. This suggests that, like p190RhoGAP and ROCK 
I, Socius may also participate in Rnd protein-mediated signal transduction pathways involved 
in the reorganization of the actin cytoskeleton. Given the competing models of Rnd3 
modulation of RhoA activity described previously in this document, it seems entirely likely 
that additional Rnd3 effectors of these pathways exist, and a major future direction will be to 
identify them. 
In contrast to the proteins above, which result in downregulation of RhoA activity, 
Rnd3 has also been shown in a yeast two-hybrid screen to interact with the Plexin-B1 protein 
(294), an activator of RhoA via PDZ-RhoGEF.  As described in the Introduction above, the 
functional consequences of this interaction were not determined, but Rnd1/Plexin-B1 
interaction was shown to mediate Semaphorin D-mediated growth cone collapse by 
activating RhoA and inactivating R-Ras.  It will be important to validate whether this or other 
functional consequences also occur as a result of the Rnd3/Plexin-B1 interaction. 
In a study using the tandem affinity purification (TAP) tag technique (described in 
detail below), Rnd3 was documented to interact with the 14-3-3-sigma protein (387). 14-3-3 
proteins act as phosphoserine/phosphothreonine binding proteins involved in translocating 
phosphorylated proteins to and from specific subcellular compartments (388-390). As yet, 
the exact role for this interaction remains to be determined, but perhaps 14-3-3-sigma is 
involved in the shuttling of phosphorylated Rnd3 from the plasma membrane, which I 
described in Chapter 2.   
In addition to its relatively well-studied effects on the cytoskeleton, there is evidence 
that Rnd3 may also be involved in regulation of the cell cycle, although there is disagreement 
136
  
about its role.  One report (255) suggested that this inhibition of cell proliferation was due to 
negative effects of Rnd3 on the translation of cyclin D1 mRNA.  Perhaps Rnd3 physically 
interacts with components of the translational machinery.  Thus, one possible direction for 
my long-term future studies could be to attempt to identify such components.  
Lastly, Rnd3 may be involved in regulating the process of cytokinesis. In support of 
this possibility, RhoA and several of its regulators and effectors have been shown to be 
critical for this process.  Initiation of cytokinesis requires the establishment of the cleavage 
plane, the assembly of the contractile ring and the ingression of the cleavage furrow (391).  
RhoA is recruited to the cleavage furrow during cytokinesis (392) and is needed for proper 
execution of cytokinesis (393, 394).  Furthermore, mDia, citron kinase and ROCK, 
downstream effectors of Rho, were found to accumulate at the cleavage furrow during 
cytokenesis (192, 395, 396). It was shown that ROCK is involved in the progression of 
cytokinesis through the phosphorylation of several proteins including myosin light chain at 
the cleavage furrow (397). Finally, the RhoA-specific GAP MgcRacGAP/CYK-4 was shown 
to localize to the mitotic spindle in metaphase and to be condensed at the midbody during 
cytokinesis, and its GAP activity was shown to be required for initiation of cytokinesis (289, 
290) through the controlled assembly of the contractile ring (291). MgcRacGAP has been 
shown to physically interact with Rnd2 both by GST-pulldown and by co-
immunoprecipitation, and to colocalize (286).  While neither Rnd1 or Rnd3 was investigated 
in this study, it could be envisioned that Rnd3 might interact with RhoA GAPs that 
specifically regulate RhoA during cytokinesis or bind ROCK and inhibit its downstream 
signaling.  With p190RhoGAP being one of the most important effectors of Rnd3, this is 
plausible.  Whether Rnd3 is localized to the mitotic apparatus still remains to be tested. What 
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other proteins interact with Rnd3 to regulate cell-cycle progression and possibly cytokinesis, 
in addition to actin cytoskeletal regulation, still remain to be identified. 
To help elucidate the identities of novel interacting proteins of Rnd3 in an unbiased 
manner, I would use the TAP tag method to retrieve Rnd3-interacting proteins and then 
identify those associated proteins via mass-spectrometry.  The TAP tag was originally 
developed for identification of protein complexes in yeast cells (398).  This purification 
method involves fusion of the TAP tag (either N- or C-terminal) to the target protein 
followed by expression in the cell system of choice.  Cell extracts are prepared and the fusion 
protein is recovered, along with known and potential novel binding partners, by two specific 
affinity purification and elution steps enabled by properties of the tag.  The original TAP tag 
consists of two IgG binding domains of Staphylococcus aureus Protein A and a calmodulin 
binding peptide (CBP), separated by a tobacco etch virus (TEV) protease cleavage site.  
Purification of the target protein and its associated proteins involves incubation of cell 
extracts with an IgG matrix (which binds tightly to the double Protein A module affinity tag), 
followed by stringent washing and incubation with TEV protease.  Incubation with TEV 
protease results in cleavage at the TEV cleavage site and removal of the first affinity tag.  
The partially enriched extract is then incubated with calmodulin beads in the presence of 
Ca2+ to bind to the CBP affinity tag, followed by stringent washing and a final release of the 
target protein and associated proteins with an elution buffer containing the Ca2+ chelating 
agent EDTA. This double (or tandem) affinity purification technique promotes the 
purification of a highly enriched sample containing the protein of interest along with both 
known and potentially novel interacting proteins that can then be concentrated and analyzed 
by mass spectrometry for positive identification (399). 
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 The TAP tag method, in combination with mass spectrometry, could be a valid 
method of uncovering the identities of novel interactors of Rnd3.  A report from Liu and 
colleagues described their successful use of a variation of the TAP tag method to uncover 
multiple novel protein interactors of the signaling molecule SMAD3 (400).  The variation to 
the original TAP tag came in the form of a FLAG tag, rather than use of a calmodulin 
binding peptide as the second affinity tag.  The authors indicated that the CBP affinity tag 
was problematic because so many cellular proteins are regulated by calmodulin. With this in 
mind, I proceeded through multiple cloning rounds to produce my own variant TAP tag 
similar to the one used by Liu and colleagues, in that its first affinity tag is a tandem Protein 
A-binding module, followed by a TEV protease site and ending in a FLAG tag to be used as 
the second affinity tag (Figure 4.1A).  I then proceeded to clone this new TAP tag into the 
expression vector pcDNA3.1(+), making two variants. One variant is a read-through, which 
will allow fusion of the TAP tag to the N-terminus of the protein of interest, and the second 
variant is a negative control that has a stop codon immediately following the FLAG tag to 
produce an empty vector expressing only the TAP tag.  I named the read-through variant 
“pTAP-Go” and the control variant which has the incorporated stop codon “pTAP-Stop”.  I 
inserted both TAP tag variants into the BamHI-EcoRI sites of pcDNA3.1(+).  I then inserted 
into the newly produced pTAP-Go vector, by use of the EcoRI-XhoI sites, the coding 
sequence of Rnd3 with an added stop codon.  I have named this construct “pTAP-Rnd3”. 
 Both the pTAP-Rnd3 and the control pTAP-Stop variant vectors expressed quite well 
in both mouse NIH 3T3 cells and human HEK-293 cells (Figure 4.1B).   Immunoblot 
analysis with anti-FLAG antibody of cell lysates expressing each construct showed that 
neither of the fusion proteins (TAP tag control or the TAP-Rnd3) had undergone significant 
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Figure 4.1: Design and validation of a novel TAP tag system. A, I have developed a novel 
TAP tag vector employing two Protein-A modules, a TEV protease site and a FLAG tag. 
Rnd3 was inserted in-frame behind the TAP tag cassette. B, Both the control TAP-Stop and 
TAP-Rnd3 express in NIH 3T3 cells. The expressed proteins are of the correct size and show 
no unwanted proteolysis.   
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proteolysis.  Both fusion proteins could be purified using either IgG or FLAG antibody 
conjugated beads, and using recombinant TEV protease, I also demonstrated that the TEV 
protease site incorporated into the new TAP tag vector can be successfully cut, with no 
unwanted cleavage elsewhere (data not shown).  This cleavage step is critical to avoid 
nonspecific binding of detector antibodies to the Protein A module.  Finally, I have generated 
HEK-293 cell lines that stably express either the control TAP tag or the TAP-Rnd3 fusion.    
If future attempts were successful in identifying bands obtained by interaction with 
TAP-Rnd3 but not TAP-stop, I would first need to confirm the interaction between Rnd3 and 
these newly identified proteins.  To accomplish this, I would perform co-
immunoprecipitation experiments in both directions - protein X binding to Rnd3 and Rnd3 
binding to protein X.  Also, I would perform colocalization experiments to visualize whether 
Rnd3 and protein X display overlapping cellular localizations.  
To determine which of the newly identified interacting proteins is a potential Rnd3 
effector, as distinct from a Rnd3 regulatory protein or one lacking in functional 
consequences, I would first determine if the newly identified proteins could still interact with 
Rnd3 effector domain mutants. Specifically, I would expect to see impaired binding to a 
Rnd3(T55A) mutant, which is analogous to the RhoA(T37A) mutant that shows impaired 
effector binding to multiple effectors. Binding of Rnd3 to p190RhoGAP was eliminated 
when this mutant was employed (13). I would also use other effector domain mutants that 
have been successfully used in studies of RhoA, since the core effector domains of Rnd3 and 
RhoA are identical (4, 401, 402).  
As mentioned previously, the region encompassing Rnd3 residues 16-93 was shown 
to be the minimal region of Rnd3 required to bind to p190RhoGAP (13), consistent with 
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studies showing that RhoA binding to the ROCKs and PKN-related kinases requires not only 
the Switch I effector domain region but also loop 6 residues (amino acids 75-92, just C-
terminal to Switch II) (174). Therefore, I would also determine whether mutations to the 
region of Rnd3 homologous to the loop 6 region of RhoA impair binding to candidate Rnd3 
effectors. In addition, the insert region of RhoA has been shown to be important for 
regulation of ROCK activation (172). I would test whether mutations in the Rho insert region 
of Rnd3 (residues 142-155) also conferred loss of binding. 
In addition, although Rnd3 is GTPase-deficient and thus constitutively GTP bound, I 
would like to determine whether the binding of Rnd3 to any of these newly identified 
proteins is GTP-dependent, which is an important criterion for a true effector protein. 
Therefore, I would use a Rnd3(T37N) mutant which is analogous to the persistently GDP-
bound RhoA(T19N) mutant.  As with Rnd3(T55A), binding of Rnd3 with p190RhoGAP was 
also eliminated when the Rnd3(T37N) mutant was employed. Hence, GTP binding is 
necessary for Rnd3 to bind to p190RhoGAP, and interaction of any novel interacting 
protein(s) that are true Rnd3 effectors would also require that Rnd3 be bound to GTP.   
The next step would be to map out, by use of truncation mutants, which regions of 
Rnd3 and the newly identified candidate effector protein(s) are important for their 
interaction.  Finally, it would be necessary to validate which of these proteins has a 
functional consequence for Rnd3 biological activity.  If the candidates have known functions 
in any of the three biological activities cited above, whether cytoskeletal organization, cell 
cycle progression or cytokinesis, the functional assays would be chosen accordingly.  
Alternatively, if they have known functions in other biological processes, different assays 
would be appropriate, and could provide insight into other possible roles for Rnd3 in cellular 
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activities.  Interacting proteins with no known biological functions would be lowest on the 
priority list for evaluation. 
 Overall, I am optimistic that, by using my TAP tag vectors, it will be possible to 
identify novel protein-protein interactors and effectors of Rnd3. Identifying novel interacting 
proteins of Rnd3 will surely help in clarifying its role in currently known cellular activities 
and possibly uncover previously unknown functions of Rnd3. 
 
Future Directions:  The role of Rnd3 in pancreatic cancer. 
 Pancreatic cancer is a devastating disease with an overall 5-year survival of only 4% 
(403).  Currently the only opportunity for improved survival continues to be surgical 
resection for those with localized disease.  Yet, this is only achievable for fewer than 15% of 
patients diagnosed, due to the fact that most patients diagnosed with pancreatic cancer 
already have metastatic disease (404).  Even for patients who are able to undergo surgical 
resection, median survival is only 17 months (404). Clearly, it is important to identify new 
and better targets for intervention in this disease. 
 Expression profiling has identified upregulation of Rnd3 in pancreatic cancer 
compared to normal pancreas (307) (D. Billadeau, personal communication). In further 
support of Rnd3 expression increasing during cancer progression, Rnd3 has been recently 
shown to be upregulated in metastatic melanoma versus primary melanoma (310) and to be 
involved in Raf-dependent metastasis of melanoma cells (386).  I would like to determine 
whether Rnd3 upregulation is merely correlated with or is functionally important in this 
progression. 
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To determine appropriate model cell lines to test my hypothesis that Rnd3 is 
functionally important in pancreatic cancer progression, I will first screen a panel of 
pancreatic cell lines for the abundance of Rnd3 protein. I expect that comparing Capan-1 and 
Capan-2 cell lines will be of interest.  Like nearly all pancreatic cancers, both cell lines 
possess a mutant K-ras allele.  Further, a prior study, from our group and the Counter group 
at Duke University, has shown that Capan-1 cells have a high level of K-Ras-GTP as 
compared to Capan-2 cells (43). A previous study has shown that Rnd3 expression is 
upregulated in Raf-induced transformed MDCK cells (250), and there is evidence that Rnd3 
is upregulated by Ras/Raf activity in a MEK/ERK-dependent manner (Singh et al., 
unpublished data).  It would be interesting to know if there is a direct correlation between 
levels of K-Ras-GTP and Rnd3 levels.   Once I have identified levels of Rnd3 protein in this 
panel, I will use these cells to determine whether Rnd3 activity is important for their 
transformed properties. 
As part of my goal to determine a possible role for Rnd3 in pancreatic cancer 
progression and metastasis, I have validated Rnd3-specific shRNA sequences capable of 
knocking down expression of Rnd3.  As seen in Figure 4.2A, Rnd3 protein was greatly 
reduced in HEK-293 cells that stably express Rnd3-specific shRNA targeted to two distinct 
sequences of Rnd3 mRNA, compared to HEK-293 cells expressing an empty shRNA vector.  
I will next use these shRNAs to try to knockdown Rnd3 expression in my panel of pancreatic 
cancer cell lines. 
Recently, I attempted this process unsuccessfully in two metastatic melanoma cell 
lines, both by transfection and by infection (Figure 4.2B). Because Rnd3 is highly 
upregulated in metastatic versus primary melanoma (310), I reasoned that there might be 
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Figure 4.2: Rnd3 protein is knocked down by specific shRNA sequences.  A, HEK-
293 cells stably expressing Rnd3-specific shRNA display significant knock-down of Rnd3 
protein in 2 out of 3 targeting vectors.  B, None of the targeting vectors show knock-down 
of Rnd3 protein in two stably-selected metastatic melanoma cell lines. 
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selective pressure against cells lacking Rnd3. Perhaps metastatic melanoma cells “need” 
Rnd3 and the viability of these cells decreased when the levels of Rnd3 dropped below a 
certain threshold for a certain period of time.  To test this theory, I intended to knockdown 
Rnd3 transiently.  Unfortunately, Andrew Aplin and colleagues recently published results 
very similar to my planned experiments (386).  This group showed that knockdown of Rnd3 
via Rnd3-specific siRNA, in metastatic melanoma cells, resulted in an increase in signaling 
from the RhoA/ROCK/LIM kinase pathway leading to increased cofilin phosphorylation, 
stress fiber formation and reduced cell invasion.  These results are consistent with my 
hypothesis that Rnd3 is required for proper RhoA signaling and subsequent cytoskeletal 
reorganization and transformation properties. Perhaps Aplin and collegues used siRNA 
oligonucleotides transiently because they too were unsuccessful at making stable metastatic 
melanoma cell lines having reduced Rnd3 expression by using vector-based shRNAs.  
Therefore, if I am unsuccessful at making stable pancreatic cancer cell lines using my 
validated Rnd3-specific shRNAs, as an alternative approach I will perform targeted 
knockdown of Rnd3 in these cells using validated Rnd3-specific siRNA oligonucleotides.   
 After achieving successful knockdown of Rnd3 in pancreatic cancer cells, I will 
perform assays looking at colony formation in soft agar, scratch-wound motility and invasion 
through Matrigel.  I predict that cells in which Rnd3 is knocked down will display either 
fewer or smaller colonies in agar as well as decreased motility and invasion. 
 To validate that any functional impairments in Rnd3 knockdown cells are due to loss 
of Rnd3, I will force express an RNAi-insensitive version of Rnd3 and confirm restoration to 
endogenous levels of Rnd3.  If the functional impairments in the knockdowns are based on 
decreased levels of Rnd3 protein, then the RNAi-insensitive Rnd3 will be able to restore 
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colony formation, motility and invasion even in the presence of knocked down endogenous 
Rnd3. 
 Lastly, using these stable knockdown cells I plan to look at tumor growth and 
metastasis in a pancreatic orthotopic mouse model. I plan to make stable cell lines that 
express both the Rnd3-specific shRNA and GFP to enable me to track tumor growth and 
metastasis.  This will be done by using either an expression vector that has an IRES or an 
expression vector that contains two promoters that allows insertion and expression of two 
separate sequences (Rnd3 and GFP).  These stable cell lines will be surgically orthotopically 
implanted into the pancreas of nude mice. Whole body fluorescent optical imaging will be 
used to visualize, in real time, tumor growth and metastasis in vivo (405-407). I will 
determine whether a reduction of Rnd3 in these cells has any effect on their metastatic 
potential in vivo. As mentioned previously, a recent study suggested that Rnd3 promotes 
melanoma invasion (386). In regards to pancreatic cancer, I predict that a reduction of Rnd3 
protein, by use of RNAi technology, will have a negative effect on the potential of pancreatic 
cancer cells to invade and metastasize in the orthotopic pancreatic cancer mouse model.  If 
this turns out to be the case, it would further support the importance of targeting Rnd3 for 
pancreatic cancer treatment.  
 
Summary 
Through the research outlined in this dissertation, I have shown that the GTPase-
deficient Rho family protein Rnd3 can be regulated by mechanisms other than GDP/GTP 
cycling. The main theme that I have observed throughout my research is that localization of 
Rnd3 dictates its function. I have shown that PKCα-mediated phosphorylation of Rnd3 
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regulates both of these processes. Phosphorylated Rnd3 loses its affinity for the plasma 
membrane and is impaired in its ability to disassemble stress fibers and thereby cause cell 
rounding.  Integrin-mediated signaling upon cell attachment causes PKCα-mediated 
phosphorylation of Rnd3 that is required for its ability to cause stress fiber disassembly and 
spreading, I suggest that stimulus-mediated phosphorylation of Ras-related small GTPases 
may be a more common mode of regulation, distinct from GDP/GTP cycling, than has been 
appreciated.  Furthermore I have shown that Rnd3 is sensitive to loss of Rce1- and Icmt-
mediated post-prenyl processing modifications.  Mislocalization due to improper post-prenyl 
processing also abrogates Rnd3 function in regulating the actin cytoskeleton. The discovery 
that the localization and function of Rnd3, along with those of most Rho proteins, is sensitive 
to loss of post-prenyl processing provides validation that both Rce1 and Icmt may represent 
potentially important drug targets for use as cancer therapeutics. 
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